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ABSTRACT  
The consumption of fructose during the perinatal period programmes for increased susceptibility 
to developing metabolic derangements immediately in childhood or later in adulthood. S-allyl-
cysteine (SAC), a phytochemical constituent of garlic, has antioxidant, antidiabetic and 
antihyperlipidaemic properties. We hypothesised that neonatal orally administered SAC could 
protect against the development of high-fructose diet-induced metabolic derangements in both 
early and adult life. 
The study was undertaken in two major experiments. In the first experiment, the potential of 
neonatal oral administration of SAC to protect against acute metabolic derangements induced by 
high-fructose diet consumption in early-life was investigated. Sixty-four suckling (male = 32; 
female = 32) 4-day old Wistar rat pups were randomly allocated to and administered the 
following treatment regimens daily for 15 days: group I - 10 ml/kg distilled water (DH), group II 
- 10 ml/kg 20% fructose solution (FS), group III - 150 mg/kg body mass per day
 
SAC, and group 
IV - (SAC + FS). On postnatal day 21 the pups’ blood cholesterol, glucose and triglyceride 
concentrations were determined. Immediately thereafter the pups were euthanised and tissues 
collected for analyses. Neonatal orally administered SAC significantly increased (p < 0.05) the 
plasma insulin concentration in male pups. The oral administration of a 20% FS decreased (p < 
0.05) plasma insulin in the female pups. However, the anti-insulinotropic effect of a 20% FS in 
female rat pups was attenuated by orally administered SAC. Neonatal orally administered SAC 
showed insulinotropic effects in male rat pups and protected female rat pups against the anti-
insulinotropic effect of a 20% FS.  
The second experiment investigated the potential of neonatal orally administered SAC to protect 
against high-fructose diet-induced metabolic derangements later in adulthood. One hundred and 
twenty-eight (males = 64; females = 64), 4-day old Wistar rat pups were randomly allocated to 
and administered treatment regimens as described for the first experiment. On postnatal day 21, 
the pups were weaned and allowed to grow on a standard rat chow (SRC) until postnatal day 56. 
The rats from each treatment regimen were then randomly split into two subgroups: one on a 
standard rat chow (SRC) and plain drinking water and another on SRC and 20% fructose 
drinking water and then subjected to these treatment regimens for eight weeks after which they 
were then euthanised and tissues collected for analyses. Neonatal orally administered 20% FS 
alone, programmed male and female rats to have increased (p < 0.05) liver lipid accretion in 
vi 
 
adulthood. The neonatal oral administration of SAC attenuated the programming of increased 
liver lipid accretion in adulthood induced by neonatal orally administered 20% FS. Thus neonatal 
oral administration of SAC could potentially protect against neonatal fructose consumption 
programming of fatty-liver related metabolic dysfunctions in adult life.  
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CHAPTER 1: INTRODUCTION AND 
JUSTIFICATION 
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1.0 Preview of thesis structure 
This thesis is made up of five chapters. Chapter one gives an introduction to the problem of 
obesity in growing children, an analysis of the research done to date in regard to the problem. It 
then articulates the justification aims and objectives and hypotheses of the proposed study.  
The second chapter provides a critical analysis of the literature pertinent to the study. In 
summary, the chapter explains and describes the concept of neonatal diet-driven metabolic 
programming and its effects in early and adult life. Important statistics on the prevalence of 
obesity and it being a risk factor for metabolic dysfunction/syndrome as manifest by insulin 
resistance, type II diabetes mellitus, dyslipidaemia and other metabolic derangements is given. 
Various animal models used in the study of metabolic programming are critiqued. A critical 
analysis of the merits and demerits of the use of conventional pharmaceutical agents versus the 
use of ethnomedicine in the management of diet-induced metabolic derangements is presented. A 
synopsis of the health beneficial effects of S-allyl-cysteine (e.g. antidiabetic, antihyperlipidaemic, 
antioxidant, hepatoprotective, renoprotective and gastroprotective activity), a phytochemical 
constituent of garlic, is also presented.  
The third chapter starts by giving an introduction and justification, aim and objectives of the first 
experiment of the study. It gives an account of the interrogation of a critical question: can the oral 
administration of S-allyl-cysteine during the neonatal growth stage protect against fructose-
induced metabolic derangements in early life? The chapter gives a detailed description of the 
methodology used to answer the question. The chapter then presents the study findings, that is, 
the effects of oral administration of S-allyl-cysteine on growth performance, markers of 
metabolic dysfunction (blood parameters and hepatic metabolites), visceral organs and surrogate 
markers of liver and kidney function of suckling Wistar rats fed a high-fructose diet. A discussion 
on the significance of the findings and their context in the state of the art are further interrogated 
in the chapter. The fourth chapter which consists of an introduction, material and methods, 
results, discussion, and conclusion reports on the findings of the second experiment and of the 
study. The introduction focuses on a critical analysis of the ‘single-hit’ or ‘double-hit’ hypothesis 
in metabolic programming. The key question that the chapter interrogates is: does neonatal oral 
administration of S-allyl-cysteine protect against high-fructose diet-induced metabolic 
derangements in adulthood? The chapter concludes by discussing the pertinent findings.  
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Chapter five gives a summary of the major findings of the study and draws the attention of the 
reader to the potential applications of the study findings and key conclusions of the study. 
Caveats on study limitations are presented and possible future work is proposed.  
Chapter six provides the list of references cited in the thesis. Also included in this chapter is the 
list of appendices.  
 
1.1 Introduction 
Worldwide there are 600 million obese adults and 42 million children, under the age of five, who 
are overweight (World Health Organisation, 2014). Sedentary lifestyles and the consumption of 
unhealthy western-type diets rich in fats and refined sugars (Pollock et al., 2012), has been 
ascribed as the main driver of the increase in obesity, non-alcoholic fatty liver disease (NAFLD) 
and metabolic syndrome (MetS) (Steyn and Temple, 2012).  
Evidence from human and animal studies shows that the consumption of fructose-rich diets in 
adulthood results in increased lipogenesis, visceral obesity, (NAFLD) and (MetS) (Gao et al., 
2012; Huynh et al., 2008; Basciano et al., 2005; Steyn et al., 2003; Roglans et al., 2002). These 
metabolic derangements are not limited to adults. The consumption of a high-fructose diet during 
early-life (gestation and lactation) increases the risk of developing obesity and insulin resistance 
in adulthood (Alzamendi et al., 2010; Huynh et al., 2008). Apart from fructose, undernutrition 
and or overnutrition during gestation and lactation have also been demonstrated to cause 
epigenetic changes (full definition of epigenetics is provided in chapter 2 under subheading 2.5) 
that may predispose offspring to develop metabolic derangements during adolescence, and 
adulthood (Devaskar and Thamotharan, 2007; Léonhardt et al., 2003).  
The normal development from the germ cell to multicellular organism is characterised by a 
sequence of events that are regulated by genetic instructions that are attained at conception (Patel 
and Srinivasan, 2002). In early critical periods in life, when there is increased plasticity, the 
organism possesses the capacity to physiologically adapt at molecular, biochemical and cellular 
levels to suboptimal stimuli (nutritional and environmental stimuli) (Hanley et al., 2010). These 
physiological adaptations by the organism to suboptimal stimuli in early-life can permanently 
persist throughout life and modify metabolism and consequently increase the susceptibility or 
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resistance of developing metabolic derangements in childhood and adulthood (Fernandez‐Twinn, 
and Ozanne, 2010). The phenomenon whereby offspring have an increased or decreased risk of 
developing systemic dysfunction in early-life (childhood) or in later-life (adulthood) due to 
earlier gestational and neonatal (the early suckling period) dietary events is termed metabolic 
programming (Zambrano et al., 2005; Gluckman, and Hanson, 2004). Diet-induced metabolic 
programming is premised on the “single-hit” and “double-hit” hypotheses. In the single-hit 
hypothesis, an early-life dietary intervention can result in the onset of metabolic derangements or 
can serve as an initiator for the onset of metabolic derangement in later life (Tamashiro and 
Moran, 2010). The “double-hit” hypothesis of metabolic programming is characterised by two 
dietary interventions; one in early-life (first-hit) which then predisposes to the onset of metabolic 
derangements following another dietary intervention in later life (the second-hit) (Stewart et al., 
2013).  
The administration in early-life (gestational and lactation) of substances (pharmacological agents 
and ethnomedicines) that can prevent or treat obesity, insulin and leptin resistance has been 
suggested as a feasible intervention for preventing adverse neonatal metabolic programming that 
predisposes offspring to systemic diseases in adult life (Guilloteau et al., 2009; Vickers et al., 
2005). Despite the existence of conventional antiobesity and antidiabetic pharmacological agents, 
an estimated 70-80% of the global population prefers to use ethnomedicines and specifically 
plants with medicinal properties to prevent, treat and manage systemic ailments (Sponchiado et 
al., 2016; Fyhrquist et al., 2002). The preference for the use of plants in ethnomedical practise is 
based a number of perceived merits: they are regarded as more natural, are claimed to have fewer 
or reduced side effects and thus are deemed safer than conventional pharmacological agents 
(Sehgal et al., 2013; Cameron et al., 2011). Ethnomedicinal plant extracts contain an array of 
biologically and pharmacologically active phytochemicals (organosulphur, polyphenols, 
vitamins, and minerals) which possess antioxidant, antidiabetic, antiobesity, antimicrobial and 
cardioprotective properties (Sandhar et al., 2011). 
Garlic (Allium sativum), a commonly consumed spice, (Eidi et al., 2006) is used in 
ethnomedicine for the treatment of several systemic diseases (Padiya et al., 2011; Shariazadeh et 
al., 2008). The phytochemical constituents of garlic include lipo- and water-soluble 
organosulphur compounds such as ajoene, diallyl sulphate, alliin, ajoene, allicin and S-allyl-
cysteine (Gapter et al., 2008). Garlic’s water soluble sulfur-containing amino acid, S-allyl- 
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cysteine (SAC), is formed when gamma-glutamyl-cysteine is catabolised by gamma-
glutamyltranspeptidase (Lee et al., 2015; Amagase et al., 2001). Studies have shown that SAC 
possess antimicrobial, antithrombotic, antioxidant, hepatoprotective, neuroprotective, 
cardioprotective, gastroprotective, antihyperlipidaemic, anti-cancer, anti-inflammatory, 
antidiabetic and antiobesity properties (Asdaq et al., 2015; Chang et al., 2015; Lee et al., 2015; 
Choi et al., 2014; Atif et al., 2009; Saravanan et al., 2009; Amagase et al., 2001). S-allyl- 
cysteine has been demonstrated to attenuate hyperglycaemia, hypertriglyceridaemia, obesity and 
to improve sensitivity to insulin by tissues in streptozotocin (STZ)-diabetic adult rat models of 
diabetes mellitus (Saravanan et al., 2009).  
 
1.2 Justification of study 
In altricial animals, rats included, neonatal life is characterised by sole dependency on the dam’s 
milk for nourishment. At this stage of life, the animals’ organs and physiological systems are 
immature and there is increased developmental plasticity (Wang et al., 2005). The introduction of 
or consumption of substances (e.g. fructose and or ethnomedicines) can cause the precocious 
maturation of organs and metabolic and physiological systems (Jiang et al., 2001; David et al., 
1995) and consequently neonatal metabolic programming. Most studies on metabolic 
derangements have tended to make use of drug-induced models using adult rats yet the increased 
prevalence of obesity and its (obesity) contribution to a host of metabolic derangements in 
growing children is well documented (Lobstein et al., 2015; Després et al., 2008). This scenario 
calls for the use of neonatal animal models that better mimic the problem at hand. Studies on 
neonatal metabolic programming have largely been indirect whereby the effects of nutritional 
intervention on pregnant and or nursing dams interrogated have been assessed on the offspring 
(Comstock et al., 2013; Vickers et al., 2011) with relatively fewer studies on the direct nutritional 
interventions in neonates, for example, effects of neonatal exposure to high-fructose on the 
metabolic programming of suckling Wistar rats (Huynh et al., 2008). The majority of studies that 
have investigated diet-induced metabolic derangements and potential interventions using rat 
models have mostly generally used male rats (Alzamendi et al., 2010) despite the evidence 
indicating dissimilarities in physiological development between male and female animals and the 
existence sex-specific (dependent) responses to interventions (de Sá Couto-Pereira et al., 2016; 
Ojeda et al., 2016; Pektaş et al., 2015; Rodríguez et al., 2015; Aiken et al., 2013; Mukai et al., 
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2014; Vickers et al., 2011). Therefore studies that use male and female rats are pivotal to the 
elucidation of the underlying physiological mechanisms that result in sexually dimorphic 
metabolic responses in rats and other animals.  
The gastrointestinal tract (GIT) is not only vital for the digestion and absorption of nutrients 
(Zabielski et al., 2008). In early-life, it is involved in regulating the growth and the development 
of the GIT epithelial lining, immune, neural and metabolic systems (Wiedmeier et al., 2011; 
Wang et al., 2005). The oral administration of substances during the neonatal growth stage could 
thus influence digestive and absorptive as well as the regulatory functions of the GIT which could 
lead to epigenetic changes that then can impact on programming for increased susceptibility to 
and or resistance to diet-induced metabolic programming (Zabielski et al., 2008; Pérez et al., 
2007). Altering nutrient availability and absorption and the development of the GIT can affect 
overall growth and epigenetic development of the growing animal (Zabielski et al., 2008; Pérez 
et al., 2007). Neonatal oral administration of a high-fructose diet has been shown to alter the 
expression of glucose transporters in the GIT and genes that regulate metabolism consequently 
resulting in adverse metabolic programming (Huynh et al., 2008; David et al., 1995). 
Fructose is an inexpensive sugar which is used to sweeten processed foods. Its (fructose) 
consumption by infants and children has been increasing rapidly in the past decade (Douard and 
Ferraris, 2013; Basciano et al., 2005). Hence there is a need for research aimed at identifying the 
potential interventions for high-fructose diet-induced neonatal metabolic programming. Despite 
the existence of evidence suggesting that early-life administration of antioxidant, antiobesity and 
antidiabetic substances (pharmaceutical agents and ethnomedicine) has potential to prevent the 
adverse effects of diet-induced neonatal metabolic programming (Vickers et al., 2005), there still 
is a dearth of research aimed at identifying probable antioxidant, antiobesity and antidiabetic 
substances that may prevent the adverse effects of diet-induced neonatal metabolic programming. 
Furthermore, the high global preference for the use of ethnomedicinal plants demands that 
researchers need to investigate the potential of traditional ethnomedicines as probable antiobesity 
and antidiabetic agents (Cameron et al., 2011; Fyhrquist et al., 2002) that may protect against the 
adverse effects of diet-induced neonatal metabolic programming. Garlic, a globally popular spice 
and ethnomedicine, contains bioactive phytochemicals such as allicin, alliin and S-allyl-cysteine 
(SAC) (Amagase, 2006). This multiplicity of phytochemicals with different biological activities 
(further discussed in chapter 2) introduces many uncontrolled variables for the efficacious 
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evaluation of the health benefits of garlic. Thus studies need to focus on a single specific purified 
phytochemicals. The health beneficial biological properties of the garlic-derived phytochemical 
SAC could potentially be used to mitigate the adverse short- and long-term metabolic 
programming effects of neonatal high-fructose diet. However, there still exists a dearth in 
information on the potential of orally administered SAC in suckling rats to protect against the 
development of adverse effects of neonatal high-fructose diet-induced metabolic programming. 
 
1.3 Aims and objectives  
The study was done in two experiments.  
i) The aim of the first experiment was to determine the potential of orally administered SAC to 
protect against the acute development of high-fructose diet-induced metabolic derangements in 
suckling male and female Wistar rat pups modelling human infants consuming high-fructose 
diets.  
The specific objectives of the first experiment of the study were to determine the effects of orally 
administered SAC in fructose-administered neonatal Wistar rats on: 
a) growth performance (body mass and linear growth). 
b) non-fasted random blood glucose, triglyceride and cholesterol concentration. 
c) insulin (a hormone that regulates metabolism) concentration and whole-body insulin 
sensitivity by computing the homoeostasis model assessment of insulin resistance (HOMA-IR 
index). 
d) liver metabolic substrate (glycogen and lipid) storage. 
e) visceral organ macro- and micro-morphometry. 
f) non-alcoholic fatty liver disease score (NAS). 
g) surrogate markers of liver (alanine aminotransferase, alkaline phosphatase, total bilirubin, 
globulin, and albumin) and kidney (creatinine and blood urea nitrogen) function and general 
health. 
ii) The aim of the second experiment of the study was to determine the potential of neonatal 
orally administered SAC to protect against metabolic derangements in adulthood induced by 
either an ‘early single-hit’, ‘late single-hit’ or ‘double-hit’ high-fructose diet.  
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The specific objectives of the second experiment of the study were to determine the effects of 
‘single-hit’ (early in neonates or late in adults) and or ‘double-hit’ (early in neonates and later in 
adulthood) by a high-fructose diet in Wistar rats to which SAC was orally administered during 
the suckling period on: 
a) growth performance (body mass and linear growth). 
b) ability to tolerate an orally administered glucose load. 
c) fasted blood metabolic substrates (glucose, and plasma triglycerides and cholesterol) 
concentration.  
d) insulin (a hormone that regulates metabolism) concentration. 
e) the HOMA-IR index.  
f) liver lipid content. 
g) visceral organ macro- and micro-morphometry. 
h) non-alcoholic fatty liver disease score (NAS).  
i) surrogate biomarkers of liver (alanine aminotransferase and alkaline phosphatase) and kidney 
(creatinine and blood urea nitrogen) function. 
Research has demonstrated that sex influences the development of the organisms’ physiological 
systems which consequently impact on how they respond to dietary interventions (Ojeda et al., 
2016; Sakuma, 2009; Viveros et al., 2009), hence this study also sought to investigate the 
presence of potential sexually dimorphic responses to the experimental interventions. 
 
1.4 Hypothesis 
1.4.1 Experiment one: hypothesis 
H1: Oral neonatal administration of SAC protects suckling male and female Wistar rat pups 
against high-fructose diet-induced metabolic derangements in early-life. 
H0: Oral neonatal administration of SAC does not protect suckling male and female Wistar rat 
pups against high-fructose diet-induced metabolic derangements in early-life. 
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1.4.2 Experiment two: hypothesis 
H1: Oral neonatal administration of SAC protects male and female Wistar rats against the 
development in adulthood of metabolic derangements induced by either neonatal or adult “early 
and late single hit” and or a neonatal followed by adult “double hit” high fructose diet.  
H0: Oral neonatal administration of SAC does not protect adult male and female Wistar rats 
against the development metabolic derangements induced by either neonatal or adult “single hit” 
and or a neonatal followed by adult “double hit” high fructose diet. 
The next chapter (chapter 2) provides a critical analysis of the literature pertinent to the study. In 
summary, the chapter explains and describes the concept of neonatal diet-driven metabolic 
programming and its effects in early and adult life, elucidates current knowledge on obesity, 
NAFLD, MetS, and diabetes mellitus. The health beneficial effects of garlic and SAC are 
described. 
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2.0 Introduction 
The increased consumption of energy dense diets and adoption of sedentary lifestyles has led to 
an upsurge in the prevalence of obesity in children and adults of developed and developing 
countries (Go et al., 2013; Gupta et al., 2012). Obesity has become a global epidemic 
(Katzmarzyk et al., 2015). Statistics by the World Health Organisation (WHO) revealed that 
worldwide more than 1.9 billion adults were overweight and 600 million were obese (WHO, 
2014). In 2010 the prevalence of childhood obesity in Africa was estimated to be 8.5% and 
projected to increase to 12.7% by 2020 (De Onis et al., 2010). Approximately between 5-25% 
African adult males are obese (WHO, 2014). North America and Australia lead the polls with 
approximately more than 25% of the adult males being obese (WHO, 2014; Figure 2.1). The 
WHO estimated that of the adult female population in Southern Africa, greater than 25% are 
obese and this level of prevalence is comparable to that of adult females in the Americas, 
Australia and Europe (WHO, 2004; Figure 2.2). Approximately between 5-20% African children 
are overweight (WHO, 2014). In the Americas region approximately between 5-9.9% of children 
are overweight; in the Eurasia region an estimated 5-20% of children are overweight (WHO, 
2014; Figure 2.3). 
 
Figure 2.1: A schematic representation of the global obesity epidemic in adult (≥ 18 years of 
age) males (WHO, 2014). 
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Figure 2.2: A schematic representation of the global obesity epidemic in adult (≥ 18 years of 
age) females (WHO, 2014).  
 
Figure 2.3: A schematic representation of the global prevalence of overweight children (≤5 
years of age) (WHO, 2014)  
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The World Health organisation notes that obesity is an increase in fat accumulation that could 
result in health complications (WHO, 2014). It (obesity) is generally assessed by computing body 
mass index (BMI) using the equation: BMI = weight (kg) / [height (m)]
 2
. The World Health 
Organisation guidelines state that adults with BMI that is greater than 25 kg/m
2
 are overweight 
and those with BMI that is greater than 30 kg/m
2
 are obese (WHO, 2014). In children BMI varies 
with age and sex, hence BMI cut-off points criteria have been developed for children (Cole et al., 
2000). Obesity reduces life expectancy and increases the risk of developing cardio-metabolic 
diseases such as non-alcoholic fatty liver disease (NAFLD), metabolic syndrome (MetS), type II 
diabetes mellitus (DM II), hypertension and coronary heart disease (Lobstein et al., 2015; 
Després et al., 2008; Weiss et al., 2004).  
 
2.1 High-fructose diet and obesity 
Fructose is an inexpensive monosaccharide naturally found in fruits, vegetables, flowers, and 
honey (Vos and Lavine, 2013). Commercially fructose is produced via the hydrolysis of 
vegetables, fruits and corn (Ouyang et al., 2008; Dwivedi and Raniwala, 1980). Fructose is used 
in the food and beverage industry as a sweetener in carbonated drinks and other sweets (Ouyang 
et al., 2008). The 10-fold increase in fructose consumption in the past four decades has been 
associated with the obesity epidemic (Pollock et al., 2012). The absorption and metabolism of 
fructose differ from that of glucose. Whereas glucose absorption in the jejunum requires glucose 
transporters 2 (GLUT2) and metabolism triggers phosphofructokinase activity in the liver 
(Rutledge and Adeli, 2007), the absorption of fructose in the jejunum is facilitated by glucose 
transporters 5 (GLUT5) and thereafter the fructose is transported to the liver (Sloboda et al., 
2014). In the liver, fructose metabolism does not stimulate phosphofructokinase but rather 
fructokinase activity (Basaranoglu et al., 2013). The latter metabolises it to 3-carbon molecules: 
glyceraldehyde-3-phosphate and dihydroxyacetone phosphate (Vos and Lavine, 2013; Rutledge 
and Adeli, 2007). These 3-carbon molecules are condensed to form triglycerides and free fatty 
acids (Miller and Adeli, 2008). The rate limiting enzyme, phosphofructokinase, inhibits the 
formation of triglycerides from glucose, promotes glycogen formation from glucose and 
stimulates insulin secretion (Vos et al., 2013). Due to the different pathway through which 
fructose is metabolised, its consumption results in increased lipogenesis which elicits the 
development metabolic disturbances such, hyperlipidaemia, hyperglycaemia, glucose intolerance, 
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hyperinsulinemia, insulin resistance, obesity and ultimately MetS and NAFLD (Mamikutty et al., 
2015; Song et al., 2012; Basciano et al., 2005). 
 
2.2 Non-alcoholic fatty liver disease  
Obesity has been identified as the main risk factor to increased prevalence of NAFLD in children 
and adults (Nomura and Yamanouchi, 2012; Roya and Parinaz, 2011). It is estimated that 30% of 
adults from developed countries have NAFLD (Gaggini et al., 2013). The prevalence of NAFLD 
in children in the USA aged 15-19 was 17.3% in 2011 (Roya and Parinaz, 2011). Non-alcoholic 
fatty liver disease, the commonest cause of liver disease in children, is a condition where hepatic 
lipid accumulation occurs without excessive alcohol consumption (Denzer, 2013). Non-alcoholic 
fatty liver disease is associated with increased serum activity of alanine aminotransferase (ALT) 
and amino aspartate (AST) (Ouyang et al., 2008) and increased risk of developing metabolic 
derangements including insulin resistance, hyperinsulinemia, DM II and MetS (Gaggini et al., 
2013). If not managed, NAFLD progresses to non-alcoholic steatohepatitis (NASH), a condition 
characterised by hepatic inflammation (Kleiner et al., 2005). Non-alcoholic steatohepatitis can 
result in cirrhosis leading to liver failure (Tappy and Lê, 2012). Histologically, NAFLD can be 
diagnosed and scored using the NAFLD activity score (NAS) or Brunt’s criteria of steatosis 
(Kleiner et al., 2005; Brunt et al., 1999).  
 
2.3 Metabolic syndrome 
While the International Diabetes Federation (IDF) estimates that globally 25% of the adults have 
MetS, globally approximately 4.2% of adolescent children have MetS (Crespo et al., 2007). 
Metabolic syndrome (MetS) is defined as a cocktail of risk factors that increase the risk of 
developing type II diabetes mellitus and cardiovascular complications (Peeters et al., 2014). The 
cocktail of risk factors for MetS include hyperglycaemia, insulin resistance, general obesity 
(determined by BMI and waist and hip circumference), visceral obesity, atherogenic 
dyslipidaemia, and hypertension (Malin et al., 2014). Increased visceral adiposity stimulates the 
production of pro-inflammatory cytokines: tumour necrosis factor-alpha (TNF-α), interleukin-1 
(IL-1), interleukin-6 (IL-6) (Wang et al., 2013). This build-up of adiposity also stimulates the 
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release of C-reactive proteins (Wang et al., 2013). Pro-inflammatory cytokines suppress the 
formation of GLUT-4 receptors and inhibit insulin receptor substrate-1 signalling pathway and 
thus resulting in hyperglycaemia and insulin resistance (Cruz et al., 2013). Hyperglycaemia and 
insulin resistance result in increased blood non-esterified fatty acids and consequently 
atherogenic dyslipidaemia (Arunkumar et al., 2012). A combination of elevated blood 
triglycerides, low-density lipoprotein and decreased high-density lipoprotein cholesterol (HDL-
C) is termed atherogenic dyslipidaemia (Peer et al., 2013; Yiyong and Shaobin, 2012). The latter 
is associated with the development of cardiovascular diseases (Esenabhalu et al., 2015; Navarro-
Millán et al., 2015). Atherogenic dyslipidaemia also stimulates increased oxidant production 
(Navarro-Millán et al., 2015). Increased oxidant production causes oxidative damage to cells, 
DNA and mitochondria resulting in the inflammation of various organs such as blood vessels and 
the pancreas (Navarro-Millán et al., 2015; Rashid and Sil, 2015). While oxidant-induced 
inflammation of the pancreas results in reduced pancreatic β-cell density and subsequently 
reduced insulin production, inflammation of the blood vessels results in non-compliance and 
hypertension (Kal et al., 2016; Shen et al., 2013). An increase in inflammatory cytokines 
combined with atherogenic dyslipidaemia, hyperglycaemia, and insulin resistance can lead to the 
onset type II diabetes mellitus (DM II) and its associated complications (LaRosa et al., 2013; 
Matsuda and Shimomurab, 2013). 
 
2.4 Diabetes mellitus 
Diabetes mellitus (DM) refers to a group of metabolic conditions that are mainly characterised by 
hyperglycaemia. Three sub-types of DM exist: type I diabetes mellitus (DM I), type II diabetes 
mellitus (DM II) and gestational diabetes mellitus. Type I diabetes mellitus results from the 
failure of pancreatic β-cells to secrete insulin but DM II occurs as a consequence of tissue 
insensitivity to the stimulatory effects of insulin (Kubo et al., 2016; Hompesch et al., 2015). 
Gestational DM occurs during pregnancy due to tissues’ inability to respond to insulin (Mader et 
al., 2016). Tissue insensitivity to insulin and or failure of pancreatic β-cells to secrete 
physiologically adequate quantities of insulin results in the derangement of blood glucose 
homoeostasis. An oral glucose tolerance test (OGTT) assesses the ability to appropriately respond 
to an oral glucose load. The OGTT is used to screen for diabetes mellitus and pre-diabetes 
mellitus (Hage et al., 2013). The inability to respond appropriately to a glucose load is associated 
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with insulin resistance (Fan et al., 2015). Diabetes mellitus is associated with the development of 
various complications such micro- and macro-vascular damage, organ failure, ischemic heart 
disease, hypertension, and strokes (Varadarajan et al., 2015).  
Research evidence suggests that the GIT can play a significant role in the aetiology of metabolic 
derangements such as obesity and diabetes mellitus (El Aidy et al., 2015; Kootte et al., 2012; 
Rubino et al., 2010). The digestive activity in the small intestine accounts for the digestion and 
absorption of 90% of macro- and micro-nutrients (Grant et al., 2015); the large intestine largely 
absorbs water and water soluble vitamins produced by colon resident bacteria (Middendorp et al., 
2014). Orally consumed substances can alter the GIT’s gut microbiota ecosystem which can 
cause adverse or beneficial effects on the regulation of metabolism and digestion and absorption 
of nutrients and can subsequently lead to the development of metabolic derangements (Nitin et 
al., 2016; Moreno-Indias et al., 2015; Kootte et al., 2012). Prenatal and early-postnatal dietary 
interventions can cause precocious (structural and functional) maturation (including increased 
lengths and masses) of small and large intestines which translate into accelerated GIT 
development (He et al., 2013). An increase in the length and masses of the small and large 
intestines can result in increased digestion and absorption of nutrients (Tatara et al., 2005) which 
could lead to increased risk and the predisposition to metabolic dysfunctions (De Wit et al., 2008; 
Nir et al., 1978). Gastrointestinal stimulated satiety has been shown to decrease in obese 
individuals (Delgado-Aros et al., 2004) and thus further alluding to the importance of the GIT 
(function and development) in the pathogenesis of metabolic disturbances such as obesity and 
DM. Nevertheless, the influence of neonatal dietary interventions on the function and 
development of the GIT and the potential subsequent onset of metabolic derangements such as 
obesity, NAFLD, MetS and DM II in childhood and adulthood still require further exploration.  
 
2.5 Metabolic programming 
Metabolic programming refers to a phenomenon whereby ‘deficit’ and or ‘surplus’ nutritional 
exposure during ‘critical’ periods of early-life (antenatal and suckling) when there is increased 
pliability results in epigenetic changes (Dearden et al., 2015). Epigenetic changes refer to 
alterations that occur in the genome, without altering the genetic code, due to exposure to specific 
dietary or environment interventions (Fernandez-Twinn et al., 2015). The epigenetic changes in 
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early-life can result in permanent alteration in molecular, cellular and physiological function that 
result in ‘thrifty phenotypes’ with increased susceptibility to developing metabolic complications 
in early (childhood) and or later (adulthood) life (Ong and Ozanne, 2015; Penfold and Ozanne, 
2015; Dunn et al., 2009). Dietary interventions in early-life have been shown to determine the 
resulting phenotype epigenetically by modifying DNA methylation, histones and non-coding 
RNAs (Wang, 2013; Sohi et al., 2011). For example, the consumption of protein restricted diets, 
calorie restricted diets, high-energy diets or high-fructose diets during gestation and lactation can 
down- or up-regulate liver genes involved in the regulation of glucose and lipid metabolism 
(Burgueño et al., 2013). Alteration of metabolic regulatory genes can then result in the 
development of obesity, peripheral insulin resistance and hyperleptinemia in the various 
developmental stages of life (Burgueño et al., 2013; Huynh et al., 2008; Devaskar and 
Thamotharan, 2007; Palinski and Napoli, 2002). Researchers have developed a variety of animal 
models for studying nutritional interventions in early-life that result in adverse metabolic 
programming (Burgueño et al., 2013; Elahi et al., 2009; Desai et al., 2004). Despite the existence 
of various models for studying metabolic programming, most of them have focused on the effects 
of early-life (gestation) dietary maternal intervention models of metabolic programming (Oliveira 
et al., 2015; Bhasin et al., 2009; Desai et al., 2004). Rarely have studies focused on the effects of 
dietary interventions in neonates during suckling on metabolic programming. 
 
2.5.1 Models of metabolic programming 
Numerous models of dietary- and chemically-induced metabolic programming have been 
established (Oliveira et al., 2015; Burgueño et al., 2013; Bhasin et al., 2009; Elahi et al., 2009; 
Zhang et al., 2009). 
  
2.5.1.1 Diet-induced models of metabolic programming 
Diet-induced models of metabolic programming are established through prenatal and early-
postnatal exposure to overnutrition or undernutrition (Oliveira et al., 2015; Burgueño et al., 2013; 
Bhasin et al., 2009; Elahi et al., 2009). These models are appropriate for investigating the 
metabolic programming effects of various suboptimal dietary stimuli. Undernutrition models of 
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metabolic programming are induced by restricting dietary caloric intake or protein intake during 
prenatal and early-postnatal life (Bhasin et al., 2013; Desai et al., 2004). The overnutrition 
models of metabolic programming are induced by prenatal and early-postnatal consumption of 
diets that are high in fat, cholesterol, carbohydrates, sucrose or fructose (Pruis et al., 2014; Plosch 
et al., 2014; Alzamendi et al., 2010; Huynh et al., 2008).  
 
2.5.1.2 Chemically-induced models of metabolic programming 
Chemically-induced models of metabolic programming are developed by inducing maternal 
diabetes using STZ prior to insemination (Oliveira et al., 2015). Such a chemically-induced 
model of metabolic programming is suitable for investigating the adverse metabolic 
programming effects of gestational diabetes on the resultant offspring (Oliveira et al., 2015).  
The various models of diet- and or chemical-induced metabolic programming are summarised in 
the Tables 2.1 to 2.4 below.  
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Table 2.1: Maternal dietary-insufficiency models of metabolic programming 
Species and exposure  Offspring neonatal metabolic 
disturbances 
Offspring adulthood 
dietary exposure 
Offspring adult metabolic 
disturbance(s) 
 Sprague-Dawley rats 
 Calorie restriction during 
gestation (Desai et al., 
2004) 
  ↓ birth weight  
  Delayed catch-up growth 
  ↑ ghrelin 
  ↓ leptin 
 Normal rat chow   ↑ caloric intake 
  ↑ bodyweight, 
  ↑ body fat 
  ↑ leptin 
  Leptin resistance  
  Hyperphagia 
 C57bl/6 mice  
 Protein restriction during 
gestation (Ozanne et al., 
2004) 
  ↓ birth weight  
  ↑ catch-up growth/obesity 
 Highly palatable diet  Obesity 
 ↓ telomere length 
 ↓ longevity  
 C57BL/6J mice 
 Protein restriction during 
gestation (Bhasin et al., 
2009) 
  ↓ essential amino acids 
  ↓ birth weight 
 Normal rat chow  ↑ catch-up growth/obesity 
 Obesity  
 Glucose intolerance 
↓ = decreased; ↑ = increased 
  
20 
 
Table 2.2: Maternal chemical-induced models of metabolic programming 
Species and exposure  Offspring adulthood dietary 
exposure 
Offspring adult metabolic disturbance(s) 
 Wistar rats 
 Diabetes induced by STZ 
administered to 5-day old female 
rats and then fed standard rat 
chow to adulthood and then 
mated (Oliveira et al., 2015) 
 Standard rat chow   ↑ bodyweight, 
 Obesity 
 ↑ diameter of adipocytes 
 ↑ insulin receptor protein  
 ↑ basal insulin 
 ↑ insulin-stimulated glucose uptake by adipose tissue  
 ↑ GLUT4 protein  
 ↑ acetyl-CoA carboxylase protein 
↓ = decreased; ↑ = increased 
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Table 2.3: Maternal dietary-surplus models of metabolic programming 
Species and exposure  Offspring neonatal 
metabolic disturbances 
Offspring adulthood 
dietary exposure 
Offspring adult metabolic 
disturbance(s) 
 C57BL/6J mice 
 Maternal palatable obesogenic 
diet (16% fat and 33% sugar) 
during gestation and lactation 
(Samuelsson et al., 2008) 
 
 ↑ birth weight 
 ↑ weaning weight 
 
 
 
  Standard rat chow  ↑ caloric intake 
 ↑ abdominal fat pad mass 
 ↑ adipocyte diameter  
 ↑ plasma triglyceride 
 Hyperleptinaemia 
 Hyperinsulinemia 
 Hypercholesterolemia 
 Hypertension  
 Glucose intolerance 
 Wistar rats; C57BL/6J mice 
 High-fat diet during gestation and 
lactation (Burgueño et al., 2013; 
Elahi et al., 2009) 
   High-fat diet  Insulin resistance  
 ↑ abdominal fat pad 
 ↑ serum leptin 
 ↑ hepatic lipid 
 Wistar rats 
 High-fat diet 6 weeks before 
gestation till the end lactation 
(Férézou-Viala et al., 2007) 
 ↓ weaning body mass   High-fat diet   ↑ body mass 
  Hyperinsulinemia 
  Hyperleptinaemia  
  Leptin resistance  
 LDL receptor–deficient mice 
 High-fat, high-cholesterol diet 
 ↓birth weight   Standard rat chow   ↑ body mass 
  Aortic atherosclerosis 
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(Napoli et al., 2002) 
 C57BL/6J mice 
 High-cholesterol diet (Bhasin et 
al., 2009) 
  Western diet (high-fat 
diet with moderate 
cholesterol) 
 Atherosclerosis 
 Hypercholesterolemia  
 C57BL/6J mice 
 Western-style diet during 
gestation and lactation (Pruis et 
al., 2014; Plosch et al., 2014) 
  Western-style diet  Hepatomegaly  
 ↑hepatic cholesterol 
 ↑hepatic triglycerides. ↑lipogenesis 
 Steatohepatitis 
 ↑ hepatic inflammation  
 ↑hepatic transaminases activity  
 Wistar rats 
 High-sucrose diet during 
gestation and lactation 
(D'Alessandro et al., 2012)  
 ↓birth weight  High-sucrose diet  ↑ plasma and hepatic triglycerides 
 Glucose tolerance 
 Insulin resistance 
 Sprague-Dawley rats 
 Palatable diet during gestation 
and lactation (Bocarsly et al., 
2012) 
 
   ↑ body mass 
 ↑ plasma triglycerides 
 ↑ alcohol consumption 
 Wistar rats 
 High-fructose (20% fructose 
solution) during gestation until 
 ↑ birth weights 
 Hyperglycaemia  
 ↑ hepatic triglycerides 
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postnatal day 10 (Clayton et al., 
2015; Vickers et al., 2011)  
 ↑non-esterified free 
fatty acid 
 ↑ALP 
 ↓ hepatic fructokinase 
mRNA 
 ↑ GLUT5 transporter 
mRNA 
 ↓ lipoprotein lipase 
(LPL) RNA  
 ↓ liver glycogen in 
males  
 ↑ liver glycogen in 
females  
 Sprague-Dawley rats 
 High-fructose (10% fructose 
solution) during gestation 
(Rodríguez et al., 2013) 
 
 Hypotriglyceridaemia  
 ↑ hepatic triglyceride 
and hepatic steatosis 
 Hyperleptinaemia 
 ↓ leptin resistance 
 ↑ lipogenic genes  
  
 Sprague-Dawley rats 
 High-fructose diet from 4-weeks 
of age, during gestation and 
  High-fructose diet  Hypercholesterolemia 
 ↑ serum triglycerides 
 ↑ serum free fatty acids 
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lactation (Ching et al., 2011)  ↑ hepatic triglycerides 
 ↑ hepatic free fatty acids 
 ↑ hepatic lipid 
 Sprague-Dawley rats 
 High-fructose, high-fat diet from 
4-weeks of age, during gestation 
and lactation (Chen et al., 2010) 
 ↑ liver mass  Standard rat diet  ↑ abdominal fat  
 Hyperinsulinemia  
 Insulin resistance 
 Sprague-Dawley rats 
 High-fructose diet during 
lactation (Alzamendi et al., 2010) 
  Standard rat diet  ↑ body mass and 
 ↑ adipocyte diameter 
 ↑ caloric intake  
  Hyperinsulinemia  
  Insulin resistance 
  Hyperleptinaemia  
  Leptin resistance 
↓ = decreased; ↑ = increased 
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Table 2.4: Neonatal dietary-surplus models of metabolic programming 
Species and neonatal exposure Adulthood dietary exposure Adulthood metabolic disturbance(s) 
 Sprague-Dawley rats 
  High-fat diet from 2 to 21 days old 
(Haney et al., 1986) 
 Standard rat chow from 21 to 31 days old  Hyperglycaemia 
 Hyperinsulinemia  
 Sprague-Dawley rats 
  High-carbohydrate diet from 2 to 21 
days old (Haney et al., 1986) 
 Standard rat chow from 21 to 31 days old  Hyperglycaemia 
 Hyperinsulinemia  
 Sprague-Dawley rats 
 High-carbohydrate diet from 4 to 24 
days old (Vadlamudi et al., 1995) 
 Standard rat chow from 24 to 60 days old  Obesity 
 Pancreatic β-cell hypertrophy  
 Hyperinsulinemia 
 Obesity 
 ↑hepatic lipogenic capacity 
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 Sprague-Dawley rats 
 High-carbohydrate diet from 4 to 24 
days old (Hiremagalur et al., 1993) 
 Standard rat chow from 24 to 55 days old  Obesity 
 ↑ adipocyte diameter  
 ↑fatty acid synthase  
 ↑glucose-6-phosphate dehydrogenase) 
 Hyperinsulinemia 
 Sprague-Dawley rats 
 High-carbohydrate diet from 4 to 24 
days old (Petrik et al., 2001) 
 None (rats euthanised when they were 24-
days old) 
 Endocrine pancreatic apoptosis. 
 ↓pancreatic islet size and density 
 Sprague-Dawley rats 
 High-carbohydrate diet from 4 to 24 
days old (Srinivasan et al., 2008; 
Srinivasan et al., 2003a) 
 Standard rat chow from 24 to 100 days 
old 
 Hyperphagia 
 Obesity  
 Hyperinsulinaemia 
 ↓hypothalamic insulin and leptin 
receptor  
 Sprague-Dawley rats 
 High-fructose diet (10% fructose 
solution) from 12 to 19 days old 
(Huynh et al., 2008) 
 High-fructose diet (65% in Standard rat 
diet) from 8-11 weeks of age 
 ↑ bodyweight 
 Hyperinsulinemia 
 ↑ skeletal fatty acid uptake 
 Increased epididymal fat mass  
↓ = decreased; ↑ = increased 
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The majority of recent studies investigating metabolic programming have focused on the effects 
of maternal dietary exposure during gestation and lactation on offspring (Oliveira et al., 2015; 
Bhasin et al., 2009; Desai et al., 2004). However, most of the recent studies have scarcely 
interrogated the effects of neonatal dietary exposure during suckling on the metabolic 
programming of adverse short- and long-term metabolic outcomes (Huynh et al., 2008; Petrik et 
al., 2001). This is despite the availability of data showing that neonatal dietary manipulations, 
when there is increased developmental plasticity, can programme adverse short- and long-term 
metabolic outcomes (Huynh et al., 2008; Petrik et al., 2001). The little amount of research on 
neonatal models of diet-induced metabolic programming has under investigated the potential of 
ethnomedicinal interventions in preventing or treating the short- and long-term metabolic 
outcomes induced by metabolic programming. 
 
2.5.2 Interventions for adverse metabolic programming  
Numerous studies endorse the administration in early-life (gestational and lactation) of 
antiobesity and antidiabetic substances (pharmacological agents and ethnomedicines) as possible 
interventions for preventing, treating and managing neonatal metabolic programming and its 
adverse outcomes (Desai et al., 2013; Li et al., 2013; Li et al., 2012; Ching et al., 2011; Barbalho 
et al., 2011; Elahi et al., 2008; Vickers et al., 2005). Li and colleagues (2013) demonstrated that 
taurine supplementation in the obesogenic diet (high-fat and high-fructose) fed mothers during 
gestation and lactation attenuated the offspring’s hepatic expression of inflammatory cytokines. 
Oral administration of bitter melon to high-fructose fed litter mother’s diet during gestation and 
lactation attenuated hypercholesterolemia and hypertriglyceridemia and increased antioxidant 
activity in the liver in the offspring (Ching et al., 2011). In a high-cholesterol maternal diet 
model, maternal administration of statin during late pregnancy attenuated hypercholesterolemia 
and hypertension in the resulting offspring (Elahi et al., 2008). Li et al. (2012) reported that the 
administration of green tea stem extract to high-fat diet fed litter mothers during gestation and 
lactation mitigated insulin resistance in the resulting offspring. “Prevention is better than cure” 
hence the increased emergence in research devoted to searching for prospective interventions 
aimed at preventing neonatal metabolic programming and its adverse outcomes such as obesity, 
NAFLD, MetS and DM II. A wide range of antiobesity and antidiabetic pharmacological agents 
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that can be used to prevent neonatal metabolic programming and its adverse outcomes exist 
(Elahi et al., 2008; Vickers et al., 2005). Nevertheless, the majority of the global population 
consider natural plant-derived ethnomedicines to not cause any adverse side effects to the body 
(Sehgal et al., 2013; WHO, 2013) and thus prefer the use of natural plant-source-derived 
ethnomedicines to prevent and or treat various ailments including metabolic disturbances 
(Sponchiado et al., 2016). The use of ethnomedicines by societies of both the developed and 
developing countries continues to expand (Burton et al., 2015; WHO, 2013). The expansion in 
the use of ethnomedicines is largely transmitted through ‘folk referral’ and in most of the cases 
without and or inadequate scientific validation (Burton et al., 2015). There is, therefore, a critical 
need to determine, using controlled experiments, the biological, medicinal, and toxicity activity 
of these ethnomedicines. Such an approach is pivotal for the advancements of ethnomedicinal 
knowledge systems, their efficacy and safe use. 
Garlic is one of the many plants used in ethnomedicine. It contains bioactive phytochemicals 
whose potential to prevent, treat and or manage negative outcomes of diet-induced metabolic 
programming still requires further scrutiny.  
 
2.6 Garlic (Allium sativum) 
The medicinal and nutritional uses of garlic have been documented in Egypt as early as 1500 BC 
(Rivlin, 2001). Garlic (Allium sativum) is commonly used as a spice worldwide (Eidi et al., 2006). 
Importantly it is also used an ethnomedicine and over the counter lipid-lowering supplement (Tsai 
et al., 2012; Hoshino et al., 2001).  
 
2.6.1 Botanical description 
Garlic is a bulbous plant that has flat grass-like leaves which are long and narrow (Kamenetsky 
and Rabinowitch, 2001). Its stalk grows from the bulb and produces spherically arranged white 
flowers that contain bulbis (seeds) covered by spathae, at the tip (Meyers, 2006). A bulb of garlic 
is made of bulblet (cloves) enveloped by a white membranous scales (Foster and Duke, 2000).   
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2.6.2 Taxonomical classification 
Allium sativum belongs to the Kingdom Plantae, Class Magnoliopsida, Order Asparagales, 
Family Amaryllidaceae, Subfamily Allioideae, Genus Allium, Species sativum. 
 
2.6.3 Ethnomedicinal uses of garlic 
The use of various garlic preparations dates back as far 1000 BC (Eidi et al., 2006). Garlic has 
been used as traditional ethnomedicine to treat gastrointestinal, cardiovascular, infectious, and 
metabolic diseases and male infertility (Bayan et al., 2014; Rohner et al., 2015; Balamash et al., 
2012; Ma et al., 2012; Eidi et al., 2006). The various garlic preparations used as ehtnomedicines 
include garlic powder, garlic oil, aqueous and solvent extracts of raw or dried garlic and aged 
garlic extracts (AGE). The latter (AGE) are prepared by steeping sliced raw garlic in hydro-
ethanol for 20 months and then dried for 72 hours between 68-72ºC (Park et al., 2009; Ahmad 
and Ahmed, 2006).  
 
2.6.4 Pharmacological activities of garlic preparations 
The consumption of garlic has the potential to positively or negatively affect GIT morphometry, 
functionality, and development. Research by Hoshino et al. (2001) showed that orally consumed 
garlic powder caused damage to epithelial cells in the small intestines of male dogs. In vitro 
studies have reported that garlic has antimicrobial effects against fungi and bacteria (Eja et al., 
2007; Iwalokun et al., 2004). Microbes are well-known for being pathogenic, however, some 
form gut flora. Gut flora is important in protection against pathogens, nutrient processing, 
stimulation and modulation of intestinal immune response and regulation of host fat storage 
(Filocamo et al., 2012). Garlic has been shown to inhibit adverse gut flora and promote the 
growth of beneficial gut flora (Filocamo et al., 2012; Ross et al., 2001). Supplementing broiler 
chicken feed with 0.5% garlic powder (w/w) resulted in improved digestion and absorption of 
nutrients in the GIT and the growth performance of the birds (Ramiah et al., 2014).The improved 
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broiler chicken growth performance was ascribed to the garlic-mediated inhibition of microbial 
pathogens that reduce the efficiency of digestion and absorption (Ramiah et al., 2014). In vivo 
studies done using rats have revealed that in the small intestines garlic inhibits glucose and 
cholesterol absorption and cholesterol synthesis (Belemkar et al., 2013; Mohammadi et al., 2013) 
and thus making garlic a potential antidiabetic and antihyperlipidaemic agent.  
Garlic extracts attenuate hyperglycaemia, glucose intolerance, dyslipidaemia, proteinuria and 
reactive oxygen species in streptozotocin (STZ)-induced diabetic rats (Islam and Choi, 2008; Liu 
et al., 2006; Anwar and Meki, 2003). Thomson et al. (2016) noted that intraperitoneally 
administered aged garlic extracts (AGE) at 300 mg/kg body mass per day or 600 mg/kg body 
mass per day for 8 weeks attenuated hyperglycaemia, dyslipidaemia, TBARS and oxidant-
induced organ (kidney and liver) damage in STZ-diabetic rats. Eidi et al. (2006) demonstrated 
that ethanolic garlic extracts ameliorated hyperglycaemia, hypercholesterolemia, 
hypertriglyceridaemia and blood urea, uric acid, creatinine, aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) in STZ-diabetic rats. Aged garlic powder has been reported to 
increase insulin and reduce fasting blood glucose and glycated haemoglobin concentrations in 3 
week-old leptin receptor deficient mice (Seo et al., 2009). Glycation is a common complication 
associated with in diabetes mellitus which exacerbates oxidant stress, neuro- and retino-pathy and 
organ damage (Singh et al., 2014). The administration of 3000 mg/kg body mass per day of AGE 
for 3 months to DM II patients was shown to reduce serum triglycerides and lipid hydroperoxide 
concentrations (Balamash et al., 2012). Work done by Gómez-Arbeláez et al. (2013) 
demonstrated that the administration of 1.2 g per day of AGE for 2 months to patients diagnosed 
with MetS increased the concentration of plasma adiponectin proteins, which (adiponectin) 
regulate glucose and lipid metabolism. In a clinical study, it was noted that DM II patients that 
were treated with a combination of metformin, a conventional drug used to treat DM and garlic 
tablets for 24 weeks had significantly greater anti-hyperlipidaemic and anti-hyperglycaemic 
states compared to DM II patients that received only metformin (Ashraf et al., 2005). Clinical 
researchers have recommended the addition of garlic to standard DM II treatment regimens as 
this results in reduced risk of developing diabetic-related cardiovascular complications (Ried et 
al., 2016; Naser, 2015; Ahmadi et al., 2013; Gómez-Arbeláez et al., 2013; Ried et al., 2013; 
Sobenin et al., 2008). In vitro and in vivo research validates and affirms the traditional and 
clinical use of garlic as an antidiabetic and antiobesity ethnomedicine. Additionally, animal and 
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human studies have confirmed that garlic reduces cardiovascular complications associated with 
obesity, MetS and DM II (Ried et al., 2016; Naser, 2015; Ahmad and Ahmed, 2006). The 
biological mechanisms by which garlic exerts its prophylactic and therapeutic effects are ascribed 
to it possessing phytochemicals that have antidiabetic, antiobesity, antioxidant and insulinotropic 
properties (Islam and Choi, 2008; Ahmad and Ahmed, 2006; Ashraf et al., 2005; Eidi et al., 
2005; Brace, 2002).  
  
2.6.5 Phytochemical constituents of garlic 
The main phytochemical constituents of garlic include water- and lipid- soluble organosulphur 
compounds such as ajoene, diallyl polysulfides, vinyldithiins, allicin, alliin and S-allyl-cysteine 
(SAC). Other phytochemical constituents of garlic include phenols (flavonoids, saponins, and 
tannins) and sterols (Kim et al., 2013; Berginc et al., 2010; Bakri and Douglas, 2005; Borek, 
2001). 
 
2.6.5.1 Allicin  
Allicin is a lipo-soluble organosulphur that was first isolated and identified in 1944 (Cavallito 
and Bailey, 1944) and is formed from the lysis of γ-glutamylcystein peptide, alliin (S-allyl-L-
cysteine-sulphoxide), by enzymes alliinase (Ankri and Mirelman, 1999). In the past, the majority 
of studies credited allicin as the primary phytochemical that bestowed on garlic its therapeutic 
properties (Amagase, 2006). However, recently studies have suggested that allicin is: unstable, 
responsible for ‘garlic breath,’ can cause adverse effects to the gastrointestinal tract lumen and 
has low bioavailability (Amagase, 2006; Freeman et al., 1995). These findings have propelled 
investigations on the therapeutic effects of other organosulphur phytochemicals that are found in 
garlic such as s-allyl-cysteine (SAC). The focus for the rest of the review will be on SAC which 
was used in this study. 
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2.6.5.2 S-allyl-cysteine 
The water-soluble, sulphur containing amino acid, SAC is formed from the hydrolysis of γ-
glutamyl-S-allyl and is found in abundance in aged garlic (Ray et al., 2011; Krause et al., 2002). 
S-allyl-cysteine has high bioavailability (103% mice and 98.2% in rats) and is the least toxic of 
the organosulphur compounds found in garlic (Amagase, 2006; Amagase et al., 2001; Nagae et 
al., 1994). It (SAC) has been shown to possess various health beneficial biological activities 
including anticancer, antioxidant, antihyperlipidaemic and antidiabetic activity (Asdaq et al., 
2015; Chang et al., 2015; Lee et al., 2015; Choi et al., 2014) and these activities are credited for 
SAC’s protective effects on various organs of the body.  
 
2.6.5.2.1 Antidiabetic activity of S-allyl-cysteine  
Hyperglycaemia, insulin resistance, and increased glycation are common features of obesity, 
NAFLD, MetS and DM II (Saravanan et al., 2010). These features are the key targets for most 
conventional pharmaceutical drugs and ethnomedicines that are used to prevent, manage or treat 
obesity, NAFLD, MetS and DM II. In an in vivo study, 150 mg/kg SAC attenuated 
hyperglycaemia in adult STZ-diabetic Wistar rats by increasing insulin, leptin, adiponectin, 
thyroid hormone concentrations and upregulating the activity of non-enzymatic and enzymatic 
antioxidants (Saravanan et al.,2013; Saravanan and Ponmurugan, 2013; Saravanan and 
Ponmurugan, 2012b; Saravanan and Ponmurugan, 2010). Saravanan et al. (2009) reported that 
the administration of S-allyl-cysteine at doses 100 mg/kg
 
and 150 mg/kg body mass for 45 days 
in STZ-induced diabetic adult Wistar rats ameliorated hyperglycaemia, hypoinsulinaemia and 
glycosylated haemoglobin. The observed antidiabetic activities of SAC were hypothesised to be 
due to its ability to inhibit gluconeogenesis by the liver and glucose absorption in the GIT, 
stimulate insulin secretion by pancreatic β-cells and increase tissue sensitivity to insulin (Iliya et 
al., 2016a; Saravanan et al., 2009). In vitro and in vivo research showed that SAC impedes the 
formation of glycation end products by inhibiting substrates and enzymes that mediate the 
formation of glycation products (Iliya et al., 2016b; Saravanan et al., 2010; Ahmad et al., 2007).  
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2.6.5.2.2 Antihyperlipidaemic activity of S-allyl-cysteine  
An increased concentration of lipids (triglycerides, cholesterols, and low-density lipoprotein) in 
blood is termed hyperlipidaemia. Hyperlipidaemia is a common component of metabolic 
conditions such as NAFLD, MetS and DM II and plays a pivotal role in the pathogenesis of 
metabolic derangements. In in vitro studies, SAC was demonstrated to inhibit cholesterol and 
free fatty acid synthesis and intracellularly it decreased triacylglycerol concentration, glycerol-3-
phosphate dehydrogenase (GPDH) activity, down-regulate adipogenic genes expression and 
increased adiponectin production in cultured liver cells and 3T3-L1 adipocytes cell lines (Chang 
et al., 2015; Lui and Yeh, 2001). Findings by Chang and colleagues (2015) demonstrated that 
SAC inhibited lipogenesis in 3T3-L1 adipocytes by upregulating genes that that promote fatty 
acid beta-oxidation. In vitro work by Hwang and colleagues (2013) revealed that SAC inhibited 
lipogenesis in steatotic HepG2 cell lines by activating AMP-activated protein kinase (AMPK) 
and suppressing sterol regulatory element binding protein-1 (SREBP-1) induced lipogenesis. The 
oral administration of 13.1 mg/kg and 32.76 mg/kg SAC ameliorated hypertriglyceridaemia and 
hypercholesterolemia and reduced plasma LDL concentrations in adult female Sprague-Dawley 
rats that were fed high-fat diet for 5 days (Asdaq, 2015). Asdaq (2015) suggested that SAC 
exerted its therapeutic effects by deactivating 3-hydroxy-3-methylglutaryl-CoA and increasing 
the activity of lecithin-cholesterol acyltransferase (LCAT) and thus creating conditions that 
favour lipid hydrolysis. Saravanan and Ponmurugan, (2012a) reported that SAC (150 mg/kg) 
demonstrated antihyperlipidaemic properties in STZ-diabetic adult Wistar rats. The mechanism 
by which SAC exerted antihyperlipidaemic properties included increasing insulin secretion and 
sensitivity and thus increasing cholesterol clearance and decreasing LDL (Saravanan and 
Ponmurugan, 2012a). The administration of SAC (0.45% in diet) was observed to attenuate 
hypertriglyceridaemia and hypercholesterolemia in non-alcoholic fatty liver diseased Otsuka 
Long-Evans Tokushima male rats by upregulating hepatic proliferator-activated receptors alpha 
and gamma (Takemura et al., 2013).  
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2.6.5.2.3 Antioxidant activity of S-allyl-cysteine  
Oxidative stress, an imbalance between free radical production and the body’s capacity to 
eliminate their adverse effects, is a common feature in various metabolic disturbances such as 
obesity, NAFLD, MetS and DM II and can result in tissue, organ damage and disturbance of 
various homeostatic systems (Schaffer et al., 2012). Orally administered SAC attenuates elevated 
blood markers of antioxidant stress: malondialdehyde, glutathione peroxidase enzyme activity, 
total glutathione and oxidised glutathione in serum and thiobarbituric acid reactive species in 
adult female Sprague-Dawley rats that were fed high-fat diet for 5 days (Asdaq, 2015) suggesting 
that SAC could potentially be used as intervention for protecting against oxidant-induced cellular 
damage and its negative consequent complications.  
 
2.6.5.2.4 Cardioprotective activity of S-allyl-cysteine  
Obesity, NAFLD, MetS and DM II are associated with the development of cardiovascular 
diseases such as hypertension and coronary heart disease (Poirier et al., 2006). S-allyl-cysteine 
has been demonstrated to protect cardiomyocytes against myocardial infarction and oxidant-
induced mitochondrial injury in adult male Sprague-Dawley rats (Wang et al., 2010; Chuah et al., 
2007). It (SAC) exerts these protective effects by reducing of hydrogen sulphide (H2S) and 
increasing the activities of antioxidant enzyme superoxide dismutase (Wang et al., 2010).  
 
2.6.5.2.5 Hepatoprotective activity of S-allyl-cysteine  
Metabolic syndrome and diabetes mellitus are associated with hyperlidaemia induced liver cell 
damage (Cordeiro et al., 2015). Increased serum activity of liver enzymes [aspartate transaminase 
(AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)] is indicative of liver 
damage (Asdaq, 2015). Studies by Saravanan et al. (2009) and Asdaq (2015) reported that the 
oral administration of SAC attenuated increased serum activity of liver enzymes (AST, ALT, and 
ALP) in STZ-diabetic adult Wistar rats and high-fat diet fed Sprague-Dawley rats, respectively.  
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2.6.5.2.6 Renoprotective activity of S-allyl-cysteine  
Renal failure is one of the most common complications of metabolic syndrome and DM II (Gluba 
et al., 2013). It (renal failure) can result in elevated blood urea and creatinine concentrations 
(Cavalcanti et al., 2006). Orally administered SAC has been reported to prevent kidney 
inflammation and mitigate elevation of blood urea and creatinine concentrations in STZ-diabetic 
adult Wistar rats (Mong and Yin, 2012; Saravanan et al., 2009). The renoprotective effects of 
SAC are due to its ability to upregulate peroxisome proliferator-activated receptors (PPAR) -α 
and -γ and increase antioxidant activity in the kidneys (Mong and Yin, 2012; Saravanan et al., 
2009).  
 
2.6.5.2.7 Gastroprotective activity of S-allyl-cysteine  
Ethnomedicines contain phytochemicals that have been reported to have potential to adversely 
affect GIT micro- and macro morphometry (Metges et al., 2011; Tatara et al., 2005). Orally 
administration of SAC (3, 5, or 10 mg/kg body mass per day) protected the GIT against ethanol- 
and nonsteroidal anti-inflammatory drugs (NSAIDs)- induced acute gastric mucosal damage by 
attenuating chemical induced release of cyclooxygenase-2 (COX-2) in adult Sprague-Dawley rats 
(Choi et al., 2015; Choi et al., 2014; Park et al., 2014). The orally administered SAC protected 
the GIT by promoting mucus secretion, increasing antioxidant activity of heme oxygenase‐1and 
suppressing COX‐2 (Choi et al., 2014; Park et al., 2014).  
  
2.6.5.2.8 Neuroprotective activity of S-allyl-cysteine  
Peripheral neuropathy, a common complication of diabetes mellitus, occurs due to 
hyperglycaemia-induced neurone damage and is characterised by pain and numbness in the 
extremities (Van Dam et al., 2013). Ito et al. (2003) reported that SAC protected neurones in the 
hippocampus against amyloid-β-induced neurotoxicity. In vitro and in vivo studies have reported 
that SAC protects neurons against ischemic-induced damage due to its free radical scavenging 
activity and ability to inhibit the extracellular signal-regulated kinases (ERK) signalling pathways 
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(Shi et al., 2015; Imai et al., 2014; Atif et al., 2009 and Kim et al., 2006). Due to it's 
neuroprotective (protection against synaptic degeneration and neuroinflammatory pathways) 
properties, SAC has been recommended as a feasible intervention for Alzheimer’s disease (Ray 
et al., 2011).  
 
2.6.5.2.9 Anticancer activity of S-allyl-cysteine  
Obesity has been linked with the development of various cancers including oral cancer (Petti, 
2009; Calle and Kaaks, 2004; Calle et al., 2003). In vitro work has demonstrated that SAC anti-
cancer activity against human oral squamous cancer CAL-27 cells, breast cancer cell and human 
ovarian cancer cell (Xu et al., 2014; Tang et al., 2009; Gapter et al., 2008). S-allyl-cysteine exerts 
its anticancer effects by inhibiting tumour cell proliferation and metastasis and downregulating 
tumour pro-malignant proteins (Xu et al., 2014; Tang et al., 2009; Gapter et al., 2008). 
 
2.6.5.2.10 Toxicity of S-allyl-cysteine  
The use of phytochemicals derived from ethnomedicinally important plants has the potential of 
eliciting adverse toxic effects. Work by Kodera and colleagues (2002) showed that in mice and 
rats, oral (po) and intraperitoneal (ip) administration of SAC (2100 to 15000 mg/kg) exhibited 
minimal toxicity with lethal doses (LD50) > 8.8 g/kg for po and > 3.2 g/kg for ip. In a subacute 
study orally (po) and intraperitoneally (ip) administered SAC (250, 500, 1000, and 2000 mg/kg 
body mass) was reported to cause dose-dependent reversible subacute toxicity at doses > 500 
mg/kg (Kodera et al., 2002). The subacute toxicity was characterised by decreased urinal 
urobilinogen, increased serum glucose, total cholesterol, and total protein concentrations, 
pancreatic atrophy, and hypertrophy of the liver and kidneys (Kodera et al., 2002).  
The next chapter (chapter 3) provides further specific background literature and a justification for 
the first experiment which (experiment) sought to determine the potential of neonatal orally 
administered SAC to protect against adverse metabolic derangements induced by an orally 
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administered high-fructose diet (20% fructose solution) in suckling Wistar rat pups modelling 
human infants fed high-fructose diets. 
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CHAPTER 3: EFFECT OF ORALLY 
ADMINISTERED S-ALLYL-CYSTEINE 
AND FRUCTOSE IN NEONATAL RATS 
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3.0 Introduction 
The prevalence of obesity in South African children was reported to be at 4.2% in 2002 (Zeelie et 
al., 2010) and it is estimated that it will increase to 22.8% by the year 2020 (Toriola et al., 2012). 
The projected increase in the prevalence of childhood obesity is due to the increase in sedentary 
lifestyles and poor dietary choices such as the consumption of foods that are rich in fructose (Go 
et al., 2013) and also in fat (Evans et al., 2014). These poor dietary choices and the practice of 
sedentary lifestyles is a characteristic feature of communities in both the developed and 
developing world (Gupta et al., 2012). Obesity has been recognised as the leading contributor to 
the increase in the prevalence of non-alcoholic fatty liver disease (NAFLD) in children (Mager et 
al., 2015). Non-alcoholic fatty liver disease, a condition characterised by the excessive 
accumulation of lipids in the liver (Alisi and Nobili, 2014), is considered an early stage condition 
in the development of metabolic syndrome (MetS) (Mager et al., 2015). Metabolic syndrome is a 
multifactorial disorder that involves the interaction of various conditions such as hyperglycaemia, 
insulin resistance, abdominal obesity, atherogenic dyslipidaemia and hypertension (Malin et al., 
2014). The manifestation of metabolic derangements such as obesity, NAFLD, and MetS during 
periods of increased plasticity (gestational and or lactation) can result in the development of 
adverse neonatal metabolic programming (Huynh et al., 2008). 
Neonatal metabolic programming refers to the phenomenon whereby dietary manipulation during 
early-life (gestation and lactation) causes epigenetic changes that result in an organism 
developing increased susceptibility or resistance to disease in later life (Guilloteau et al., 2009). 
The feeding of a high-fructose diet to suckling rat pups has been demonstrated to cause obesity, 
NAFLD and MetS in early-life and increased susceptibility to develop cardio-metabolic 
complications in adult life (Jegatheesan et al., 2015; Huynh et al., 2008). Early-life (gestational 
and or lactation) administration of antidiabetic and antiobesity pharmacological agents has been 
advocated as a feasible intervention for preventing the diet-induced neonatal metabolic 
programming that predisposes offspring to systemic diseases later in adult life (Guilloteau et al., 
2009; Vickers et al., 2005). In altricial species, the oral administration of antidiabetic substances 
in neonatal life when the GIT is undeveloped has the potential to alter the GIT microbiota 
ecosystem (Buddington et al., 2011). This alteration can consequently result in altered GIT 
development, structure, and functionality (Rist et al., 2013; Schumann et al., 2005). In neonatal 
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life, the GIT plays an elementary role in nutrition partitioning, gene expression and development 
of various physiological systems including the endocrine system (Rist et al., 2013; Buddington et 
al., 2011; Srinivasan et al., 2003b). Thus altering GIT development, structure and functionality in 
neonatal life can potentially result in altered growth, development and the programming of short- 
and long-term adverse metabolic outcomes. 
An array of conventional pharmacological agents that are used to prevent and or treat obesity, 
NAFLD, MetS and DM II exist (Padiya et al., 2011; Kraja et al., 2010). However, 80% of the 
global population still depends on ethnomedicines to treat ailments hence the observed global 
growth in the ethnomedicinal business (Sponchiado et al., 2016). Ethnomedicines are naturally 
occurring and are thus considered to be in harmony with the body and to have a minimal 
potential for causing adverse effects (Sehgal et al., 2013). Research envisioned at cultivating 
information about ethnomedicines is pivotal at driving the growth of indigenous knowledge 
systems (Sponchiado et al., 2016). Ethnomedicines contain numerous health beneficial bioactive 
phytochemicals that contribute to their medicinal properties (Sandhar et al., 2011).  
Garlic, Allium sativum, is globally used as a spice and as an ethnomedicine for treating systemic 
disorders (Banerjee and Maulik, 2002). It has been reported to possess anticancer, antidiabetic, 
antimicrobial, immunoboosting, hepatoprotective, antifibrinolytic and cardioprotective effects 
(Santhosha et al., 2013). The phytochemical constituents that give garlic its medicinal properties 
include organo-soluble compounds, alliin, allicin, diallyl disulphide, trans-ajoen and water-
soluble organosulphur peptide S-allyl cysteine (SAC). S-allyl cysteine, found in abundance in 
aged garlic extracts (AGE), has been shown in vitro and in vivo to possess hepatoprotective, 
antioxidant, antiobesity and antidiabetic properties (Saravanan et al., 2009; Lin et al., 2008; 
Ahmad et al., 2007). Research has demonstrated that SAC attenuates oxidative stress, 
hyperglycaemia and dyslipidaemia in adult STZ-diabetic and high-fat diet rat models by 
increasing lipid breakdown, insulin sensitivity and insulin secretion (Saravanan and Ponmurugan, 
2010; Lin et al., 2008; Ahmad et al., 2007). The health beneficial medicinal properties of SAC 
render it a plausible candidate for preventing high-fructose diet-induced metabolic disturbances 
in early-life. Thus this study sought to determine if the neonatal oral administration of SAC could 
protect suckling Wistar rats against the development of high-fructose diet-induced metabolic 
derangements by specifically determining SAC’s effects on growth performance, markers of 
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metabolic dysfunction (blood glucose, triglyceride, cholesterol, insulin concentration and hepatic 
glycogen and lipid content), viscera morphometry and surrogate markers of liver (alanine 
aminotransferase, alkaline phosphatase, total bilirubin, globulin, and albumin) and kidney 
(creatinine and blood urea nitrogen) function. 
Hypothesis 
H1: Oral neonatal administration of SAC protects suckling male and female Wistar rat pups 
against high-fructose diet-induced metabolic derangements in early-life. 
H0: Oral neonatal administration of SAC does not protect suckling male and female Wistar rat 
pups against high-fructose diet-induced metabolic derangements in early-life. 
 
3.1 Materials and methods 
3.1.1 Source of S-allyl-cysteine 
Reagent grade (RG), S-allyl-cysteine was procured from ChromaDex (California, Irvine, USA). 
 
3.1.2. Ethical clearance for the study 
Ethical clearance for the study was granted by the Animal Ethics Screening Committee (AESC) 
of the University of Witwatersrand. The AESC clearance number was 2015/07/B. Copies of the 
certificate (and further modifications to the study) are included as appendices (see Appendices 1 
and 2). 
 
3.1.3 Animals, feeding, and housing 
Sixty-four, four-day-old male (n = 32) and female (n = 32) suckling Wistar rat pups from first-
time breeders were used in the study. The rat litters were housed in the Central Animal Services 
unit with their respective dams in Perspex cages with stainless steel mesh lids and were allowed 
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ad libitum suckling of their mother’s milk throughout the experiment. Bedding made up of clean 
wood shavings was provided and changed twice per week. Room temperature was maintained at 
24 ± 2
o
C with a 12-h light/dark cycle (lights on from 07:00 h to 19:00 h). The pups were 
acclimatised for two days (postnatal days 4 and 5) prior to the commencement of the experiment.  
 
3.1.4 Experimental design  
The pups were randomly allocated (on postnatal day 6) to and administered one of the following 
treatment regimens: group I - 10 ml/kg body mass per day distilled water (DH), group II - 10 
ml/kg body mass per day 20% fructose solution (w/v) [FS], group III - 150 mg/kg
 
body mass per 
day of S-allyl-cysteine (SAC) dissolved in distilled water, group IV - 150 mg/kg body mass per 
day of SAC dissolved in distilled water and 10 ml/kg body mass per day of 20% fructose solution 
(w/v) [SAC + FS]. The respective treatment regimens were orally administered as a single bolus 
daily to the respective rat pups for 15 days (postnatal day 6 to 20) using a 22 G plastic cannula 
(Vasocan® Braunüle®, B. Braun Medical (Pty) Ltd, Northriding, Johannesburg, South Africa). 
The random allocation was such that there were 8 male and 8 female pups per treatment regimen. 
 
3.1.5 Body mass measurement 
The pups were weighed daily using an electronic scale (Snowrex Electronic Scale, Clover Scales, 
Johannesburg) to monitor growth performance. The body mass measurements also permitted for 
the maintenance of a constant dosage of the treatment regimens relative to body mass over the 15 
day treatment period. 
 
3.1.6 Terminal procedures 
3.1.6.1 Determination of terminal body mass and non-fasted blood metabolites  
On postnatal day 21, the rat pups’ terminal body masses were measured using an electronic scale 
(Snowrex Electronic Scale, Clover Scales, Johannesburg). Thereafter a drop of blood was 
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obtained from the tail vein via pinprick and used to determine non-fasted blood glucose using a 
calibrated Contour plus glucometer (Bayer, Isando, South Africa) as per the manufacturer’s 
instructions. The rat pups were not fasted overnight prior to termination as they were still young 
(preweaning) and dependent on their dams’ milk for nourishment. Moreover an overnight fast 
would have required maternal separation which has been shown to cause stress and altered 
metabolic function (Zalosnik et al., 2014; da Silva Lima et al., 2011). The pups were then 
euthanised by intraperitoneal administration of 100 mg/kg
 
body mass of sodium pentobarbital 
(Eutha-naze, Bayer, Johannesburg, South Africa). Following euthanasia, blood was collected via 
cardiac puncture using 21 G needles and 5 ml syringes into 4 ml heparinised blood collection 
tubes (Becton Dickinson VACUTAINER Systems Europe, Meylan Cedex, France). A drop of the 
blood was then used to determine the concentration of blood triglycerides and cholesterol using 
calibrated Accutrend triglyceride and cholesterol meters (Roche, Mannheim, Germany) according 
to the manufacturer’s instructions. The remaining heparinised blood samples were spun for 15 
min at 5000 g at 22°C in a Senova NovaFuge centrifuge (Senova Labtech, Shanghai, China). The 
plasma was then collected into microtubes and stored at -20°C for later determination of plasma 
insulin concentration and surrogate markers of liver and kidney function.  
 
3.1.6.2 Determination of visceral organ morphometry 
Following blood collection, the abdomen was cut open by a midline incision. The liver, small 
and large intestines were carefully dissected out. The small and large intestines were gently 
stretched out on a dissection board and their lengths were measured using a ruler mounted on the 
dissection board. The contents of the small and large intestines were gently emptied after which 
the visceral organs were weighed on an electronic balance (Presica 310M, Presica Instruments 
AG, Switzerland). A sample of the liver was stored at -20ºC for determination of liver glycogen 
and lipid content. Liver samples for histology analysis were preserved in 10% phosphate 
buffered formalin. 
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3.1.6.3 Determination of liver histo-morphometry 
The preserved liver samples were embedded in paraffin wax, sectioned, and then stained with 
haematoxylin and eosin on a glass slide and covered with a glass coverslip (Reyes-Gordillo et 
al., 2007). To assess hepatocellular changes, specifically hepatocyte size and cell numbers within 
a linear field (100μm) the slides were viewed under a light microscope using an eyepiece 
micrometer (Reichert®, Austria) at high power magnification of 400 X. Photographs of the 
slides sections were captured using a camera mounted onto the microscope. The NAFLD 
Activity Score (NAS), which is a semi-quantitative grading and scoring system, was used to 
grade the ballooning, lobular inflammation, and hepatic steatosis (Kleiner et al., 2005). A 
detailed description of the NAS criteria is attached in appendix 3.  
 
3.1.7 Liver glycogen and lipid content determination 
Liver glycogen content was determined by using a method of indirect acid hydrolysis of glycogen 
to glucose as described by Passonneau and Lauderdale, (1974). In summary, 0.1 g of liver sample 
was placed in 1 ml of 0.03 M HCl and thereafter homogenised using an Ultraturrax homogeniser 
(Janke and Kunkel, Ika-Werk, Germany). Then 1ml of 1 M HCl was added prior to the mixture 
being boiled for 2 hours in a water bath. Thereafter the sample was allowed to cool following 
which it was then neutralised by adding 1 ml of 1 M NaOH. The glucose concentration of the 
hydrosylate was then determined using an Accu-Chek Active glucometer (Roche, Germany). 
The total liver lipid content was determined by the soxhlet method (ether extract) of extraction as 
described by AOAC (2005; method number 920.39).  
 
3.1.8 Determination of plasma insulin concentration and computation of HOMA-IR index  
Plasma insulin concentration was determined by enzyme-linked immunosorbent assay (ELISA) 
using a rat insulin kit [Elabscience ®, Rat INS (Insulin) ELISA kit, Wuhan, Hubei Province, 
China] according to the manufacturer’s instructions. A detailed description of the protocol used is 
attached in appendix 4. Briefly, the assay used a sandwich enzyme immunoassay method 
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utilising a monoclonal antibody specific for rat insulin with a sensitivity range of 3.125-200 
ng/mL. Absorbencies were read at 450 nm using a microplate reader (Multiskan Ascent, Lab 
system, model nº 354, Helsinki, Finland). A standard curve was constructed using calibrator 
concentrations. The concentrations of insulin in the samples were then determined from the 
constructed standard curve.  
Whole-body insulin sensitivity was then computed using the homoeostasis model assessment of 
insulin resistance as illustrated in the equation below: 
HOMA-IR = [fasting insulin concentration (ng/mL) x fasting glucose concentration (mg/dL)]/405 
(Matthews et al., 1985). 
To convert mmol/L fasting glucose concentration to mg/dL, mmol/L was multiplied by 18.01.  
 
3.1.9 Determination of linear growth 
The right hind leg was removed from each of the carcases, defleshed and then the femur and tibia 
were separated. The bones were then dried to a constant mass in an oven (Salvis ®, Salvis Lab, 
Switzerland) at 40
o
C for 7 days. The dry tibiae masses were then determined using an electronic 
scale (Presica 310M, Presica Instruments AG, Switzerland). The lengths of the tibiae were 
measured between tibia head and medial malleolus using digital vernier callipers [Major Tech 
(Pty) Ltd, KTV 150 digital calliper, Elandsfontein, South Africa]. The density of the tibiae were 
approximated by computing the Seedor index (Seedor et al., 1991): 
Seedor index (mg/mm) = dry mass of bone (mg) /bone length (mm).  
Radiographs of the tibiae were taken using a Shimadzu MVX 200 X-ray machine (Shimadzu 
Corp, Kyoto, Japan). Briefly, the bones were placed on the 0.71 mA photographic plate at a 
distance of 1 metre from the X-ray light source with settings of 5.3 kVp.  
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3.1.10 Determination of biochemical surrogate markers of liver and kidney health 
The plasma activities of ALT and ALP and concentration of albumin, globulin, total protein, total 
bilirubin, blood urea nitrogen and creatinine of the rat pups were determined using a colorimetric-
based clinical chemistry analyser (IDEXX VetTest® Clinical Chemistry Analyser, IDEXX 
Laboratories Inc., USA) as per the manufacturer’s instructions. Briefly, each stored plasma 
sample was thawed and allowed to warm to room temperature, and then gently inverted to mix 
the contents. The plasma sample was then placed into the analyser which automatically drew up 
150 μL of the plasma and dispensed 10 μL onto each of the pre-loaded disks and the sample was 
then analysed and a print out of results provided. 
 
3.1.11 Statistical analysis 
Parametric data are expressed as mean ± SD and non-parametric data are expressed as median 
and range (min, max). The data was analysed using GraphPad Prism 5 software (Graph-Pad 
Software Inc., San Diego, CA, USA). Statistical significance was considered when p ≤ 0.05. 
Body mass data within groups was analysed using a repeated measures analysis of variance 
(ANOVA). A one-way ANOVA was used to analyse other multiple group data followed by mean 
comparison using a Bonferroni post hoc test. The Kruskal-Wallis test (non-parametric one-way 
ANOVA) was used to analyse non-alcoholic fatty liver disease score (NAS) multiple group data 
followed by Dunns post hoc test to compare medians. 
The model used for the analysis of variance for daily body masses was: 
Yijk = μ + Ti + Bj + Ck + eijk; where; 
Yijk = daily body mass  
μ = overall mean common to all observations 
Ti = effect of treatment regimen (n = 1,2,..4) 
Bj = fixed effect of individual rat (1,2,3.........32)  
Ck = fixed effect of sampling day on body mass (= 1,2......16) 
 eijk = residual random error 
The model used for variables determined at study termination was: 
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Yijk = μ + Ti + Bj + eijk; where; 
Yijk = response variable of interest 
μ = overall mean to all observations 
Ti = effect of treatment (n = 1,2,..4) 
Bj = fixed effect of individual rat (1,2,3.........32)  
eijk = residual random error 
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3.2 Results 
3.2.1 Growth performance  
3.2.1.1 Body mass  
Figure 3.1 below shows induction and terminal body masses of male rat pups.  
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Figure 3.1: Effect of S-allyl-cysteine on terminal body masses of the male rat pups fed a 
high-fructose diet. 
*** p < 0.0001.Induction body masses of the rats were similar across treatment regimens. Across 
treatment regimens, the rat pups significantly grew (p < 0.0001). However terminal body masses 
of the rats were similar across treatment regimens. DH = 10 ml/kg body mass per day distilled 
water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg body 
mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 
ml/kg body mass per day 20% fructose solution (w/v); PND = postnatal day. Data presented as 
mean ± SD; n = 8 per treatment. 
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Although the male rat pups across treatment regimens grew significantly (p < 0.0001) over the 
experimental period (Figure 3.1), the induction and terminal body masses of the male rat pups 
across treatment regimens were similar (Figure 3.1).  
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Figure 3.2 below shows induction and terminal body masses of female rat pups.  
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Figure 3.2: Effect of S-allyl-cysteine on terminal body masses of the female rat pups fed a 
high-fructose diet. 
*** p < 0.0001. Induction body masses of the rats were similar across treatment regimens. Across 
treatment regimens, the rat pups significantly grew (p < 0.0001). However terminal body masses 
of the rats were similar across treatment regimens. DH = 10 ml/kg body mass per day distilled 
water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg body 
mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 
ml/kg body mass per day 20% fructose solution (w/v); PND = postnatal day. Data presented as 
mean ± SD; n = 8 per treatment. 
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Although the female rat pups across treatment regimens grew (p < 0.0001) significantly over the 
experimental period compared to their induction masses (Figure 3.2), the induction and terminal 
body masses of the female rat pups across treatment regimens were similar (Figure 3.2).  
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3.2.1.2 Linear growth 
Table 3.1 below shows tibia masses, lengths and densities (Seedor indices) of male rat pups at the 
end of the study.  
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Table 3.1: Effects of S-allyl-cysteine on tibia lengths, masses and Seedor indices of suckling male rat pups fed a high-fructose 
diet  
Parameter DH FS SAC SAC + FS Significance level 
Tibia length (mm) 18.60 ± 1.07
 
19.02 ± 1.61
 
19.10 ± 0.17
 
18.76 ± 1.58
 
ns 
Tibia mass (mg) 32.50 ± 4.14
 
33.00 ± 2.88
 
33.00 ± 3.30
 
31.33 ± 2.50
 
ns 
Tibia Seedor index (mg/mm) 1.75 ± 0.23
 
1.75 ± 0.22
 
1.73 ± 0.18
 
1.68 ± 0.21
 
ns 
ns = not significant, p > 0.05. Tibiae lengths, masses and densities (Seedor indices) were similar for rats across the treatment regimens. 
DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg 
body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body mass per day 20% 
fructose solution (w/v). Data presented as mean ± SD; n = 8 per treatment regimen. 
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Tibiae masses, lengths, and densities (Seedor indices) of male pups were similar across the 
treatment regimens (Table 3.1).  
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Table 3.2 below shows tibia masses, lengths and densities (Seedor indices) of female rat pups at 
the end of the study.  
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Table 3.2: Effects of S-allyl-cysteine on tibia lengths, masses and Seedor indices of suckling female rat pups fed a high-fructose 
diet 
Parameter DH FS SAC SAC + FS Significance level 
Tibia length (mm) 18.72 ± 1.27
 
18.30 ± 1.34 17.89 ± 1.53
 
17.84 ± 1.40
 
ns 
Tibia mass (mg) 31.50 ± 12.38
 
33.13 ± 3.60
 
33.13 ± 3.36
 
31.63 ± 3.58
 
ns 
Tibia Seedor index (mg/mm) 1.70 ± 0.21
 
1.81 ± 0.20
 
1.86 ± 0.27
 
1.78 ± 0.22
 
ns 
ns = not significant, p > 0.05. Tibiae lengths, masses and densities (Seedor indices) were similar for rats across the treatment regimens. 
DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg 
body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body mass per day 20% 
fructose solution (w/v). Data presented as mean ± SD; n = 8 per treatment. 
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Tibiae masses, lengths, and densities (Seedor indices) of female pups were similar across 
treatment regimens (Table 3.2).  
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The male rat pups’ radiographs of tibiae are shown in Figure 3.3 below.  
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Figure 3.3: Radiograph images tibiae of male rat pups. 
DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% 
fructose solution (w/v); SAC = 150 mg/kg body mass per day S-allyl-cysteine; SAC + FS = 150 
mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body mass per day 20% fructose solution 
(w/v). 
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There were no grossly subjectively observable differences in the radiographical densities of the 
tibiae from male rat pups across treatment regimens (Figure 3.3). 
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The female rat pups’ radiographs of tibiae are shown in Figure 3.4 below.  
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Figure 3.4: Radiograph images tibiae of female rat pups. 
DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% 
fructose solution (w/v); SAC = 150 mg/kg body mass per day S-allyl-cysteine; SAC + FS = 150 
mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body mass per day 20% fructose solution 
(w/v). 
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There were no grossly subjectively observable differences in the radiographical densities of the 
tibiae from female rat pups across treatment regimens (Figure 3.4). 
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3.2.2 Blood parameters and hepatic metabolites 
3.2.2.1 Non-fasted blood parameters 
The blood glucose, triglyceride and cholesterol concentrations and plasma insulin concentration 
and HOMA-IR indices of male rat pups are shown in Table 3.3 below.  
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Table 3.3: Effect of S-allyl-cysteine on glucose, triglyceride, cholesterol and insulin concentrations, and HOMA-IR indices of 
non-fasted suckling male rat pups fed a high-fructose diet 
ns = not significant, p > 0.05. *** p < 0.001, ** p < 0.01.
 ab
Within row means with different superscripts are significantly different at p 
≤ 0.05. Non-fasted blood glucose, triglyceride and cholesterol concentrations were similar in the rat pups across treatment regimens. 
Rat pups administered SAC alone had significantly higher (p = 0.0006) plasma insulin concentration compared to rats that were 
administered with DH. HOMA-IR was significantly higher (p = 0.0009 and p = 0.0157 respectively) in rats that were administered 
SAC alone compared to rats that were administered DH or SAC + FS. DH = 10 ml/kg body mass per day distilled water; FS = 10 
ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg 
body mass per day S-allyl-cysteine + 10 ml/kg body mass per day 20% fructose solution (w/v); HOMA-IR = Homeostatic model of 
insulin resistance. Data presented as mean ± SD; n = 8 per treatment. 
Parameter DH FS SAC SAC + FS Significance level 
Glucose (mmol/L) 6.18 ± 0.51
a 
6.47 ± 0.60
a 
6.65 ± 0.36
a 
6.15 ± 0.40
a 
ns 
Triglycerides (mmol/L) 3.94 ± 1.57
a 
4.89 ± 1.31
a 
3.82 ± 1.47
a 
4.04 ± 1.21
a 
ns 
Cholesterol (mmol/L) 5.26 ± 0.78
a 
4.70 ± 0.59
a 
4.45 ± 0.41
a 
4.70 ± 0.68
a 
ns 
Insulin (ng/mL) 24.78 ± 3.25
a
 35.40 ± 9.87
ab
 46.68 ± 11.13
b
 34.68 ± 7.40
ab
 *** 
HOMA-IR 7.43 ± 0.92
a
 10.44 ± 3.06
 ab
 13.70 ± 2.94
b
 9.47 ± 2.01
a
 ** 
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There were no differences in the concentrations of the non-fasted blood glucose, triglyceride, and 
cholesterol of male pups across treatment regimens (Table 3.3). The administration of SAC 
significantly increased (p = 0.0006) male rat pups’ plasma insulin concentration compared to 
male pups administered DH (control) (Table 3.3). Compared to male rat pups administered DH or 
SAC + FS, male rat pups administered SAC had significantly higher (p = 0.0009 and p = 0.0157, 
respectively) HOMA-IR (Table 3.3).  
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The blood glucose, triglyceride and cholesterol concentrations, plasma insulin concentration and 
HOMA-IR indices of female rat pups are shown in Table 3.4 below.  
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Table 3.4: Effect of S-allyl-cysteine on glucose, triglyceride, cholesterol and insulin concentrations, and HOMA-IR indices of 
non-fasted suckling female rat pups fed a high-fructose diet 
Parameter DH FS SAC SAC + FS Significance level 
Glucose (mmol/L) 6.17 ± 0.43
a 
6.00 ± 0.31
a 
5.92 ± 0.75
a 
6.22 ± 0.59
a 
ns 
Triglycerides (mmol/L) 4.36 ± 1.34
a 
4.16 ± 0.82
a 
3.63 ± 0.76
a 
4.08 ± 1.18
a 
ns 
Cholesterol (mmol/L) 5.09 ± 0.68
a 
4.95 ± 0.63
a 
5.27 ± 0.75
a 
4.88 ± 0.80
a 
ns 
Insulin (ng/mL) 37.90 ± 0.87
a
  25.50 ± 4.14
b
 44.96 ± 7.40
a
 38.76 ± 6.34
a
 ** 
HOMA-IR 10.60 ± 0.97
a
 6.80 ± 1.43
b
 11.99 ± 2.03
a
 11.13 ± 1.94
a
 ** 
ns = not significant, p > 0.05. ** p < 0.01. 
abWithin row means with different superscripts are significantly different at p ≤ 0.05. Non-
fasted blood glucose, triglyceride and cholesterol concentrations were similar in the rat pups across treatment regimens. Rats 
administered FS had significantly (p < 0.01) lower insulin and HOMA-IR compared to all other treatment regimens. DH = 10 ml/kg 
body mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg body mass per 
day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body mass per day 20% fructose solution 
(w/v); HOMA-IR = Homeostatic model of insulin resistance. Data presented as mean ± SD; n = 8 per treatment. 
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There were no significant differences in the concentration of the non-fasted blood glucose, 
triglyceride, and cholesterol concentration of male pups across treatment regimens (Table 3.4). 
The female rat pups to which a 20% FS was orally administered had significantly lower (p < 
0.01) plasma insulin concentration and significantly lower (p < 0.01) HOMA-IR indices 
compared to their counterparts that were orally administered with DH, SAC or SAC + FS (Table 
3.4).  
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3.2.2.2 Liver glycogen content 
Liver glycogen (as glucose equivalent in liver homogenate) of male rat pups is shown in Figure 
3.5 below.  
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Figure 3.5: Effect of S-allyl-cysteine on the hepatic glycogen content of non-fasted suckling 
male rats fed high-fructose diet. 
Liver glycogen (represented as glucose equivalents in the liver homogenate) content was similar 
in the rats across treatment regimens. DH = 10 ml/kg body mass per day distilled water; FS = 10 
ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg body mass per day S-
allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body mass 
per day 20% fructose solution (w/v). Data presented as mean ± SD; n = 8 per treatment. 
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There were no significant differences in the liver glycogen content of male rat pups across 
treatment regimens (Figure 3.5). 
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Liver glycogen (as glucose equivalent in liver homogenate) of female rat pups is shown in Figure 
3.6 below.  
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Figure 3.6: Effect of S-allyl-cysteine on the hepatic glycogen content of non-fasted suckling 
female rats fed high-fructose diet. 
* p < 0.05. Rats orally administered FS only or SAC only had significantly lower (p = 0.0177 and 
p = 0.0051, respectively) liver glycogen (represented as glucose equivalents in the liver 
homogenate) compared to rats administered DH. DH = 10 ml/kg body mass per day distilled 
water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg body 
mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 
ml/kg body mass per day 20% fructose solution (w/v). Data presented as mean ± SD; n = 7-8 per 
treatment. 
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Unlike in male rat pups where the oral administration of FS and or SAC or the combination of FS 
and SAC had no effect on the liver glycogen content in female rat pups, the oral administration 
FS alone or SAC alone significantly reduced (p = 0.0177 and p = 0.0051, respectively) the liver 
glycogen content compared to female rat pups administered DH (Figure 3.6). 
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3.2.2.3 Liver lipid content 
Figure 3.7 below shows the total hepatic lipid content of male rat pups.  
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Figure 3.7: Effect of S-allyl-cysteine on the hepatic lipid content of non-fasted suckling male 
rats fed a high-fructose diet. 
Liver lipid content was similar in all rats across treatment regimens. DH = 10 ml/kg body mass 
per day distilled water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 
150 mg/kg body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-
allyl-cysteine + 10 ml/kg body mass per day 20% fructose solution (w/v). Data presented as mean 
± SD; n = 8 per treatment. 
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The treatment regimens had no effect on male rat pups’ liver lipid content (Figure 3.7).   
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Figure 3.8 below shows the total hepatic lipid content from female rat pups.  
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Figure 3.8: Effect of S-allyl-cysteine on the hepatic lipid content of non-fasted suckling 
female rats fed a high-fructose diet. 
Rats administered FS or SAC + FS had significantly lesser (p < 0.0001) liver lipid content 
compared to rats administered DH or SAC. Liver lipid was significantly greater (p < 0.0001) in 
rats administered SAC compared to their counterparts administered DH. DH = 10 ml/kg body 
mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC 
= 150 mg/kg body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-
allyl-cysteine + 10 ml/kg body mass per day 20% fructose solution (w/v). Data presented as mean 
± SD; n = 8 per treatment. 
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The oral administration of 20% FS alone or SAC + FS in female rat pups resulted in significantly 
lesser (p < 0.0001) liver lipid content compared to the liver lipid content from female rat pups 
administered DH or SAC (Figure 3.8). In female rat pups, the administration of SAC caused a 
significant increase (p < 0.0001) liver lipid than in female rat pups administered DH (Figure 3.8).  
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3.2.3 Visceral organs morphometry 
3.2.3.1 Liver, small and large intestine morphometry 
Table 3.5 below shows the male rat pups’ visceral organ absolute and relative (to tibia length) 
masses and lengths (small intestine and large intestine). 
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Table 3.5: Effect of S-allyl-cysteine on visceral organ masses and lengths in suckling male rats fed a high-fructose diet 
Organ DH FS SAC SAC + FS Significance level 
Liver (g) 1.11 ± 0.30
a
 1.35 ± 0.45
a
 1.47 ± 0.25
a
 1.39 ± 0.45
a
 ns 
Liver TLr (g/mm) 0.059± 0.012
a
 0.070 ± 0.018
ab
 0.081 ± 0.006
b
 0.073 ± 0.019
ab
 ** 
SI (mm) 496.30 ± 110.6
a
 571.30 ± 73.00
a
 567.20 ± 38.41
a
 569.40 ± 62.47
a
 ns 
SI (g) 1.05 ± 0.27
a
 1.32 ± 0.38
a
 1.32 ± 0.27
a
 1.32 ± 0.39
a
 ns 
SI TLr (g/mm) 0.056 ± 0.011
a
 0.068 ± 0.014
a
 0.072 ± 0.011
a
 0.069 ± 0.016
a
 ns 
LI (mm) 83.75 ± 9.16
a
 90.63 ± 12.08
a
 91.67 ± 7.90
a
 87.56 ± 15.69
a
 ns 
LI (g) 0.18 ± 0.04
a
 0.21 ± 0.06
a
 0.23 ± 0.04
a
 0.21 ± 0.06
a
 ns 
LI TLr (g/mm) 0.009 ± 0.002
a
 0.011 ± 0.002
a
 0.012 ± 0.001
a
 0.011 ± 0.002
a
 ns 
ns = not significant, p > 0.05. **p < 0.01. 
ab
Within row means with different superscripts are significantly different at p ≤ 0.05. Rats 
administered SAC had significantly (p = 0.0007) heavier relative (tibia length) liver masses compared to the mass of the livers of rats 
administered DH. DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); 
SAC = 150 mg/kg body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body 
mass per day 20% fructose solution (w/v); LI = Large intestine; SI = small intestine; TLr = relative to tibia length. Data presented as 
mean ± SD; n = 8 per treatment. 
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The oral administration of SAC significantly increased (p = 0.0008) the male rat pups’ relative 
liver masses (relative to tibia length) compared to the relative liver masses from male rat pups to 
which DH was orally administered (Table 3.5). Treatment regimens had no effect on male rat 
pups’ absolute visceral organ (liver, small intestine and large intestine) masses and lengths (small 
intestine and large intestine) (Table 3.5).  
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Table 3.6 below shows the female rat pups’ visceral organ (liver, small intestine and large 
intestine) absolute and relative masses (relative to tibia length) and lengths (small intestine and 
large intestine). 
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Table 3.6: Effect of S-allyl-cysteine on visceral organ masses and lengths in suckling female rats fed a high fructose diet 
Organ  DH FS SAC SAC + FS Significance level 
Liver (g) 1.20 ± 0.35 1.15 ± 0.36 1.04 ± 0.38 1.16 ± 0.37 ns 
Liver TLr (g/mm) 0.063 ± 0.015 0.062 ± 0.015 0.058 ± 0.016 0.064 ± 0.017 ns 
SI (mm) 535.00 ± 59.34 537.50 ± 66.49 514.40 ± 49.38 540.60 ± 71.29 ns 
SI (g) 1.14 ± 0.31 1.16 ± 0.38 0.97 ± 0.30 1.12 ± 0.32 ns 
SI TLr (g/mm) 0.062 ± 0.013 0.062 ± 0.017 0.054 ± 0.013 0.062 ± 0.014 ns 
LI (mm) 86.25 ± 7.90 85.63 ± 9.04 85.63 ± 11.48 78.75 ± 8.34 ns 
LI (g) 0.19 ± 0.04 0.18 ± 0.06 0.18 ± 0.05 0.18 ± 0.06 ns 
LI TLr (g/mm) 0.009 ± 0.002 0.011 ± 0.003 0.013 ± 0.001 0.01 ± 0.002 ns 
ns = not significant, p > 0.05. Visceral organ masses and lengths were similar in the rat pups across treatment regimens. DH = 
10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg 
body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body mass per day 
20% fructose solution (w/v); LI = Large intestine; SI = small intestine; TLr = relative to tibia length. Data presented as mean ± 
SD; n = 8 per treatment. 
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In female rat pups, treatment regimens had no effect on absolute and relative (relative to tibia 
length) visceral organ (liver, small intestine and large intestine) masses and lengths (small 
intestine and large intestine) (Table 3.6).  
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3.2.3.2 Liver histo-morphometry 
Table 3.7 below shows hepatocyte cell size and numbers of hepatocytes in representative linear 
fields (100 µm) of male rat pups.  
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Table 3.7: Effects of S-allyl-cysteine on hepatocyte size and density of suckling male rat pups fed a high-fructose diet 
Parameter DH FS SAC SAC + FS Significance level 
Hepatocyte size (µm)  7.83 ± 1.15
 
5.50 ± 1.32
 
7.00 ± 2.18
 
7.00 ± 0.50
 
ns 
Hepatocyte density (cells per 
100 µm) 
16.83 ± 0.76
 
16.50 ± 0.50
 
16.17± 1.26
 
16.67±1.53
 
ns 
ns = not significant, p > 0.05. The number of intact hepatocytes in a linear field (100 µm) and hepatocyte size were similar in the rat 
pups across treatment regimens. DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose 
solution (w/v); SAC = 150 mg/kg body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 
ml/kg body mass per day 20% fructose solution (w/v). Data presented as mean ± SD; n = 3 per treatment. 
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Hepatocyte cell size and numbers of hepatocytes in a 100µm linear field were similar across 
treatment regimens in male pups (Table 3.7). 
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Table 3.8 below shows hepatocyte cell size and numbers of hepatocytes in representative linear 
fields (100 µm) of female rat pups. 
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Table 3.8: Effects of S-allyl-cysteine on hepatocyte size and density of suckling female rat pups fed a high-fructose diet 
Parameter DH FS SAC SAC + FS Significance level 
Hepatocyte size (µm)  4.83 ± 1.15
 
5.16 ± 1.60
 
6.66 ± 1.60
 
6.33 ± 0.58
 
Ns 
Hepatocyte density (cells per 
100 µm) 
17.00 ± 2.78
 
18.83 ± 1.26
 
20.17 ± 1.53
 
17.00 ± 2.00
 
Ns 
ns = not significant, p > 0.05. The number of intact hepatocytes in a linear field (100 µm) and hepatocyte size were similar in the rat 
pups across treatment regimens. DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose 
solution (w/v); SAC = 150 mg/kg body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 
ml/kg body mass per day 20% fructose solution (w/v). Data presented as mean ± SD; n = 3 per treatment. 
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Hepatocyte size and numbers of hepatocytes in a 100µm linear field were similar across 
treatment regimens in female pups (Table 3.8). 
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Non-alcoholic fatty liver disease activity score (NAS) of male rats after being administered their 
respective treatment regimens are shown in Table 3.9 below. 
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Table 3.9: Effects of S-allyl-cysteine on non-alcoholic fatty liver disease activity score (NAS) of suckling male rat pups fed a 
high-fructose diet 
Parameter DH FS SAC SAC + FS Significance level 
Steatosis score 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) ns 
Ballooning score 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) ns 
Lobular inflammation score  2 (2, 2) 2 (2, 2) 1 (1, 2) 2 (2, 3) ns 
NAS 2 (2, 2) 2 (2, 2) 1 (1, 2) 2 (2, 3) ns 
ns = not significant. The non-alcoholic fatty liver disease activity scores (NAS) of male rats were similar across treatment regimens. 
DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg 
body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body mass per day 20% 
fructose solution (w/v); NAS = non-alcoholic fatty liver disease activity score. Total NAS is the sum of values recorded for each 
category. Total NAS score interpretation: <2 = not steatohepatitis; 3–4 = uncertain; >5 = probable or definite steatohepatitis. Data 
presented as median and range (min, max); n = 3 per treatment.  
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The treatment regimens had no effect on NAS of male rat pups (Table 3.9).   
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Non-alcoholic fatty liver disease activity score (NAS) of female rat pups after being administered 
their respective treatment regimens are shown in Table 3.10 below. 
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Table 3.10: Effects of S-allyl-cysteine on non-alcoholic fatty liver disease activity score (NAS) of suckling female rat pups fed a 
high-fructose diet 
Parameter DH FS SAC SAC + FS Significance level 
Steatosis score 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) ns 
Ballooning score 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) ns 
Lobular inflammation score  1 (1, 3) 1 (1, 2) 2 (2, 2) 2 (2, 2) ns 
NAS 1 (1, 3) 1 (1, 2) 2 (2, 2) 2 (2, 2) ns 
ns = not significant. The non-alcoholic fatty liver disease activity scores (NAS) of female rats were similar across treatment regimens. 
DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg 
body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body mass per day 20% 
fructose solution (w/v); NAS = non-alcoholic fatty liver disease activity score. Total NAS is the sum of values recorded for each 
category. Total NAS score interpretation: <2 = not steatohepatitis; 3–4 = uncertain; >5 = probable or definite steatohepatitis. Data 
presented as median and range (min, max); n = 3 per treatment. 
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The treatment regimens had no effect on NAS of female rat pups (Table 3.10).   
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Representative liver histology photo sections (H and E staining, 400 X magnification) of male rat 
pups from the different treatment groups are shown in Figure 3.9 below.  
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Figure 3.9: Photos of sections showing the liver histology (H and E staining, 400 X 
magnification) of suckling male rats following the treatment regimens. 
Circle B shows foci of lobular inflammation and arrows D point to sinusoids. No histological 
differences were noted in the liver samples from rats across treatment regimens. DH = 10 ml/kg 
body mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); 
SAC = 150 mg/kg body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per 
day S-allyl-cysteine + 10 ml/kg body mass per day 20% fructose solution (w/v).  
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Liver histology of the male rat pups was similar across treatment regimens and no pathology was 
noted (Figure 3.9).  
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Representative liver histology photo sections (H and E staining, 400 X magnification) of female 
rat pups from the different treatment groups are shown in Figure 3.10 below.  
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Figure 3.10: Photos of sections the liver histology (H and E staining, 400 X magnification) of 
suckling female rats following the treatment regimens. 
Arrows C and D point to central veins and sinusoids respectively. No differences were noted in 
the liver histology across treatment regimens. DH = 10 ml/kg body mass per day distilled water; 
FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg body mass per 
day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body 
mass per day 20% fructose solution (w/v).  
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Liver histology of the female rat pups was similar across treatment regimens and no pathology 
was noted (Figure 3.10).  
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3.2.4 Plasma surrogate markers of liver and kidney function 
Table 3.11 below shows the male rat pups’ plasma activity of alanine aminotransferase and 
alanine phosphatase and plasma concentrations of total bilirubin, globulin, albumin, blood urea 
nitrogen, and creatinine.
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Table 3.11: The effect of S-allyl-cysteine on plasma surrogate biomarkers of health in suckling male rats fed a high-fructose 
diet 
Parameter DH FS SAC SAC + FS Significance level 
ALT (U/L) 49.33 ± 8.33
a
 62.17 ± 13.45
a
 64.50 ± 12.53
a
 66.00 ± 7.01
a
 ns 
ALP (U/L) 187.8 ± 34.71
a
 209.50 ± 25.54
a
 203.50 ± 22.45
a
 211.3 ± 23.20
a
 ns 
Total bilirubin (mg/dL) 7.83 ± 3.65
a
 5.33 ± 1.96
a
 3.67 ± 1.03
a
 5.83 ± 3.43
a
 ns 
Globulin (g/dL) 23.50 ± 1.22
a
 23.83 ± 1.17
a
 22.00 ± 3.16
a
 22.67 ± 1.50
a
 ns 
Albumin (g/dL) 21.00 ± 1.25
a
 22.67 ± 1.50
ab
 25.00 ± 1.55
b
 24.83 ± 1.33
b
 *** 
Total protein (g/dL) 44.83 ± 2.23
a
 46.83 ± 2.23
a
 47.00 ± 2.09
a
 47.50 ± 1.38
a
 ns 
Blood urea nitrogen (mg/dL) 6.25 ± 0.37
a
 5.83 ± 0.49
a
 6.43 ± 1.04
a
 6.43 ± 1.13
a
 ns 
Creatinine (mg/dL) 15.00 ± 4.65
a
 10.50 ± 3.67
a
 11.67 ± 4.18
a
 10.50 ± 3.67
a
 ns 
ns = not significant, ***p < 0.0001. 
ab
Within row means with different superscripts are significantly different at p < 0.05. Rats 
administered SAC or SAC + FS had significantly (p < 0.0001) higher plasma albumin concentration compared to the plasma albumin 
concentration of rats administered DH. DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% 
fructose solution (w/v); SAC = 150 mg/kg body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-
cysteine + 10 ml/kg body mass per day 20% fructose solution (w/v); ALP = Alanine phosphatase ALT = Alanine aminotransferase. 
Data presented as mean ± SD; n = 8 per treatment. 
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The oral administration of SAC alone or SAC + FS significantly increased (p < 0.0001) plasma 
albumin concentration in male rat puts compared to the oral administration of DH (Table 3.11). 
Plasma activity of alanine aminotransferase and alanine phosphatase and plasma concentrations 
of total bilirubin, globulin, blood urea nitrogen, and creatinine were similar in male rat pups 
across treatment regimens (Table 3.11). 
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Table 3.12 below shows the female rat pups’ plasma activity of alanine aminotransferase and 
alanine phosphatase and plasma concentrations of total bilirubin, globulin, albumin, blood urea 
nitrogen, and creatinine.  
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Table 3.12: The effect of S-allyl-cysteine on plasma surrogate biomarkers of health in suckling female rats fed a high-fructose 
diet 
Parameter DH FS SAC SAC + FS Significance level 
ALT (U/L) 47.67 ± 11.45 50.67 ± 15.67 45.33 ± 10.97 60.33 ± 14.31 ns 
ALP (U/L) 206.5 ± 40.08 185.70 ± 17.67 155.50 ± 47.04 178.0 ± 27.03 ns 
Total bilirubin (mg/dL) 5.00 ± 2.53 6.50 ± 2.34 7.16 ± 2.71 6.66 ± 5.53 ns 
Globulin (g/dL) 23.50 ± 1.51 24.17 ± 1.33 25.00 ± 2.45 23.00 ± 2.30 ns 
Albumin (g/dL) 22.00 ± 2.00 22.17 ± 1.94 22.33 ± 4.45 21.67 ± 3.14 ns 
Total protein (g/dL) 45.83 ± 2.48 46.17 ± 3.54 47.00 ± 2.76 44.67 ± 1.63 ns 
Blood urea nitrogen (mg/dL) 6.80 ± 0.93 7.22 ± 1.80 6.08 ± 0.80 6.02 ± 0.88 ns 
Creatinine (mg/dL) 10.50 ± 3.67 13.50 ± 4.93 12.00 ± 4.65 13.50 ± 4.93 ns 
ns = not significant p > 0.05. All surrogate markers of liver and kidney function were similar in the rat pups across treatment regimens. 
DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% fructose solution (w/v); SAC = 150 mg/kg 
body mass per day S-allyl-cysteine; SAC + FS = 150 mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body mass per day 20% 
fructose solution (w/v); ALP = Alanine phosphatase ALT = Alanine aminotransferase. Data presented as mean ± SD; n = 8 per 
treatment.  
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The treatment regimens had no effect on plasma activity of alanine aminotransferase and 
alanine phosphatase and plasma total bilirubin, globulin, albumin, blood urea nitrogen, and 
creatinine concentration of female rat pups (Table 3.12). 
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3.3 Discussion 
3.3.1 Growth performance 
Although the terminal body masses of male or female rat pups across treatment regimens 
were similar, both male and female rat pups significantly grew compared to their induction 
masses (Figures 3.1 and 3.2). These findings suggest that the treatment regimens had no 
adverse effects on the growth performance of the male and female rat pups as measured by 
mass. It is important to note though that, as a measure of growth, body mass is not an 
accurate index as it is affected transiently by visceral/subcutaneous obesity, hydration status, 
and gut fill (Cameron, 2002) as well as the thickness of the integument and size of 
integumentary appendages (Vítek et al., 2008). Long bones grow in response to growth 
hormone in a dose-dependent manner and hence long bone linear growth is a more accurate 
long-term measure of growth performance (Butler et al., 1956) before fusion of the growth 
plates. The similarity in the tibial lengths, masses and Seedor indices from the rat pups (male 
and female) across treatment regimens further suggest that the treatment regimens had no 
adverse effect on the growth performance of rat pups. 
  
3.3.2 Blood parameters and hepatic metabolites  
In the current study, the oral administration of 10 ml/kg body mass per day of 20% fructose 
solution (FS) for 15 days to suckling male or female rat pups did not result in 
hyperglycaemia, hypertriglyceridemia, and hypercholesterolemia. This suggests that the 
administration of the 20% fructose solution during this neonatal growth phase did not induce 
metabolic derangements with regards to glucose and lipid metabolism. On the contrary 
studies using adult rat models, documented that the consumption of high-fructose diets for 2-
12 weeks resulted in increased lipogenesis, atherogenic dyslipidaemia (visceral obesity, 
hepatic hyperlipidaemia, hypercholesterolemia, and hypertriglyceridemia), hyperglycaemia 
and insulin resistance (Huynh et al., 2008; Lindqvist et al., 2008; Thorburn et al., 1989). 
Ghezzi et al. (2012) and de Moura et al. (2009) contend that since at a young age Wistar rats 
are more resistant to the development of diet-induced derangements as they are less prone to 
being obese than older animals. Obesity is a major risk factor for diet-induced metabolic 
derangements (Mager et al., 2015). Several possible explanatory mechanisms have been 
proposed. Included amongst the possible mechanisms are that at a young age, GLUT 4 
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transporters that are responsible for the uptake of glucose are less likely to be dysfunctional 
(Ghezzi et al., 2012; Machado et al., 1994) resulting in an efficient uptake of glucose. In 
addition, in young rats, intestinal brush border fructose transporters (GLUT 5) are decreased 
and immature: they start to increase and mature post-weaning (Jiang et al., 2001). Thus the 
observed lack of derangements in blood glucose concentration and lipid profile following the 
oral administration of a 20% fructose solution during the neonatal growth phase could be 
ascribed to functional capacities of the GLUT 4 and GLUT 5 transporters during the period 
of intervention. Whilst it is notable that the introduction of fructose at pre-weaning (suckling) 
has been shown to promote the precocious development of GLUT 5 transporters (David et 
al., 1995), it is not possible to draw definitive conclusions from the findings of the current 
study regarding the ability of the orally administered 20% fructose solution during neonatal 
growth phase on the induction of precocious maturation of GLUT 5 transporters. Future 
studies would require the measurement of the GLUT 5 transporters in under similar study 
settings.  
The current study also reports reduced plasma insulin concentrations in female rat pups to 
which 20% fructose solution was orally administered for 15 days (Table 3.4). This finding 
suggests that oral administration of a 20% fructose solution to suckling female Wistar rat 
pups may have exerted anti-insulinotropic effects in female rat pups but not in their male 
counterparts. According to our knowledge, no study has reported on the possible inhibitory 
effects of a high-fructose diet (in this case a 20% fructose solution) to insulin secretion by 
either young and or adult rats. The difference in the response to neonatal orally administered 
20% fructose solution by the male and female rats pup indicates the existence of sex- and 
age-related variations to a fructose insult. The consumption of high-fructose diets has been 
shown to decrease postprandial satiety, leptin and insulin response in normal-weight human 
adults (Teff et al., 2004). These decreased responses have been associated with a reduction in 
circulating insulin concentrations in normal-weight human adults (Teff et al., 2004; Kong et 
al., 1999). Insulin stimulates satiety (Melanson et al., 2008). Alzamendi et al. (2010) 
hypothesised that orally administered fructose in early-life (gestation and lactation) 
dysregulates hypothalamic control of satiety. Thus we hypothesise that the oral 
administration of a10 ml/kg body mass per day of 20% fructose solution for 15 days during 
the neonatal growth phase (suckling) may have altered satiety control through the 
dysregulation of hypothalamic control of satiety, leptin and insulin response and 
consequently caused decreased plasma insulin concentration in the female rat pups. Research 
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has demonstrated that young female rats are more sensitive than young male rats to the 
adverse metabolic programming outcomes of maternal high-fructose diets (Vicker et al., 
2011; Ojeda et al., 2016). Nonetheless, the mechanisms associated with our findings on 
female rat pups’ sexually dimorphic insulin response to high-fructose diet require further 
interrogation. The oral administration of SAC + FS had no effect on plasma insulin 
concentration which suggests that SAC attenuated insulin-lowering effects of a 20% fructose 
solution seen in female rat pups. We speculate that the mechanisms by which SAC attenuated 
the insulin-lowering effects of a 20% fructose solution might have been associated with its 
reported insulinotropic effects (Saravanan et al., 2009; Augusti and Sheela, 1996).  
Whilst Saravanan et al. (2009) reported that SAC attenuates hyperglycaemia, 
hypercholesterolemia and hypertriglyceridemia in STZ-diabetic adult rats, Liu and Yeh 
(2001) noted in vitro that SAC inhibited fatty acid and triglyceride synthesis in cultured rat 
hepatocyte cells. It is proposed that SAC exerts it's antidiabetic and antiobesity effects by 
binding to and blocking the insulin-inactivating sites in the liver and thus increasing the 
availability of free insulin (Augusti and Sheela, 1996). In the current study, the oral 
administration of SAC alone had no effect on female pups’ blood glucose, cholesterol and 
triglyceride concentration.  
It should be noted that although the plasma insulin concentrations of suckling female rat pups 
to which SAC and DH (control) was orally administered were not significantly different, the 
female rat pups to which SAC was orally administered showed a trend of a higher insulin 
concentration compared to their counterparts on DH. The oral administration of SAC alone 
increased plasma insulin concentration and HOMA-IR in male rat pups but had no effect on 
their blood glucose, cholesterol, and triglyceride concentration (Table 3.3). It could be 
inferred from the results that orally administered SAC’s effects on insulin secretion are 
sexually dimorphic. These findings seem to confirm the antidiabetic activity of SAC and 
hence its potential use as an antidiabetic agent. These findings are in agreement with those by 
Saravanan et al. (2009) who noted that SAC attenuated hypoinsulinemia in STZ-diabetic 
male adult rats. S-allyl-cysteine is reported to stimulate insulin secretion by pancreatic β-cells 
and prevent insulin inactivation (Saravanan et al., 2009).  
The sexually dimorphic response to SAC observed in suckling rat pups may be related to the 
variation in the timing of development of physiological systems. In male rats, an upsurge in 
testosterone in late gestation and neonatal periods has been shown to accelerate development 
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of various brain structures including the hypothalamic system (Sakuma, 2009) and 
consequently resulting in the earlier development of the endocrine systems (Viveros et al., 
2009). In addition, greater incretins concentrations have been reported in male rat pups than 
in female rat pups (Ojeda et al., 2016). Therefore the sexually dimorphic responses to orally 
administered SAC and or the 20% fructose solution (simulating a high-fructose diet) 
observed in the suckling rats could be due to the sex-related variation in the development of 
the endocrine system.  
In the present study, the oral administration of 20% fructose solution alone or SAC + FS 
resulted in a significant reduction in the liver lipid content of female rat pups (Figure 3.8). 
Additionally, the liver glycogen content was reduced in female rat pups to which a 20% 
fructose solution alone was orally administered in the present study (Figure 3.6). These 
findings suggest that the orally administered 20% fructose solution may have altered 
synthesis and storage of liver metabolites. The findings from the present study are in 
disagreement with Araujo et al. (2015) and Yadav et al. (2007), who reported that the 
consumption of a high-fructose diet (10% fructose w/v) resulted in increased hepatic lipid 
and glycogen content in adult male rats. However, this disagreement in findings could be 
attributed to the differences in the age and sex of the rats that were used in the current study 
(21-days old) and that by Araujo et al. (2015) and Yadav et al. (2007) who used adult rats.  
Insulin, an anabolic hormone, stimulates tissues’ uptake of glucose and promotes lipogenesis 
in the liver and adipose tissue (Samuel and Shulman, 2012). Thus the reduced hepatic lipid 
and glycogen content observed in female rat pups to which a 20% fructose solution was 
orally administered could be attributed to the reduced insulin observed in them (Table 3.4). 
The treatment regimens administered in the current study had no effect on male rat pups’ 
liver glycogen and lipid content further suggesting that female rat pups could be more 
susceptible to the metabolic effects of high-fructose diet during suckling when compared to 
their male counterparts. Our findings are similar to those reported by Ojeda et al. (2016) who 
observed that in early-life female rat pups were more sensitive than males to adverse effects 
of a maternal high-fructose diet.  
Interestingly, the present study also reports that in female rat pups the administration of SAC 
alone for 15 days increased liver lipid content and decreased liver glycogen content (Figures 
3.6 and 3.8). We hypothesise that the changes in liver glycogen and lipid content in female 
rat pups might have been triggered by the SAC’s speculated insulinotropic effects (Iliya et 
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al., 2016a; Saravanan et al., 2009). Insulin, a major metabolic regulatory hormone, stimulates 
glycogenesis and lipogenesis and inhibits lipolysis in tissues (Samuel and Shulman, 2012). 
Koopmans et al. (1999) reported that in adult Sprague-Dawley rats, prolonged 
hyperinsulinemia stimulated de novo lipogenesis, inhibited glycogenesis and triggered insulin 
resistance. Insulin-activated glycogen synthesis is inhibited by excess lipid accumulation in 
the liver (Samuel and Shulman, 2012), hence this may explain the decreased glycogen noted 
in suckling female rats that were orally administered SAC in the current study.  
The potential beneficial effects of SAC (insulinotropic effect) could possibly result in adverse 
metabolic effects such as increased hepatic lipid accumulation and consequently NAFLD in 
growing females. An increase in liver lipid content could potentially cause NAFLD and 
subsequently increase the risk of developing metabolic derangements such as MetS, DM II, 
and cardiovascular complications. In vitro work by Lui and Yeh (2001) demonstrated that 
SAC inhibits cholesterol and free fatty acid synthesis in cultured liver cells. In non-alcoholic 
fatty liver diseased 29-day old Otsuka Long-Evans Tokushima male rats, the consumption of 
SAC (0.45% w/v in feed) upregulated hepatic proliferator-activated receptors alpha and 
gamma resulting in mitigated hypertriglyceridemia, hypercholesterolemia and NAFLD 
(Takemura et al., 2013). Our results are in disagreement with those of Takemura et al. (2013) 
and Lui and Yeh, (2001). The difference between our results and those of Takemura et al. 
(2013) could be attributed to differences in the physiological effects of SAC in neonatal and 
adult rats, experimental model [preventative model used by the current study versus the 
treatment model used by Takemura et al. (2013)] and doses used [150 mg/kg body mass per 
day of SAC used in the current study versus 0.45% SAC in feed used by Takemura et al. 
(2013)]. The demonstrated lipogenic effect of SAC in female rats’ livers during neonatal life 
in the present study requires further scrutiny in order not only to elucidate fully the 
underlying physiological mechanisms but to explore the possible long-term implications an 
issue which is partially investigated in the study described in chapter four of this thesis. 
 
3.3.3 Visceral organs 
Orally administered substances can alter growth and development of visceral organs such as 
the liver and GIT (Metges, 2011). While the GIT is vital for food digestion and nutrient 
absorption, the liver is regarded as the metabolic powerhouse (Metges, 2011). The current 
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study shows that in male rat pups, the oral neonatal administration of SAC resulted in 
significantly heavier relative (to tibia length) liver masses compared to rat pups to which 
distilled water (control) was administered (Table 3.5). Despite the observed heavier liver 
masses in male rat pups (relative to tibia length) as a result of neonatal oral administration of 
SAC; this administration of SAC did not result in an increase in hepatocyte size and number 
of intact hepatocytes in a linear field in both male and female rat pups. Whilst this finding 
suggests that SAC may have stimulated liver growth in male rat pups but not in female rat 
pups hence the former’s heavier livers (relative to tibia length). However, it is unlikely since 
there were no differences in the absolute masses of the rat pups’ livers. The observed 
differences could possibly be due to the differences in bone lengths which although not 
statistically significantly different showed a trend to being slightly smaller in the DH 
(control) groups.  
The liver is a major site of metabolism and hence is prone to toxic insults which can be 
assessed histologically. The present study reports no differences in hepatic ballooning, 
inflammation and steatosis scores and NAS and no observable pathological differences in the 
micro-morphometry of the liver samples from the male and female rat pups across treatment 
regimens. These findings suggest that none of the treatment regimens had adverse effects on 
the hepatic histological morphometry of male and female rat pups. Remarkably, although 
neonatal orally administered SAC induced increased total liver lipid content in female rat 
pups, this did not translate to adverse liver histomorphometric and pathological effects when 
scored using established criteria.  
Studies have shown that administration to neonates of phytochemicals such as 
phytohaemagglutinin, polyamines and allicin induces precocious maturation of the GIT 
(Tatara et al., 2008; Linderoth et al., 2006; Linderoth et al., 2005; Löser et al., 1999). The 
similarities in absolute and relative (to tibia length) masses and lengths of the small intestine 
and large intestine of male and female rat pups across treatment regimens suggests that the 
neonatal oral administration of DH, SAC, FS and or SAC + FS had no adverse effects on the 
small and large intestines macro-morphometry. Although both SAC and allicin are 
phytochemicals derived from garlic, unlike allicin the SAC did not impact on the gross 
morphometry of the GIT. Hence further supporting the biosafety of SAC compared to allicin 
(Amagase, 2006; Amagase et al., 2001).  
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3.3.4 Surrogate markers of liver and kidney function 
The use of ethnomedicinal-derived phytochemicals to manage systemic ailments has various 
potential adverse consequences such as cytotoxicity and organ damage (Nehar et al., 2015). 
Thus when investigating the potential of ethnomedicinal-derived phytochemicals it is 
essential to also interrogate their probable detrimental health effects. The liver, regarded as 
the metabolic engine, has various functions including synthesis and storage of metabolites 
and hormones (Samuel and Shulman, 2012), detoxification of xenobiotic substances 
(Skrypnik et al., 2016) and conjugation of bilirubin (Erlinger et al., 2014). Through these 
functions, it is exposed to many chemicals and toxins presented to the body. 
While increased plasma activity of ALT is indicative of intra-hepatic damage, depending on 
the isoform that is increased, plasma ALP activity is associated with post-hepatic liver 
damage, increased bone turnover and or inflammatory intestinal diseases (Lens et al., 2014; 
Philip et al., 2014; Schutte et al., 2013). Bilirubin, a waste product formed from haemolysis, 
is solubilised in the liver and excreted in the faeces and urine. Increased plasma bilirubin 
concentrations are indicative of pre-hepatic, intra-hepatic and post-hepatic liver disease (Pratt 
and Kaplan, 2000). In mice, SAC protects against acetaminophen-induced hepatotoxicity by 
mitigating oxidative stress induced damage and attenuating C-reactive protein (CRP) and 
ALT activity (Hsu et al., 2006). The neonatal oral administration 20% fructose solution, SAC 
and or SAC + FS had no effect on the surrogate markers of liver function (ALT, ALP, and 
total TBIL) in the male and female rat pups. These findings suggest that the neonatal orally 
administered of 20% fructose solution, SAC and or SAC + FS had no toxic adverse effects on 
the liver function of both the male and female rat pups. 
Albumin and globulin, major plasma proteins synthesised by the liver, are responsible for 
numerous physiological functions (Azab et al., 2013). Decreased albumin and globulin 
plasma concentration are associated with advanced liver damage (Sekhar et al., 2014). 
Hyperalbuminemia commonly occurs in patients with severe dehydration (Rybakowski et al., 
2012; Shane et al., 2010) and it may also be induced by high-protein intake (Mutlu et al., 
2006). In the current study male rat pups to which SAC and or SAC + FS was orally 
administered during the neonatal growth phase had increased plasma albumin concentration 
(Table 3.11). Although the current study did not directly evaluate the hydration status of the 
rat pups, there were no overt clinically signs of dehydration such as decreased skin elasticity 
and dry mucous membranes (Chisti et al., 2013). Thus our findings of hyperalbuminemia 
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noted in suckling male rat pups that were orally administered SAC may be attributed to SAC 
probably altering albumin metabolism in male rat pups. Our findings are in agreement with 
Saravanan and Ponmurugan, (2012b), who reported that orally administered SAC (150 
mg/kg) prevented hypoalbuminemia in STZ-diabetic adults Wistar rats by inhibiting protein 
catabolism and promoting albumin synthesis and secretion. It is unclear why this was noted 
in male rat pups only in the current study.  
The kidneys are responsible for various important physiological functions such as producing 
hormones, reabsorbing glucose and minerals, excreting urea, creatinine and sodium and 
producing urine. Whereas urea is synthesised from ammonia generated either by oxidative 
breakdown of amino acids and or via transamination reaction in the liver (Wyss and 
Kaddurah-Daouk, 2000), creatinine is produced as a breakdown product of creatinine kinase 
in skeletal and cardiac muscle (Macedo et al., 2010; Beddhu et al., 2003). Urea and creatinine 
are filtered by the kidney from blood and are excreted in urine (Brisco et al., 2013). As such 
they are used as surrogate markers of kidney function thus any impairment to renal function 
results in increased plasma urea and creatinine (Cavalcanti et al., 2006). An assessment of the 
urea:creatinine ratio is used to classify the type of renal impairment, namely prerenal, 
intrarenal and postrenal (Brisco et al., 2013). In the current study, the treatment regimens had 
no effect on the plasma creatinine and blood urea nitrogen of pups suggesting that they 
(treatment regimens) did not have any toxic or adverse effects on the kidneys of suckling 
male and female rat pups. 
 
3.4 Conclusion 
Orally administered S-allyl-cysteine exhibited no toxicity to the liver and kidneys of suckling 
Wistar rat pups. Neonatal (suckling) oral administration of a 20% fructose solution or SAC 
resulted in sexually dimorphic effects on the rat pups’ plasma insulin concentration and 
hepatic glycogen and lipid storage. Specifically, the neonatal oral administration of a 20% FS 
to suckling female rat pups caused hypoinsulinemia which, (hypoinsulinemia) was attenuated 
by the neonatal oral administration of SAC. While in male rat pups the neonatal oral 
administration of SAC alone increased plasma insulin concentration, in female rat pups it 
increased hepatic lipid accretion. Although SAC exhibited insulinotropic potential in male 
and female rat pups which make it a probable antidiabetic agent, its use in young females 
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should be done with caution as it may increase the risk of developing NAFLD as it was 
observed to increase liver lipid content in female rat pups that were modelling human infants.  
The next chapter (chapter 4) provides background literature and a justification and then states 
the aim, objectives and hypotheses of the second experiment which sought to interrogate the 
long-term effects and the potential of neonatal orally administered SAC to protect against a 
‘single-hit’ and ‘double-hit’, high-fructose diet-induced metabolic derangements. The chapter 
also details the materials and methods and narrates the findings of the study and discusses the 
findings of the second experiment.   
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CHAPTER 4: EFFECTS OF EARLY 
ADMINISTRATION OF S-ALLYL-
CYSTEINE ON THE RESPONSE TO A 
HIGH FRUCTOSE DIET  
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4.0 Introduction 
Children that are overweight or obese are most likely to grow up to become obese adults 
(Pandita et al., 2016). This suggests that metabolic derangements in early-life may play a key 
role in the epidemic prevalence of obesity in adulthood. Globally, approximately 2.1 billion 
adults are overweight or obese (Smith and Smith, 2016). Obesity increases morbidity by 
raising the risk of developing cardio-metabolic complications such as NAFLD, MetS, DM II, 
coronary heart disease and ischaemic heart failure (Reinehr, 2016; Alisi and Nobili, 2014; 
Sookoian et al., 2013; Cole et al., 2000). The consumption of unhealthy diets, sedentary 
lifestyles, a reduction in sleep, urbanisation, stressful environment, medical conditions (for 
example hypothyroidism), genetic predisposition socio-economic status and neonatal 
exposure to suboptimal diets which results in epigenetic changes and metabolic programming 
contribute to the onset and maintenance of obesity and its consequent metabolic 
derangements (Franks and McCarthy, 2016; Mohamed et al., 2014).  
Investigations into the lifestyle, environmental, genetic and epigenetic factors that contribute 
to the obesity epidemic are essential in the effort to find interventions to prevent, manage, 
and treat obesity and its numerous consequential complications. Researchers have focused on 
investigating the role of lifestyle and genetic factors on the increased prevalence of obesity, 
NAFLD and MetS (Albracht-Schulte et al., 2016; Reinehr, 2016). However the 
Developmental Origins of Health and Disease (DOHaD) hypothesis states that perinatal 
exposure to suboptimal nutritional and environmental stimuli can cause epigenetic changes 
that alter the functioning of various physiological systems and consequently increase the 
susceptibility or resistance of developing metabolic derangements in adulthood (Nomura and 
Yamanouchi, 2012; Vickers et al., 2011; Chen et al., 2010). Epigenetic changes result in the 
upregulation and or down-regulation of gene expression without altering the genome 
sequence (Laker et al., 2013). The main mechanisms that cause epigenetic changes are 
methylation of the DNA and histone modification (Vickers et al., 2011). The methylation of 
DNA entails the addition of methyl groups to the fifth carbon of the cytosine ring (Laker et 
al., 2013) while histone modification results from the alteration of DNA packaging proteins 
through processes such as acetylation, methylation and or phosphorylation (Miao et al., 
2014). The changes in the DNA structure through methylation and or changes in the DNA 
packaging proteins have been and are linked to the single-hit and double-hit hypotheses of 
diet-induced metabolic programming. 
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According to the single-hit hypothesis of metabolic programming, exposure to single-hit of 
suboptimal nutrition immediately after birth can result in the manifestation of metabolic 
derangements in the individual either immediately or after a period of latency (Almond and 
Currie, 2011). The double-hit (two-hit hypothesis or multiple-hit hypothesis) hypothesis was 
first coined by cancer geneticist researcher, Dr. Alfred George Knudson in 1971 to address 
the multifactorial genetic interactions that lead to the development of cancer. This hypothesis 
has been adopted by researchers interrogating multifactorial interactions involved in the 
development metabolic programming. The double-hit hypothesis of metabolic programming 
states the ‘first-hit’ or ‘single-hit’ events in perinatal life alone are not sufficient to cause the 
onset of metabolic derangements in adult life (Tamashiro and Moran, 2010). It is argued that 
the ‘first-hit’ events merely increase the risk of developing metabolic derangements when a 
‘second-hit’ multifactorial stimuli or factors are introduced in adulthood (Stewart et al., 
2013). Huynh et al. (2008) demonstrated that the ‘first-hit’ oral administration of 10% 
fructose solution to suckling Wistar rats increased susceptibility to developing metabolic 
dysfunction, obesity, and hyperinsulinemia following a ‘second-hit’ with 65% fructose w/w 
in the feed in adulthood.  
The consumption of bitter melon powder (1% w/w in diet) by rats fed a high-fructose diet 
‘first-hit’ during gestation and lactation protected their resultant offspring against a ‘second-
hit’ high-fructose diet-induced metabolic derangements in adulthood. The protective effects 
of bitter melon powder against the adverse ‘double-hit’ high-fructose diet-induced metabolic 
programming noted by Ching et al. (2011) were ascribed to the bitter melon powder’s 
antioxidant, antiobesity and antidiabetic properties. Other studies have also demonstrated that 
the maternal administration of antiobesity and antidiabetic substances during gestation and 
lactation protected offspring against the adverse outcomes of ‘single-hit’ and ‘double-hit’ 
diet-induced metabolic programming (Carvalho et al., 2016; Desai et al., 2013; Li et al., 
2012; Barbalho et al., 2011; Elahi et al., 2008). There is a dearth of studies that investigated 
and or investigate the potential of neonatal orally administered ethnomedicines with 
antiobesity and antidiabetic activity to protect against the adverse metabolic outcomes of 
‘early single-hit’, ‘late single-hit’ and ‘double-hit’ diet-induced metabolic programming in 
adulthood. 
S-allyl-cysteine (SAC), a water soluble organosulphur phytochemical constituent of garlic 
Hoshino et al., 2001) possesses antioxidant, antiobesity and antidiabetic properties which are 
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beneficial to health (Asdaq, 2015; Saravanan et al., 2013; Saravanan and Ponmurugan, 2013). 
These beneficial effects of SAC suggest that it may be a viable intervention for protecting 
against the ‘early single-hit’, ‘late single-hit’ and ‘double-hit’ high-fructose diet-induced 
adverse metabolic derangements in adulthood. Nonetheless, there are no studies that have 
investigated the potential of neonatal orally administered SAC to protect against the adverse 
metabolic outcomes of early or late ‘single-hit’ and ‘double-hit’ high-fructose diet in 
adulthood. For the purposes of the current study ‘early single-hit’ high-fructose diet refers to 
neonatal orally administered 20% fructose solution, ‘late single-hit’ high fructose diet refers 
to consumption of 20% fructose drinking water in adulthood and ‘double-hit’ high-fructose 
diet refers to a combination of neonatal orally administered 20% fructose solution (early 
fructose-hit) and 20% fructose drinking water in adulthood (late fructose-hit). This study 
sought to determine the potential of orally administered SAC to suckling Wistar rats to 
protect against the development of metabolic derangements in adulthood when the rats were 
challenged by a “second hit” of a high-fructose diet in adulthood. The study specifically 
sought to determine the effects on growth performance (body mass and linear growth), blood 
metabolites (glucose, triglycerides, cholesterol and insulin concentration), liver lipid content, 
viscera morphometry and surrogate markers of liver (alanine aminotransferase and alkaline 
phosphatase) and kidney (creatinine and blood urea nitrogen) function.  
Hypothesis  
H1: Oral neonatal administration of SAC protects adult male and female Wistar rats against 
the development metabolic derangements induced by either neonatal or adult “single hit” and 
or a combinatorial neonatal and later adult “double hit” high fructose diet.  
H0: Oral neonatal administration of SAC does not protect adult male and female Wistar rats 
against the development of metabolic derangements induced by either neonatal or adult 
“single hit” and or a combinatorial neonatal and later adult “double hit” high fructose diet. 
 
4.1 Materials and methods 
4.1.1 Animals, feeding and Housing 
One hundred and twenty-eight, four-day-old, male and female Wistar rat pups from 12 first-
time female breeders (litter size: minimum 8, maximum 12) were used in the study. The litter 
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size range used in the study was based studies that have shown that litter sizes that are too 
small or too large result in over nourishment and under undernourishment respectively, which 
alters metabolic function (Habbout et al., 2013; Patterson et al., 2010). The study was done in 
three experimental stages: experimental stage 1 was from postnatal day 6 to 20; experimental 
stage 2 was from postnatal day 21 to 55, and stage 3 was from postnatal day 56 to 116. 
During the first experimental stage, the rat pups in the litters were housed with their 
respective dams in Perspex cages lined with wood shavings in the Central Animal Services 
(CAS). After weaning (postnatal day 21 to onwards) the rats (weanling) were housed 
individually in Perspex cages. Room temperatures were maintained 24 ± 2 °C with a 12-h 
light/dark cycle (lights on from 07:00 h to 19:00 h) for all experimental stages. The rats had 
ad libitum access to standard rat chow pellets during the second experimental stage. 
 
4.1.2 Experimental design 
The first experimental stage, which was the neonatal intervention stage, was designed as 
described in chapter 3, subheading 3.1.4. Briefly, the pups were randomly allocated to and 
administered one of the following treatment regimens: group I - 10 ml/kg body mass per day 
of distilled water (DH), group II - 10 ml/kg body mass per day of 20% fructose solution (w/v) 
[FS], group III - 150 mg/kg body mass per day of S-allyl-cysteine dissolved in distilled water 
(SAC), group IV - 150 mg/kg body mass per day of SAC dissolved in distilled water and 10 
ml/kg body mass per day of 20% fructose solution (w/v) [SAC + FS]. The random allocation 
was such that the male to female rat ratio was close to 1:1 as possible per treatment regimen 
and respective treatment regimens were administered daily to the respective rat pups for 15 
days (postnatal day 6 to 20).  
During the second experimental stage, which was the growth stage (postnatal day 22 to 55), 
the rats were weaned (postnatal day 21) and housed individually and their mothers returned to 
stock. In the second experimental stage, all rats were allowed ad libitum access to standard 
rat feed and plain drinking water.  
The third experimental stage, which was the adulthood intervention stage, was conducted 
from postnatal 56 to 116. On postnatal day 56, the male and female rats from each treatment 
regimen during stage 1 were randomly allocated to two subgroups: subgroup I: continued on 
a standard rat chow (ad libitum) and plain drinking water (PDW) and sub-group II: standard 
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rat chow (ad libitum) and 20% fructose (w/v) drinking water (high-fructose diet group, FW). 
The rats in each of the subgroups were kept on their respective treatment regimens for 8 
weeks and thereafter fasted overnight and then subjected to an oral glucose tolerance test and 
then returned on their respective treatment regimens and then euthanised 48 hours later. 
 
 
Figure 4.1: A schematic representation of the study design 
DH = 10 ml/kg body mass per day distilled water; FS = 10 ml/kg body mass per day 20% 
fructose solution (w/v); SAC = 150 mg/kg body mass per day S-allyl-cysteine; SAC + FS = 
150 mg/kg body mass per day S-allyl-cysteine + 10 ml/kg body mass per day 20% fructose 
solution (w/v); SRC + PDW = standard rat chow + plain drinking water; SRC + FW = 
standard rat chow + fructose drinking water; OGTT = oral glucose tolerance test; PND = 
postnatal day. 
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4.1.3 Measurements 
4.1.3.1 Body mass 
The rats were weighed daily in the first experimental stage (postnatal days 6 to 21) and twice 
a week during the second and third experimental stages (from postnatal day 22 to 55 and 
from postnatal day 56 to 116, respectively). An electronic balance (Snowrex Electronic Scale, 
Clover Scales, Johannesburg) was used to weigh the rats.  
 
4.1.3.2 Oral glucose tolerance test  
After 8 weeks (postnatal day 56 to 114) of high-fructose diet intervention during adulthood, 
the rats were fasted overnight and fasting blood glucose concentration determined from a 
drop of blood obtained from the tail vein via pinprick (Loxham et al., 2007). The blood 
glucose concentration was determined using a calibrated Contour Plus glucometer (Bayer 
(Pty) LTD, Isando, South Africa) as per the manufacturer’s instructions. Thereafter the rats 
were gavaged with 2 g/kg glucose (Kannappan and Anuradha, 2009) and blood collected 
from the tail vein to determine glucose concentration post-gavage at fixed time intervals (15, 
30, 60 and 120 minutes using a calibrated glucose meter. The rats were put back on their 
respective treatment regimens for 48 hours to allow them to recover. 
 
4.1.4 Terminal procedures 
4.1.4.1 Determination of terminal body mass and fasted blood glucose 
At the end of the third experimental stage (postnatal day 116), the rats were fasted overnight 
and then their terminal body masses were measured by placing them in a pre-weighed box on 
an electronic scale (Snowrex Electronic Scale, Clover Scales, Johannesburg). The rats were 
then euthanized by intraperitoneal injection of an overdose of sodium pentobarbitone (Eutha-
naze, Bayer (Pty) LTD, Isando, South Africa) at 200 mg/kg
 
body mass.  
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4.1.4.2 Blood collection, processing, and storage 
Following euthanasia, blood was collected via cardiac puncture using 18 G needles and 10 ml 
syringes into 6 ml heparinised blood collection tubes (Becton Dickinson Vacutainer Systems 
Europe, Meylan Cedex, France) and then spun for 15 min at 5000 g at 22 
0
C in a Senova 
NovaFuge centrifuge (Senova Labtech Co, LTD, Shanghai, China). Plasma was then 
collected and then stored at -20 
0
C for determination of triglycerides, cholesterol, and insulin 
concentrations and surrogate markers of liver (ALT and ALP) and kidney (creatinine and 
blood urea nitrogen) function. 
 
4.1.4.3 Determination of visceral organ morphometry  
Visceral organ morphometry was determined as described in chapter 3 under subheading 
3.1.6.3. Additionally the visceral (mesenteric and perirenal) fat and epididymal fat (in males 
only) were dissected out and their masses determined by placing them in a pre-weighed 
weighing boat on an electronic scale (Presica 310M, Presica Instruments AG, Switzerland).  
 
4.1.4.4 Determination of liver histo-morphometry 
Liver histomorphometry and scoring was done as described in chapter 3 under subheading 
3.1.6.4 
 
4.1.5 Determination of fasting plasma triglycerides and cholesterol 
Fasted plasma triglyceride concentration was determined using a calibrated Accutrend 
triglyceride meter (Roche, Mannheim, Germany) as per the manufacturer’s instructions.  
The fasted plasma cholesterol concentration was determined using a colorimetric-based 
clinical chemistry analyser (IDEXX VetTest® Clinical Chemistry Analyser, IDEXX 
Laboratories Inc., USA) as described in chapter 3 under subheading 3.19. 
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4.1.6 Determination of hepatic lipid content  
The liver lipid content was determined as described chapter 3 under subheading 3.1.7. 
 
4.1.7 Determination of plasma insulin concentration 
The determination of plasma insulin concentration and computation of HOMA-IR were done 
as described in chapter 3 under subheading 3.1.8. 
 
4.1.8 Determination of linear growth 
The evaluation of morphometric (masses and lengths) parameters of tibiae, computation of 
Seedor indices and capturing of radiograph images were done as described in chapter 3 under 
subheading 3.1.9. 
 
4.1.9 Determination of surrogate markers of liver and kidney function 
The determination of the plasma ALT, ALP and amylase activity and plasma blood urea 
nitrogen and creatinine concentration was done using a colorimetric-based clinical chemistry 
analyser (IDEXX VetTest® Clinical Chemistry Analyser, IDEXX Laboratories Inc., USA) as 
described in chapter 3 under subheading 3.1.10. 
 
4.1.10 Statistical analysis 
Parametric data are expressed as mean ± SD and non-parametric data are expressed as 
median and range (min, max). The data were analysed using GraphPad Prism 5 software 
(Graph-Pad Software Inc., San Diego, CA, USA). Statistical significance was considered 
when p ≤ 0.05. Data on body mass and oral glucose tolerance test were analysed using a 
repeated measures analysis of variance (ANOVA). A one-way ANOVA was used to analyse 
other multiple group data followed by mean comparison using a Bonferroni post hoc test to 
compare means. The Kruskal-Wallis test (non-parametric one-way ANOVA) was used to 
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analyse non-alcoholic fatty liver disease score (NAS) multiple group data followed by Dunns 
post hoc test to compare medians.  
The model used for the analysis of variance for weekly body masses and the glucose 
tolerance test was: 
Yijk = μ + Ti + Bj + Ck + eijk; where; 
Yijk = weekly body mass and or blood glucose concentration at time C post gavage 
μ = overall mean common to all observations 
Ck = fixed effect of sampling time on blood glucose concentration (= 1,2......5) 
Ti = effect of treatment regimen (n = 1,2.....8) 
Bj = fixed effect of individual rat (1,2,3.........64)  
eijk = residual random error 
The model used for ANOVA for variables determined at study termination was: 
Yijk = μ + Ti + Bj + eijk; where; 
Yijk = response variable of interest 
μ = overall mean to all observations 
Ti = effect of treatment (n = 1,2,..8) 
Bj = fixed effect of individual rat (1,2,3.........64)  
eijk = residual random error  
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4.2 Results 
4.2.1 Growth performance  
4.2.1.1 Body mass 
Figure 4.2 below shows the induction, weaning, and terminal body masses of male rats across 
the treatment regimens. 
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Figure 4.2: Effect of high-fructose diet on body masses of the male rat pups orally 
administered S-allyl-cysteine during suckling. 
*** p < 0.0001. Induction, weaning, PND 56, and terminal body masses of the rats were 
similar across treatment regimens. The rats grew (p < 0.0001) significantly compared to their 
induction and weaning masses. DH + PDW = gavage with 10 ml/kg body mass per day 
distilled water during suckling + plain drinking water in adulthood; DH + FW = gavage with 
10 ml/kg body mass per day distilled water during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% 
fructose solution (w/v) during suckling + plain drinking water in adulthood; FS + FW = 
gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 20% 
fructose (w/v) in their drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg 
body mass per day S-allyl-cysteine during suckling + plain drinking water in adulthood; SAC 
+ FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% 
fructose (w/v) in their drinking water in adulthood; SF + PDW = gavage with 150 mg/kg 
body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; SF + FW = gavage with 150 
mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose 
solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in adulthood; IM 
= induction mass; PND = postnatal day; TM = terminal mass; WM = weaning mass. Data 
presented as mean ± SD; n = 8-9 per treatment regimen. 
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There were no difference in the male rats’ body masses at induction, weaning, PND 56 and 
termination across treatment regimens. However, across treatment regimens, the male rats 
grew significantly (p < 0.0001) from induction to weaning, from weaning to PND 56 and 
from PND 56 to termination of the study (Figure 4.2).  
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Figure 4.3 shows the induction, weaning and terminal body masses of female rats across 
treatment regimens. 
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Figure 4.3: Effect of high-fructose diet on body masses of the female rat pups orally 
administered S-allyl-cysteine during suckling. 
*** p < 0.0001. Induction, weaning, PND 56, and terminal body masses were similar across 
all treatment regimens. The rats grew (p < 0.0001) significantly compared to their induction 
and weaning masses. DH + PDW = gavage with 10 ml/kg body mass per day distilled water 
during suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body 
mass per day distilled water during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg 
body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 
150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood; IM = induction mass; PND = 
postnatal day; TM = terminal mass; WM = weaning mass. Data presented as mean ± SD; n = 
7-9 per treatment. 
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There were no difference in female rats’ body masses at induction, weaning, PND 56 and 
termination across treatment regimens.However, across treatment regimens, the female rats 
grew significantly (p < 0.0001) from induction to weaning, from weaning to PND 56 and 
from PND 56 to termination of the study (Figure 4.3).  
139 
 
4.2.1.2 Linear growth 
Table 4.1 below shows lengths, masses and Seedor indices of tibiae of male rats following 
oral administration of their respective treatment regimens.  
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Table 4.1: Effects of high-fructose diet on tibia masses, lengths and Seedor indices of 
adult male rats orally administered S-allyl-cysteine during suckling  
Treatments Tibia mass (mg) Tibia length (mm) Tibia Seedor index (mg/mm) 
DH + PDW 342.60 ± 17.04 39.89 ± 0.74 8.58 ± 0.42 
DH + FW 337.60 ± 15.93 39.60 ± 0.77 8.53 ± 0.40 
FS + PDW 337.80 ± 12.94 39.41 ± 1.54 8.58 ± 0.52 
FS + FW 326.20 ± 14.13 39.69 ± 0.76 8.22 ± 0.27 
SAC + PDW 338.30 ± 22.08 39.66 ± 0.74 8.53 ± 0.61 
SAC + FW 341.80 ± 23.38 38.62 ± 3.40 8.88 ± 0.70 
SF + PDW 346.10 ± 27.66 39.46 ± 0.56  8.78 ± 0.75  
SF + FW 337.80 ± 14.62 39.23 ± 1.13  8.62 ± 0.46  
Tibiae lengths, masses, and densities (Seedor indices) from rats across treatment regimens 
were similar. DH + PDW = gavage with 10 ml/kg body mass per day distilled water during 
suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass 
per day distilled water during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg 
body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 
150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood. Data presented as mean ± SD; n = 8-
9 per treatment. 
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There were no differences in tibiae masses, lengths and densities of male rats across 
treatment regimens (Table 4.1).   
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Table 4.2 below shows lengths, masses and Seedor indices of tibiae of female rats following 
oral administration of their respective treatment regimens 
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Table 4.2: Effects of high-fructose diet on tibia masses, lengths and densities (Seedor 
indices) of adult female rats orally administered S-allyl-cysteine during suckling 
Treatments Tibia mass (mg) Tibia length (mm) Tibia Seedor index (mg/mm) 
DH + PDW 289.30 ± 7.80 37.06 ± 1.33 7.82 ± 0.33 
DH + FW 269.10 ± 17.11 36.30 ± 0.95 7.43 ± 0.62 
FS + PDW 286.80 ± 7.42 36.01 ± 0.42 7.80 ± 0.28 
FS + FW 284.60 ± 11.46 36.55 ± 1.39 7.80 ± 0.43 
SAC + PDW 286.80 ± 9.53 35.77 ± 0.42 8.02 ± 0.23 
SAC + FW 268.90 ± 33.50 36.66 ± 1.47 7.35 ± 1.02 
SF + PDW 279.40 ± 13.33 35.58 ± 0.92 7.95 ± 0.51 
SF + FW 287.40 ± 16.90 35.42 ± 0.56 8.11 ± 0.42 
Tibiae lengths, masses, and densities (Seedor indices) from rats across treatment regimens 
were similar. DH + PDW = gavage with 10 ml/kg body mass per day distilled water during 
suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass 
per day distilled water during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg 
body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 
150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood. Data presented as mean ± SD; n = 7-
9 per treatment. 
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There were no differences in the tibiae masses, lengths and densities of the female rats across 
treatment regimens (Table 4.2).   
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Figure 4.4 below shows the radiograph images of representative tibiae from male rats across 
treatment regimens.  
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Figure 4.4: Tibiae radiograph images of adult male rats. 
DH + PDW = gavage with 10 ml/kg body mass per day distilled water during suckling + 
plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass per day 
distilled water during suckling + 20% fructose (w/v) in their drinking water in adulthood; FS 
+ PDW = gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) during 
suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg body mass 
per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking 
water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-allyl-
cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 150 
mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood.  
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There were no observable differences in the radiographical densities of tibiae from male rats 
across treatment regimens (Figure 4.4). 
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Figure 4.5 below shows the radiograph images of representative tibiae from female rats 
across treatment regimens.  
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Figure 4.5: Tibiae radiograph images of adult female rats. 
DH + PDW = gavage with 10 ml/kg body mass per day distilled water during suckling + 
plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass per day 
distilled water during suckling + 20% fructose (w/v) in their drinking water in adulthood; FS 
+ PDW = gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) during 
suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg body mass 
per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking 
water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-allyl-
cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 150 
mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood. 
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There were no observable differences in the radiographical densities of tibiae from female 
rats across treatment regimens (Figure 4.5). 
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4.2.2 Glucose handling 
4.2.2.1 Oral glucose tolerance test 
Figure 4.6 shows the blood glucose concentration at basal/pre-gavage (0 min) and at 15, 30, 
60 and 120 minutes post-gavage with 50% percent glucose solution at 2 g/kg body mass of 
male rats following 8 weeks on their respective treatment regimens.  
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Figure 4.6: Effects of high-fructose diet on glucose tolerance of adult male rats orally 
administered S-allyl-cysteine during suckling. 
** p < 0.01. Blood glucose concentration of rats administered DH + PDW, DH + FW and 
SAC + FW peaked 15 minutes post gavage and was significantly greater (p < 0.01) than the 
basal concentration and returned to basal concentration 120 minutes post-gavage. FS + PDW, 
FS + FW, SAC + PDW, SF + PDW and SF + FW rats’ blood glucose concentration peaked 
30 minutes post-gavage and was significantly greater (p < 0.01) than the basal concentration 
and returned to basal concentration 120 minutes post-gavage. DH + PDW = gavage with 10 
ml/kg body mass per day distilled water during suckling + plain drinking water in adulthood; 
DH + FW = gavage with 10 ml/kg body mass per day distilled water during suckling + 20% 
fructose (w/v) in their drinking water in adulthood; FS + PDW = gavage with 10 ml/kg body 
mass per day 20% fructose solution (w/v) during suckling + plain drinking water in 
adulthood; FS + FW = gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) 
during suckling + 20% fructose (w/v) in their drinking water in adulthood; SAC + PDW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine during suckling + plain drinking 
water in adulthood; SAC + FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine 
during suckling + 20% fructose (w/v) in their drinking water in adulthood; SF + PDW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 
20% fructose solution (w/v) during suckling + plain drinking water in adulthood; SF + FW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 
20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in 
adulthood. Data presented as mean ± SD; n = 8-9 per treatment. 
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Male rats that were administered the following treatment regimens: neonatal oral 
administration of distilled water plus plain drinking water in adulthood (DH + PDW; 
control), neonatal oral administration of distilled water plus 20% fructose drinking water in 
adulthood (DH + FW) and neonatal oral administration of SAC plus 20% fructose drinking 
water in adulthood (SAC + FW) had significantly greater (p < 0.01) blood glucose 
concentration 15 minutes post-gavage compared to basal blood glucose concentration (Table 
4.6). The blood glucose concentration of male rats administered the following treatment 
regimens: neonatal oral administration of 20% fructose solution plus plain drinking water in 
adulthood (FS + PDW), neonatal oral administration of 20% fructose solution plus 20% 
fructose drinking water in adulthood (FS + FW), neonatal oral administration of SAC plus 
plain drinking water in adulthood (SAC + PDW), neonatal oral administration of SAC and 
20% fructose solution plus plain drinking water in adulthood (SF + PDW) and neonatal oral 
administration of SAC and 20% fructose solution plus 20% fructose drinking water in 
adulthood (SF + FW) was significantly higher (p < 0.01) than basal blood glucose 
concentration 30 minutes post-gavage (Table 4.6). The blood glucose concentration of male 
rats across treatment regimens returned to basal at 120 minutes post-gavage (Figure 4.6). 
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The blood glucose concentration of the female rats at time 0 (basal/pre-gavage), 15, 30, 60 
and 120 minutes post-gavage with a 50% glucose solution at 2g/kg body mass following 8 
weeks on their respective treatment regimens is shown in Figure 4.7.  
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Figure 4.7: Effects of high-fructose diet on glucose tolerance of adult female rats orally 
administered S-allyl-cysteine during suckling. 
** p < 0.01. Blood glucose concentration of rats administered DH + PDW, FS + PDW and 
SF + FW peaked 15 minutes post gavage and was significantly greater (p < 0.01) than the 
basal concentration and returned to basal concentration 120 minutes post-gavage. DH + FW, 
FS + FW, SAC + PDW, SAC + FW and SF + PDW rats’ blood glucose concentration 
peaked30 minutes post-gavage and were significantly greater (p < 0.01) than the basal 
concentration and returned to basal concentration 120 minutes post-gavage. DH + PDW = 
gavage with 10 ml/kg body mass per day distilled water during suckling + plain drinking 
water in adulthood; DH + FW = gavage with 10 ml/kg body mass per day distilled water 
during suckling + 20% fructose (w/v) in their drinking water in adulthood; FS + PDW = 
gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + plain 
drinking water in adulthood; FS + FW = gavage with 10 ml/kg body mass per day 20% 
fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-allyl-cysteine during 
suckling + plain drinking water in adulthood; SAC + FW = gavage with 150 mg/kg body 
mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 
ml/kg body mass per day 20% fructose solution (w/v) during suckling + plain drinking water 
in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 
ml/kg body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) 
in their drinking water in adulthood. Data presented as mean ± SD; n = 7-9 per treatment. 
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Female rats that were administered the following treatment regimens: neonatal oral 
administration of distilled water plus plain drinking water in adulthood (DH + PDW; 
control), neonatal oral administration of 20% fructose solution plus plain drinking water in 
adulthood (FS + PDW) and combined neonatal oral administration of SAC and 20% fructose 
solution plus 20% fructose drinking water in adulthood (SAC + FW) had significantly greater 
(p < 0.01) blood glucose concentration 15 minutes post-gavage compared to basal blood 
glucose concentration (Table 4.7). The blood glucose concentration of female rats 
administered the following treatment regimens: neonatal oral administration of distilled water 
plus 20% fructose drinking water in adulthood (DH + FW), neonatal oral administration of 
20% fructose solution plus 20% fructose drinking water in adulthood (FS + FW), neonatal 
oral administration of SAC plus plain drinking water in adulthood (SAC + PDW), neonatal 
oral administration of SAC plus fructose drinking water in adulthood (SAC + FW), and 
neonatal oral administration of SAC and 20% fructose solution plus plain drinking water in 
adulthood (SF + PDW) was significantly higher (p < 0.01) than basal blood glucose 
concentration 30 minutes post-gavage (Table 4.7). The blood glucose concentration of female 
rats across treatment regimens returned to basal at 120 minutes post-gavage (Figure 4.7). 
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4.2.2. Area under the curve: oral glucose tolerance test 
Figure 4.8 below shows the area under the curve calculated from the oral glucose tolerance 
test results of the male rats.  
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Figure 4.8: Effects of high-fructose diet on total area under the curve of oral glucose 
tolerance of adult male rats orally administered S-allyl-cysteine during suckling. 
The total area under the curve of oral glucose tolerance of male rats was similar across 
treatment regimens. DH + PDW = gavage with 10 ml/kg body mass per day distilled water 
during suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body 
mass per day distilled water during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg 
body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 
150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood. Data presented as mean ± SD; n = 8-
9 per treatment. 
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There were no significant differences in total area under the curve of oral glucose tolerance of 
male rats across treatment regimens (Figure 4.8). 
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Figure 4.9 shows the area under the curve calculated from the oral glucose tolerance test 
results in the female rats.  
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Figure 4.9: Effects of high-fructose diet on total area under the curve of oral glucose 
tolerance of adult female rats orally administered S-allyl-cysteine during suckling. 
The total area under the curve of oral glucose tolerance of female rats was similar across 
treatment regimens. DH + PDW = gavage with 10 ml/kg body mass per day distilled water 
during suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body 
mass per day distilled water during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg 
body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 
150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood. Data presented as mean ± SD; n = 7-
9 per treatment. 
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There were no significant differences in total area under the curve of oral glucose tolerance of 
female rats across treatment regimens (Figure 4.9). 
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4.2.3 Blood parameters 
4.2.3.1 Fasting blood glucose and plasma insulin concentration and HOMA-IR index 
Table 4.3 shows the fasting blood glucose, plasma insulin concentrations and the HOMA-IR 
indices of the male rats after being administered their respective treatment regimens. 
 
  
164 
 
Table 4.3: Effects of high-fructose diet on fasting blood glucose, insulin and HOMA-IR 
indices of adult male rats orally administered S-allyl-cysteine during suckling 
Treatments Blood glucose (mmol/L) Insulin ng/mL HOMA-IR 
DH + PDW 4.45 ± 0.30 21.01 ± 7.48 4.16 ± 1.50 
DH + FW 4.15 ± 0.68 40.58 ± 22.05 6.97 ± 3.73 
FS + PDW 4.30 ± 0.41 29.95 ± 20.15 5.90 ± 4.00 
FS + FW 4.43 ± 0.51 35.47 ± 22.89 7.24 ± 5.11 
SAC + PDW 4.35 ± 0.63 27.73 ± 13.49 5.17 ± 2.73 
SAC + FW 3.94 ± 0.56 24.36 ± 17.59 4.18 ± 3.10 
SF + PDW 4.38 ± 0.68 27.75 ± 7.38 5.13 ± 1.35 
SF + FW 3.98 ± 0.52 11.52 ± 7.91 2.08 ± 1.46 
Fasting blood glucose, plasma insulin and HOMA-IR were similar across treatment 
regimens. DH + PDW = gavage with 10 ml/kg body mass per day distilled water during 
suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass 
per day distilled water during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 
ml/kg body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) 
in their drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per 
day S-allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose 
(w/v) in their drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass 
per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during 
suckling + plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass 
per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during 
suckling + 20% fructose (w/v) in their drinking water in adulthood; HOMA-IR = 
Homeostatic model of insulin resistance. Data presented as mean ± SD; n = 8-9 per 
treatment. 
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There were no significant differences in fasting blood glucose, plasma insulin and HOMA-
IR of male rats across treatment regimens (Table 4.3). 
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Table 4.4 shows the fasting blood glucose, plasma insulin concentrations and HOMA-IR 
indices of female rats after being administered their respective treatment regimens. 
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Table 4.4: Effects of high-fructose diet on fasting blood glucose, insulin and HOMA-IR 
indices of adult female rats administered S-allyl-cysteine during suckling 
Treatments Blood glucose (mmol/L) Insulin ng/mL HOMA-IR 
DH + PDW 4.52 ± 0.60 11.58 ± 7.27 2.28 ± 1.36 
DH + FW 4.41 ± 0.38 32.47 ± 11.86 6.40 ± 2.58 
FS + PDW 4.67 ± 0.72 17.11 ± 14.35 3.63 ±3.62 
FS + FW 4.11 ± 0.50 19.05 ± 15.60 3.27 ± 2.58 
SAC + PDW 4.76 ± 0.67 16.67 ± 5.60 3.45 ± 0.75 
SAC + FW 4.30 ± 0.68 15.49 ± 15.58 3.06 ± 3.33 
SF + PDW 4.51 ± 0.47 22.73 ± 12.08 4.61 ± 2.70 
SF + FW 4.44 ± 0.45 19.73 ± 15.34 4.14 ± 3.30 
Fasting blood glucose, insulin and HOMA-IR were similar in female rats across all the 
treatment regimens. DH + PDW = gavage with 10 ml/kg body mass per day distilled water 
during suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg 
body mass per day distilled water during suckling + 20% fructose (w/v) in their drinking 
water in adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose 
solution (w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 
10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 20% fructose 
(w/v) in their drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body 
mass per day S-allyl-cysteine during suckling + plain drinking water in adulthood; SAC + 
FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% 
fructose (w/v) in their drinking water in adulthood; SF + PDW = gavage with 150 mg/kg 
body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; SF + FW = gavage with 150 
mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose 
solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in adulthood; 
HOMA-IR = Homeostatic model of insulin resistance. Data presented as mean ± SD; n = 7-
9 per treatment. 
  
168 
 
There were no significant differences in fasting blood glucose, plasma insulin and HOMA-IR 
of female rats across treatment regimens (Table 4.4). 
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4.2.3.2 Plasma triglyceride and cholesterol concentrations 
 
Table 4.5 shows the plasma triglyceride and cholesterol concentrations in male rats following 
their respective treatment regimens.  
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Table 4.5: Effects of high-fructose diet on plasma triglyceride and cholesterol 
concentrations of adult male rats orally administered S-allyl-cysteine during suckling  
Treatments Triglyceride (mmol/L) Cholesterol (mmol/L) 
DH + PDW 1.71 ± 0.41 1.22 ± 0.51 
DH + FW 1.70 ± 0.48 1.32 ± 0.48 
FS + PDW 1.77 ± 0.57 1.60 ± 0.34 
FS + FW 1.97 ± 0.64 1.30 ± 0.55 
SAC + PDW 1.60 ±0.83 1.30 ±0.40 
SAC + FW 1.87 ± 0.88 1.57 ± 0.73 
SF + PDW 1.47 ± 0.40 1.35 ± 0.40 
SF + FW 2.04 ± 0.41 1.10 ± 0.24 
Plasma triglyceride and cholesterol concentrations of male rats were similar across treatment 
regimens. DH + PDW = gavage with 10 ml/kg body mass per day distilled water during 
suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass 
per day distilled water during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 
ml/kg body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) 
in their drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per 
day S-allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose 
(w/v) in their drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass 
per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during 
suckling + plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass 
per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during 
suckling + 20% fructose (w/v) in their drinking water in adulthood. Data presented as mean 
± SD; n = 8-9 per treatment. 
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There were no significant differences in plasma triglyceride and cholesterol concentrations of 
male rats across treatment regimens (Table 4.5).  
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Table 4.6 shows the plasma triglyceride and cholesterol concentrations of female rats 
following their respective treatment regimens.  
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Table 4.6: Effects of high-fructose diet on plasma triglyceride and cholesterol 
concentrations of adult female rats orally administered S-allyl-cysteine during suckling  
 Treatments Triglyceride (mmol/L) Cholesterol (mmol/L) 
DH + PDW 1.78 ± 0.78 1.47 ± 0.21 
DH + FW 2.45 ± 0.73 1.26 ± 0.28 
FS + PDW 1.67 ± 0.44 1.56 ± 0.30 
FS + FW 1.99 ± 0.83 1.62 ± 0.28 
SAC + PDW 1.70 ± 0.88 1.50 ± 0.33 
SAC + FW 1.83 ± 0.52 1.30 ± 0.50 
SF + PDW 1.47 ±0.72 1.36 ± 0.27 
SF + FW 2.07 ± 0.81 1.52 ±0.21 
Plasma triglyceride and cholesterol concentrations of female rats were similar across 
treatment regimens. DH + PDW = gavage with 10 ml/kg body mass per day distilled water 
during suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg 
body mass per day distilled water during suckling + 20% fructose (w/v) in their drinking 
water in adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose 
solution (w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 
10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 20% fructose 
(w/v) in their drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body 
mass per day S-allyl-cysteine during suckling + plain drinking water in adulthood; SAC + 
FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% 
fructose (w/v) in their drinking water in adulthood; SF + PDW = gavage with 150 mg/kg 
body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; SF + FW = gavage with 150 
mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose 
solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in adulthood. 
Data presented as mean ± SD; n = 7-9 per treatment. 
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There were no significant differences in the plasma triglyceride and cholesterol concentration 
of female rats across treatment regimens (Table 4.6).  
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4.2.4 Visceral organ morphometry  
4.2.4.1 Small and large intestine lengths and masses  
Table 4.7 shows the small and large intestine absolute and relative masses and lengths of 
male rats after being administered their respective treatment regimens. 
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Table 4.7: Effects of high-fructose diet on small and large intestine macro-morphometry of adult male rats orally administered S-allyl-
cysteine during suckling  
Treatments SI (g) SI TLr (g/mm) SI (mm) LI (g) LI TLr (g/mm) LI (mm) 
DH + PDW 6.23 ± 0.58 0.16 ± 0.01 1163 ± 27.51 1.73 ± 0.22 0.04 ± 0.005 230.6 ± 12.86 
DH + FW 6.31 ± 0.67 0.16 ± 0.02 1127 ± 91.45 1.70 ± 0.30 0.04 ± 0.007 223.3 ± 11.18 
FS + PDW 6.44 ± 0.28 0.16 ± 0.01 1170 ± 35.46 1.85 ± 0.22 0.04 ± 0.005 225.0 ± 10.69 
FS + FW 6.57 ± 0.49 0.16 ± 0.01 1212 ± 143.9 1.73 ± 0.27 0.04 ± 0.007 231.1 ± 9.280 
SAC + PDW 6.48 ± 0.38 0.16 ± 0.01 1149 ± 16.91 1.78 ± 0.14 0.04 ± 0.003 232.8 ± 19.22 
SAC + FW 6.53 ± 0.54 0.17 ± 0.02 1118 ± 38.24 1.66 ± 0.16 0.04 ± 0.005 222.2 ± 21.08 
SF + PDW 6.24 ± 0.45 0.16 ± 0.01 1168 ± 30.23 1.70 ± 0.16 0.04 ± 0.004 232.5 ± 19.09 
SF + FW 6.47 ± 0.62 0.16 ± 0.02 1067 ± 119.1 1.55 ± 0.09 0.04 ± 0.003 220.0 ± 8.944 
Small and large intestine masses and lengths of male rats were similar across treatment regimens. DH + PDW = gavage with 10 ml/kg body 
mass per day distilled water during suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass per day distilled 
water during suckling + 20% fructose (w/v) in their drinking water in adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% 
fructose solution (w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg body mass per day 20% fructose 
solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per 
day S-allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 150 mg/kg body mass per day S-allyl-
cysteine during suckling + 20% fructose (w/v) in their drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + plain drinking water in adulthood; SF + FW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 20% 
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fructose (w/v) in their drinking water in adulthood; LI = large intestine; SI = small intestine; TLr = relative to tibia length. Data presented as 
mean ± SD; n = 8-9 per treatment. 
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There were no significant differences in small and large intestine masses and lengths from the 
male rats across treatment regimens (Table 4.7).   
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Table 4.8 shows the small and large intestine absolute and relative masses and lengths of 
female rats after being administered their respective treatment regimens. 
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Table 4.8: Effects of high-fructose diet on small and large intestine macro-morphometry of adult female rats orally administered S-allyl-
cysteine during suckling 
Treatments SI (g) SI TLr (g/mm) SI (mm) LI (g) LI TLr (g/mm) LI (mm) 
DH + PDW 4.85 ± 0.60 0.13 ± 0.02 1070 ± 50.20 1.40 ± 0.09 0.04 ± 0.003 211.7 ± 27.87 
DH + FW 4.90 ± 0.28 0.13 ± 0.01 1033 ± 29.63 1.25 ± 0.08 0.03 ± 0.002 207.5 ± 14.88 
FS + PDW 4.85 ± 0.38 0.13 ± 0.01 1054 ± 22.64 1.41 ± 0.11 0.04 ± 0.003 206.9 ± 16.24 
FS + FW 4.95 ± 0.35 0.13 ± 0.01 1058 ± 50.07 1.33 ± 0.14 0.03 ± 0.003 202.5 ± 8.864 
SAC + PDW 4.91 ± 0.46 0.12 ± 0.01 1055 ± 36.25 1.40 ± 0.17 0.04 ± 0.004 196.3 ± 29.73 
SAC + FW 4.75 ± 0.48 0.13 ± 0.01 1030 ± 30.55 1.22 ± 0.06 0.03 ± 0.003 204.3 ± 5.345 
SF + PDW 4.82 ± 0.16 0.13 ± 0.01 1050 ± 29.44 1.32 ± 0.10 0.04 ± 0.002 210.7 ± 13.67 
SF + FW 4.70 ± 0.25 0.13 ± 0.01 1036 ± 48.35 1.23 ± 0.13 0.03 ± 0.003 196.5 ± 13.75 
Small and large intestine masses and lengths of male rats were similar across treatments. DH + PDW = gavage with 10 ml/kg body mass per 
day distilled water during suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass per day distilled water 
during suckling + 20% fructose (w/v) in their drinking water in adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose 
solution (w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + 20% fructose (w/v) in their drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine 
during suckling + 20% fructose (w/v) in their drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-allyl-
cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + plain drinking water in adulthood; SF + FW = gavage 
with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 20% 
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fructose (w/v) in their drinking water in adulthood; LI = large intestine; SI = small intestine; TLr = relative to tibia length. Data presented as 
mean ± SD; n = 7-9 per treatment.  
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There were no significant differences in small and large intestine masses and lengths from 
female rats across treatment regimens (Table 4.8).   
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4.2.4.2 Visceral fat and epididymal fat pad masses  
Table 4.9 shows the absolute and relative masses of visceral fat and epididymal fat masses 
from male rats after being administered their respective treatment regimens. 
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Table 4.9: Effects of high-fructose diet on visceral fat pad and epididymal fat pad 
masses of adult male rats orally administered S-allyl-cysteine during suckling 
Treatments VFP (g) VFP TLr (g/mm) EFP (g) EFP TLr (g/mm) 
DH + PDW 4.93 ± 0.93
a
 0.12 ± 0.02
a
 3.59 ± 0.59
a
 0.09 ± 0.01
a
 
DH + FW 7.44 ± 0.99
b
 0.20 ± 0.03
b
 4.30 ± 0.93
b
 0.11 ± 0.02
b
 
FS + PDW 5.26 ± 0.52
a
 0.13 ± 0.01
a
 3.32 ± 0.55
a
 0.08 ± 0.01
a
 
FS + FW 7.67 ± 0.93
b
 0.20 ± 0.03
b
 4.77 ± 0.77
b
 0.12 ± 0.02
b
 
SAC + PDW 5.70 ± 1.17
a
 0.14 ± 0.03
a
 3.78 ± 0.74
a
 0.09 ± 0.02
a
 
SAC + FW 7.32 ± 1.18
b
 0.20 ± 0.04
b
 4.32 ± 0.70
b
 0.12 ± 0.02
b
 
SF + PDW 5.56 ± 0.57
a
 0.14 ± 0.01
a
 3.41 ± 0.39
a
 0.08 ± 0.01
a
 
SF + FW 8.17 ± 1.19
b
 0.21 ± 0.03
b
 4.92 ± 0.82
b
 0.12 ± 0.02
b
 
ab
Within column means with different superscripts are significantly different at p < 0.0001. 
Regardless of neonatal oral administration intervention, all male rats that consumed FW in 
adulthood had significantly heavier (p < 0.05) visceral and epididymal fat masses compared 
to all male rats that consumed PDW in adulthood. DH + PDW = gavage with 10 ml/kg body 
mass per day distilled water during suckling + plain drinking water in adulthood; DH + FW 
= gavage with 10 ml/kg body mass per day distilled water during suckling + 20% fructose 
(w/v) in their drinking water in adulthood; FS + PDW = gavage with 10 ml/kg body mass 
per day 20% fructose solution (w/v) during suckling + plain drinking water in adulthood; FS 
+ FW = gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) during 
suckling + 20% fructose (w/v) in their drinking water in adulthood; SAC + PDW = gavage 
with 150 mg/kg body mass per day S-allyl-cysteine during suckling + plain drinking water in 
adulthood; SAC + FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine during 
suckling + 20% fructose (w/v) in their drinking water in adulthood; SF + PDW = gavage 
with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 20% 
fructose solution (w/v) during suckling + plain drinking water in adulthood; SF + FW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 
20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; EFP = epididymal fat pad; TLr = relative to tibia length; VFP = visceral fat pad. 
Data presented as mean ± SD; n = 8-9 per treatment. 
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The consumption of ‘late single-hit’ high-fructose diet resulted in significantly heavier (p < 
0.0001) visceral and epididymal fat masses in male rats (Table 4.9). Orally administered 
‘early single-hit’ high-fructose diet did not predispose the male rats to have heavier visceral 
and epididymal fat masses in adulthood (Table 4.9). A ‘double-hit’ (neonatal orally 
administered 20% fructose solution followed by 20% fructose drinking water in adulthood) 
resulted in significantly increased (p < 0.0001) visceral and epididymal fat masses in male 
rats, but the increase in visceral and epididymal fat masses was not significantly different or 
higher to the ‘late single-hit’ high-fructose diet-induced increase (Table 4.9). Neonatal orally 
administered SAC did not prevent the ‘late single-hit’ or ‘double-hit’ (early and late) high-
fructose diet-induced increase in visceral and epididymal fat masses (Table 4.9). 
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Table 4.10 shows the visceral fat pad absolute and relative masses of female rats after being 
administered their respective treatment regimens. 
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Table 4.10: Effects of high-fructose diet on visceral fat pad masses (absolute and relative 
to tibia length) of adult female rats orally administered S-allyl-cysteine during suckling 
Treatments VFP (g) VFP TLr (g/mm) 
DH + PDW 5.08 ± 1.20
a
 0.14 ± 0.03
a
 
DH + FW 7.44 ± 0.65
b
 0.20 ± 0.02
b
 
FS + PDW 5.18 ± 1.43
a
 0.14 ± 0.04
a
 
FS + FW 8.80 ± 0.21
b
 0.24 ± 0.05
b
 
SAC + PDW 5.13 ± 1.07
a
 0.14 ± 0.03
a
 
SAC + FW 8.04 ± 0.88
b
 0.22 ± 0.02
b
 
SF + PDW 5.06 ± 1.57
a
 0.14 ± 0.04
a
 
SF + FW 8.18 ± 2.21
b
 0.23 ± 0.06
b
 
ab
Within column means with different superscripts are significantly different at p ≤ 0.0001. 
Regardless of neonatal oral administration intervention, all female rats that consumed FW 
in adulthood had significantly heavier (p < 0.05) visceral and epididymal fat masses 
compared to all female rats that consumed PDW in adulthood. DH + PDW = gavage with 
10 ml/kg body mass per day distilled water during suckling + plain drinking water in 
adulthood; DH + FW = gavage with 10 ml/kg body mass per day distilled water during 
suckling + 20% fructose (w/v) in their drinking water in adulthood; FS + PDW = gavage 
with 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + plain 
drinking water in adulthood; FS + FW = gavage with 10 ml/kg body mass per day 20% 
fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-allyl-cysteine 
during suckling + plain drinking water in adulthood; SAC + FW = gavage with 150 mg/kg 
body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their drinking 
water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-allyl-
cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day 
S-allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during 
suckling + 20% fructose (w/v) in their drinking water in adulthood; TLr = relative to tibia 
length; VFP = visceral fat pad. Data presented as mean ± SD; n = 7-9 per treatment. 
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The consumption of ‘late single-hit’ high-fructose diet resulted in significantly heavier (p < 
0.0001) visceral fat mass in female rats (Table 4.10). Orally administered ‘early single-hit’ 
high-fructose diet did not predispose the female rats to have increased visceral fat mass in 
adulthood (Table 4.10). A ‘double-hit’ (neonatal orally administered 20% fructose solution 
plus 20% fructose drinking water in adulthood) also resulted in significantly heavier (p < 
0.0001) visceral fat mass in female rats, but the increase in the visceral fat mass was not 
significantly different or higher to the ‘late single-hit’ high-fructose diet-induced increase 
(Table 4.10). Neonatal orally administered SAC did not prevent the ‘late single-hit’ or 
‘double-hit’ (early and late) fructose-induced increase in visceral fat mass (Table 4.10). 
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4.2.4.3 Liver masses (absolute and relative) and total liver lipid content 
Liver masses (absolute and relative) and total liver lipid content of male rats are shown in 
Table 4.11.  
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Table 4.11: Effects of high-fructose diet on liver masses (absolute and relative to tibia 
length) and total liver lipid content of adult male rats orally administered S-allyl-
cysteine during suckling 
Treatments Liver (g) Liver TLr (g/mm) Total liver lipid (%) 
DH + PDW 8.46 ± 0.87
a
 0.21 ± 0.02
a
 2.82 ± 0.09
a
 
DH + FW 9.53 ± 0.92
a
 0.24 ± 0.02
a
 2.81 ± 0.09
a
 
FS + PDW 9.30 ± 0.42
a
 0.23 ± 0.01
a
 4.05 ± 0.01
b
 
FS + FW 9.75 ± 0.84
a
 0.24 ± 0.02
a
 3.13 ± 0.03
c
 
SAC + PDW 8.99 ± 0.45
a
 0.23 ± 0.01
a
 3.01 ± 0.22
c
 
SAC + FW 9.82 ± 0.63
a
 0.26 ± 0.02
a
 2.80 ± 0.08
a
 
SF + PDW 9.14 ± 1.03
a
 0.23 ± 0.03
a
 2.60 ± 0.12
d
 
SF + FW 9.34 ± 0.53
a
 0.24 ± 0.01
a
 3.00 ± 0.04
c
 
abcWithin column means with different superscripts are significantly different at p ≤ 0.05. 
Liver masses were similar across treatment regimens. Liver lipid content was significantly 
higher (p < 0.05) in FS + PDW male rats compared to DH + PW, DH + FW or FS + FW male 
rats. SAC + PDW male rats had significantly higher (p < 0.05) liver lipids compared to DH + 
PDW, DH + FW and SAC + FW male rats. Liver lipid was significantly lower (p < 0.05) in 
SF + PDW male rats compared to FS + PDW, FS + FW, SF + FW, DH + PDW or DH + FW 
male rats. DH + PDW = gavage with 10 ml/kg body mass per day distilled water during 
suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass 
per day distilled water during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg 
body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 
150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood. Data presented as mean ± SD; n = 8-
9 per treatment. 
191 
 
Orally administered ‘early single-hit’ high-fructose diet resulted in significantly (p < 0.05) 
higher liver lipid content in adult male rats (Table 4.11). A ‘double-hit’ (early and late) high-
fructose diet resulted in significantly increased (p < 0.05) liver lipid content in adult male 
rats, but the increase in liver lipid content was not significantly higher to the ‘early single-hit’ 
induced increase in liver lipid content (Table 4.11). The consumption of ‘late single-hit’ high-
fructose diet did not result in increased liver lipid content in adult male rats (Table 4.11). 
Neonatal orally administered SAC protected against ‘early single-hit’ high-fructose diet-
induced increase in liver lipid content but not protect against the ‘double-hit’ (early and late) 
high-fructose diet-induced increase in liver lipid content (Table 4.11). Neonatal orally 
administered SAC resulted in significantly increased (p < 0.05) liver lipid content in male rats 
(Table 4.11). A combination of neonatal orally administered SAC and ‘late single-hit’ high-
fructose diet did not result in significantly increase liver lipid content in male rats (Table 
4.11). 
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Liver masses (absolute and relative) and total liver lipid content of female rats are shown in 
Table 4.12.  
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Table 4.12: Effects of high-fructose diet on liver masses (absolute and relative to tibia 
length) and total liver lipid content of adult female rats orally administered S-allyl-
cysteine during suckling 
 
abcdWithin column means with different superscripts are significantly different at p ≤ 0.05. 
Liver masses were similar across treatment regimens. Liver lipid content was significantly 
higher (p < 0.05) in DH + FW female rats compared to DH + PDW female rats. FS + PDW 
female rats had significantly higher (p < 0.05) liver lipids compared to FS + FW, DH + PW, 
SF + PDW or SF + FW female rats. Liver lipid content was significantly higher (p < 0.05) in 
SAC + PDW female rats compared to DH + PDW or SAC + FW female rats. DH + PDW = 
gavage with 10 ml/kg body mass per day distilled water during suckling + plain drinking 
water in adulthood; DH + FW = gavage with 10 ml/kg body mass per day distilled water 
during suckling + 20% fructose (w/v) in their drinking water in adulthood; FS + PDW = 
gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + plain 
drinking water in adulthood; FS + FW = gavage with 10 ml/kg body mass per day 20% 
fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-allyl-cysteine during 
suckling + plain drinking water in adulthood; SAC + FW = gavage with 150 mg/kg body 
mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 
ml/kg body mass per day 20% fructose solution (w/v) during suckling + plain drinking water 
in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 
ml/kg body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) 
in their drinking water in adulthood. Data presented as mean ± SD; n = 7-9 per treatment. 
  
Treatments Liver (g) Liver TLr (g/mm) Total liver lipid (%) 
DH + PDW 5.45 ± 0.78
a
 0.15 ± 0.02
a
 2.83 ± 0.01
a
 
DH + FW 5.89 ± 0.57
a
 0.16 ± 0.02
a
 3.26 ± 0.24
b
 
FS + PDW 5.36 ± 0.53
a
 0.15 ± 0.01
a
 4.11 ± 0.03
c
 
FS + FW 5.83 ± 0.51
a
 0.16 ± 0.01
a
 2.80 ± 0.02
a
 
SAC + PDW 5.71 ± 0.70
a
 0.16 ± 0.02
a
 3.32 ± 0.03
b
 
SAC + FW 5.63 ± 0.52
a
 0.15 ± 0.01
a
 2.79 ± 0.07
a
 
SF + PDW 5.80 ± 0.55
a
 0.16 ± 0.01
a
 2.72± 0.01
a
 
SF + FW 5.72 ± 0.60
a
 0.16 ± 0.02
a
 2.97 ± 0.03
a
 
194 
 
Orally administered ‘early single-hit’ high-fructose diet resulted in significantly (p < 0.05) 
higher liver lipid content in adult female rats (Table 4.12). The consumption of ‘late single-
hit’ high-fructose diet resulted in significantly increased (p < 0.05) liver lipid content in adult 
female rats, but the increase in liver lipid content was not significantly higher to the ‘early 
single-hit’ induced increase in liver lipid content (Table 4.12). A ‘double-hit’ (early and late) 
high-fructose diet did not result in significantly increased liver lipid content in adult female 
rats (Table 4.12). Neonatal orally administered SAC protected the female rats against ‘early 
single-hit’ high-fructose diet and or ‘late single-hit’ high-fructose diet-induced increases in 
liver lipid content (Table 4.12). Neonatal orally administered SAC resulted in significantly 
increased (p < 0.05) liver lipid content in female rats (Table 4.12). A combination of neonatal 
orally administered SAC and ‘late single-hit’ high-fructose diet did not result in significantly 
increased liver lipid content in female rats (Table 4.12). 
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4.2.4.4 Liver histo-morphometry  
 
Table 4.13 shows the hepatocyte cell size and numbers of hepatocytes of male rats after being 
administered their respective treatment regimens.  
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Table 4.13: Effects of high-fructose diet on the size and density of hepatocytes from 
adult male rats orally administered S-allyl-cysteine during suckling 
Treatments Hepatocyte size (µm) Hepatocyte density (cells per 100 µm) 
DH + PDW 9.83 ± 1.61 10.16 ± 0.76 
DH + FW 9.83 ± 1.15 10.00 ± 1.00 
FS + PDW 9.66 ± 1.53 10.16 ± 0.28 
FS + FW 9.67 ± 0.58 10.33 ± 0.57 
SAC + PDW 9.16 ± 1.25 10.67 ± 1.26 
SAC + FW 9.67 ± 0.30 10.67 ± 0.76 
SF + PDW 9.50 ± 0.5 11.00 ± 1.00 
SF + FW 9.67 ± 0.28 10.17 ± 0.57 
Hepatocyte size and density of male rats were similar across treatment regimens. DH + 
PDW = gavage with 10 ml/kg body mass per day distilled water during suckling + plain 
drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass per day distilled 
water during suckling + 20% fructose (w/v) in their drinking water in adulthood; FS + PDW 
= gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg body mass per day 
20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-allyl-cysteine 
during suckling + plain drinking water in adulthood; SAC + FW = gavage with 150 mg/kg 
body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their drinking 
water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-allyl-
cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling 
+ 20% fructose (w/v) in their drinking water in adulthood. Data presented as mean ± SD; n = 
3 per treatment. 
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There were no significant differences in hepatocyte size and density from male rats across 
treatment regimens (Table 4.13).  
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Table 4.14 shows the hepatocyte cell size and density of hepatocytes of female rats after 
being administered their respective treatment regimens. 
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Table 4.14: Effects of high-fructose diet on the size and density of hepatocytes from 
adult female rats orally administered S-allyl-cysteine during suckling 
Treatments Hepatocyte size (µm) Hepatocytes (cells per 100 µm) 
DH + PDW 8.00 ± 0.86 13.00 ± 0.50 
DH + FW 8.33 ± 0.76 12.00 ± 0.50 
FS + PDW 8.00 ± 0.50 12.00 ± 0.86 
FS + FW 8.17 ± 1.04 12.00 ± 1.32 
SAC + PDW 8.17 ± 0.28 13.00 ± 0.50 
SAC + FW 8.33 ± 1.04 12.67 ± 0.28 
SF + PDW 8.50 ± 0.86 12.00 ± 1.32 
SF + FW 8.17 ± 0.76 12.67 ± 1.26 
Hepatocyte size and density of female rats were similar across treatment regimens. DH + 
PDW = gavage with 10 ml/kg body mass per day distilled water during suckling + plain 
drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass per day distilled 
water during suckling + 20% fructose (w/v) in their drinking water in adulthood; FS + PDW 
= gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg body mass per day 20% 
fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-allyl-cysteine during 
suckling + plain drinking water in adulthood; SAC + FW = gavage with 150 mg/kg body 
mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 
ml/kg body mass per day 20% fructose solution (w/v) during suckling + plain drinking water 
in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 
ml/kg body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) 
in their drinking water in adulthood. Data presented as mean ± SD; n = 3 per treatment. 
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There were no significant differences in hepatocyte size and density of female rats across 
treatment regimens (Table 4.14).  
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Table 4.15 shows non-alcoholic fatty liver disease activity score (NAS) of male rats after 
being administered their respective treatment regimen. 
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Table 4.15: Effects of high-fructose diet on non-alcoholic fatty liver disease activity 
score (NAS) of adult male rats orally administered S-allyl-cysteine during suckling 
Treatments Steatosis score Ballooning 
score 
Lobular inflammation 
score 
Total 
NAS 
DH + PDW 0 (0, 0) 0 (0, 0) 2.5 (0, 3) 2.5 (0, 3) 
DH + FW 0 (0, 1) 0 (0, 1) 2 (2, 3) 2.5 (2, 4) 
FS + PDW 0 (0, 2) 0 (0, 0) 2 (1, 2) 2 (1, 4) 
FS + FW 0 (0, 2) 0 (0, 0) 2 (2, 3) 3 (2, 5) 
SAC + PDW 0 (0, 0) 0 (0, 0) 2 (2, 3) 2 (2, 3) 
SAC + FW 0 (0, 0) 0 (0, 0) 2 (1, 3) 2 (1, 3) 
SF + PDW 0 (0, 0) 0 (0, 1) 2 (1, 3) 2 (2, 3) 
SF + FW 0 (0, 1) 0 (0, 1) 2 (0, 3) 2.5 (0, 5) 
Non-alcoholic fatty liver disease activity scores (NAS) of male rats were similar across 
treatment regimens. DH + PDW = gavage with 10 ml/kg body mass per day distilled water 
during suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body 
mass per day distilled water during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg 
body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 
150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood; NAS = non-alcoholic fatty liver 
disease activity score. Total NAS is the sum of values recorded for each category. Total NAS 
score interpretation: <2 = not steatohepatitis; 3–4 = uncertain; >5 = probable or definite 
steatohepatitis. Data presented as median and range (min; max); n = 4-5 per treatment. 
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The treatment regimens had no significant effect on non-alcoholic fatty liver disease activity 
score (NAS) of male rats (Table 4.15).  
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Table 4.16 shows non-alcoholic fatty liver disease activity score (NAS) of female rats after 
being administered their respective treatment regimens. 
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Table 4.16: Effects of high-fructose diet on non-alcoholic fatty liver disease activity score 
(NAS) of adult female rats orally administered S-allyl-cysteine during suckling 
Treatments Steatosis score  Ballooning 
score 
Lobular inflammation 
score 
Total NAS 
DH + PDW 0 (0, 0) 0 (0, 0) 3 (2, 3) 3 (2, 3) 
DH + FW 0 (0, 1) 0 (0, 1) 2 (1, 3) 2 (1, 5) 
FS + PDW 1 (0, 2) 0 (0, 0) 2 (2, 2) 3 (2, 4) 
FS + FW 0 (0, 2) 0 (0, 0) 2 (2, 2) 2 (2, 4) 
SAC + PDW 0 (0, 1) 0 (0, 1) 3 (1, 3) 3.5 (1, 4) 
SAC + FW 1 (0, 0) 0 (0, 0) 2 (1, 3) 3 (1, 4) 
SF + PDW 0 (0, 1) 0 (0, 1) 2 (1, 2) 2 (1, 3) 
SF + FW 0 (0, 0) 0 (0, 1) 2 (1, 3) 2.5 (1, 3) 
Non-alcoholic fatty liver disease activity scores (NAS) of female rats were similar across 
treatment regimens. DH + PDW = gavage with 10 ml/kg body mass per day distilled water 
during suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body 
mass per day distilled water during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg 
body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 
150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood; NAS = non-alcoholic fatty liver 
disease activity score. Total NAS is the sum of values recorded for each category. Total NAS 
score interpretation: <2 = not steatohepatitis; 3–4 = uncertain; >5 = probable or definite 
steatohepatitis. Data presented as median and range (min, max); n = 4-5 per treatment. 
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The treatment regimens had no significant effect on non-alcoholic fatty liver disease activity 
score (NAS) of female rats (Table 4.16).  
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Representative liver histology photo sections (H and E staining, 400 X magnification) of 
adult male rat from the different treatment groups are shown in Figure 4.10 below.   
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Figure 4.10: Effects of high-fructose diet on liver histology (H and E staining, 400 X 
magnification) of representative adult male rats orally administered S-allyl-cysteine 
during suckling. 
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Arrows A point to hepatic microvesicular steatosis and circle B shows foci of lobular 
inflammation. DH + PDW = gavage with 10 ml/kg body mass per day distilled water during 
suckling + plain drinking water in adulthood; DH + FW = gavage with 10 ml/kg body mass 
per day distilled water during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 20% fructose solution 
(w/v) during suckling + plain drinking water in adulthood; FS + FW = gavage with 10 ml/kg 
body mass per day 20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SAC + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine during suckling + plain drinking water in adulthood; SAC + FW = gavage with 
150 mg/kg body mass per day S-allyl-cysteine during suckling + 20% fructose (w/v) in their 
drinking water in adulthood; SF + PDW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
plain drinking water in adulthood; SF + FW = gavage with 150 mg/kg body mass per day S-
allyl-cysteine and 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood.  
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‘Early single-hit’, ‘late single-hit’ and ‘double-hit’ (early and late) high-fructose diet resulted 
in the development of microvesicular steatosis in male rats (Figure 4.10). Orally administered 
neonatal SAC prevented ‘early single-hit’ and ‘late single-hit’ high-fructose diet-induced 
microvesicular in male rats but did not prevent and ‘double-hit’ (early and late) high-fructose 
diet-induced microvesicular steatosis (Figure 4.10). Although neonatal orally administered 
SAC alone increased liver lipid content (Table 4.11) in male rats, it did not cause 
microvesicular steatosis (Figure 4.10).  
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Representative liver histology photo sections (H and E staining, 400 X magnification) of 
adult female rat from the different treatment groups are shown in Figure 4.11 below.  
   
212 
 
 
Figure 4.11: Effects of high-fructose diet on liver histology (H and E staining, 400 X 
magnification) of representative adult female rats orally administered S-allyl-cysteine 
during suckling. 
213 
 
Arrows A point to hepatic microvesicular steatosis. DH + PDW = gavage with 10 ml/kg 
body mass per day distilled water during suckling + plain drinking water in adulthood; DH + 
FW = gavage with 10 ml/kg body mass per day distilled water during suckling + 20% 
fructose (w/v) in their drinking water in adulthood; FS + PDW = gavage with 10 ml/kg body 
mass per day 20% fructose solution (w/v) during suckling + plain drinking water in 
adulthood; FS + FW = gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) 
during suckling + 20% fructose (w/v) in their drinking water in adulthood; SAC + PDW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine during suckling + plain drinking 
water in adulthood; SAC + FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine 
during suckling + 20% fructose (w/v) in their drinking water in adulthood; SF + PDW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 
20% fructose solution (w/v) during suckling + plain drinking water in adulthood; SF + FW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 
20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in 
adulthood.   
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The ‘early single-hit’, ‘late single-hit’ and ‘double-hit’ (early and late) high-fructose diets 
resulted in the development of microvesicular steatosis in female rats (Figure 4.11). Orally 
administered neonatal SAC prevented ‘early single-hit’, ‘late single-hit’ and ‘double-hit’ 
(early and late) high-fructose diet-induced microvesicular in female rats (Figure 4.11). The 
neonatal orally administered SAC alone resulted in microvesicular steatosis (Figure 4.11).  
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4.2.5 Surrogate biomarkers of liver and kidney function  
Table 4.17 shows the plasma activities of alanine aminotransferase and alanine phosphatase 
and plasma concentrations creatinine and blood urea nitrogen of male rats following their 
respective treatment regimens.  
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Table 4.17: Effects of high-fructose diet on surrogate markers of liver and kidney 
function of adult male rats orally administered S-allyl-cysteine during suckling 
Treatments ALT (U/L) ALP (U/L) BUN (mg/dL) Creatinine (mg/dL) 
DH + PDW 51.00 ± 9.35 63.33 ± 19.99 7.59 ± 0.83 34.22 ± 5.04 
DH + FW 51.78 ± 8.01 66.22 ± 9.22 6.25 ± 0.48 37.11 ± 5.77 
FS + PDW 54.67 ± 8.17 88.00 ± 14.78 7.20 ± 0.78 35.22 ± 7.51 
FS + FW 56.67 ± 12.07 69.33 ± 19.84 6.48 ± 0.68 38.11 ± 6.133 
SAC + PDW 65.22 ± 14.75 81.00 ± 14.20 7.30 ± 1.07 38.11 ± 7.60 
SAC + FW 55.00 ± 14.80 92.38 ± 31.35 6.45 ± 1.57 38.50 ± 8.04 
SF + PDW 65.50 ± 14.96 86.75 ± 23.21 7.64 ± 0.66 37.25 ± 4.16 
SF + FW 63.83 ± 17.20 77.50 ± 16.07 6.32 ± 0.70 36.50 ± 3.67 
Plasma activity of ALT and ALP and plasma concentration of BUN and creatinine were 
similar across treatment regimens. DH + PDW = gavage with 10 ml/kg body mass per day 
distilled water during suckling + plain drinking water in adulthood; DH + FW = gavage 
with 10 ml/kg body mass per day distilled water during suckling + 20% fructose (w/v) in 
their drinking water in adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 
20% fructose solution (w/v) during suckling + plain drinking water in adulthood; FS + FW 
= gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood; SAC + PDW = gavage with 150 
mg/kg body mass per day S-allyl-cysteine during suckling + plain drinking water in 
adulthood; SAC + FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine during 
suckling + 20% fructose (w/v) in their drinking water in adulthood; SF + PDW = gavage 
with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 20% 
fructose solution (w/v) during suckling + plain drinking water in adulthood; SF + FW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 
20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; ALP = alanine phosphatase; ALT = alanine aminotransferase; BUN = blood urea 
nitrogen. Data presented as mean ± SD; n = 8-9 per treatment. 
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The treatment regimens had no significant effect on the plasma activity of alanine 
aminotransferase and alanine phosphatase and plasma concentrations of creatinine and blood 
urea nitrogen of the male rats (Table 4.17). 
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Table 4.18 shows the plasma activities of alanine aminotransferase and alanine phosphatase 
and plasma concentrations creatinine and blood urea nitrogen of the female rats following 
their respective treatment regimens. 
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Table 4.18: Effects of high-fructose diet on surrogate markers of liver and kidney 
function of adult male rats orally administered S-allyl-cysteine during suckling 
Treatments ALT (U/L) ALP (U/L) BUN (mg/dL) Creatinine (mg/dL) 
DH + PDW 53.17 ± 13.23 56.83 ± 7.68 6.25 ± 0.65 39.50 ± 4.93 
DH + FW 54.25 ± 12.20 55.25 ± 19.65 6.088 ± 1.14 39.63 ± 8.10 
FS + PDW 54.13 ± 7.04 56.75 ± 14.72 7.40 ± 1.08 46.25 ± 9.31 
FS + FW 49.38 ± 8.23 56.38 ± 13.56 6.39 ± 1.45 40.63 ± 6.70 
SAC + PDW 49.78 ± 19.80 68.78 ± 9.13 7.425±1.313 41.88 ± 11.34 
SAC + FW 53.00 ± 9.70 62.00 ± 10.18 6.014 ± 0.87 39.00 ± 14.32 
SF + PDW 52.71 ± 6.07 74.29 ± 15.20 6.94 ± 1.17 45.29 ± 9.62 
SF + FW 56.11 ± 14.95 55.11 ± 12.60 6.88 ± 1.26 42.00 ± 3.97 
Plasma activity of ALT and ALP and plasma concentration of BUN and creatinine were 
similar across treatment regimens. DH + PDW = gavage with 10 ml/kg body mass per day 
distilled water during suckling + plain drinking water in adulthood; DH + FW = gavage 
with 10 ml/kg body mass per day distilled water during suckling + 20% fructose (w/v) in 
their drinking water in adulthood; FS + PDW = gavage with 10 ml/kg body mass per day 
20% fructose solution (w/v) during suckling + plain drinking water in adulthood; FS + FW 
= gavage with 10 ml/kg body mass per day 20% fructose solution (w/v) during suckling + 
20% fructose (w/v) in their drinking water in adulthood; SAC + PDW = gavage with 150 
mg/kg body mass per day S-allyl-cysteine during suckling + plain drinking water in 
adulthood; SAC + FW = gavage with 150 mg/kg body mass per day S-allyl-cysteine during 
suckling + 20% fructose (w/v) in their drinking water in adulthood; SF + PDW = gavage 
with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 20% 
fructose solution (w/v) during suckling + plain drinking water in adulthood; SF + FW = 
gavage with 150 mg/kg body mass per day S-allyl-cysteine and 10 ml/kg body mass per day 
20% fructose solution (w/v) during suckling + 20% fructose (w/v) in their drinking water in 
adulthood; ALP = alanine phosphatase; ALT = alanine aminotransferase; BUN = blood urea 
nitrogen. Data presented as mean ± SD; n = 7-9 per treatment. 
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The treatment regimens had no significant effect on the plasma activity of alanine 
aminotransferase and alanine phosphatase and plasma concentrations of creatinine and blood 
urea nitrogen of the female rats (Table 4.18). 
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4.3 Discussion 
The consumption of high-fructose diets is associated with the development of metabolic 
derangements inclusive of visceral obesity, insulin resistance and atherogenic dyslipidaemia. 
This current study aimed to investigate whether neonatal orally administered SAC protects 
Wistar rats against adverse metabolic outcomes induced by early or late ‘single-hit’ or 
‘double-hit’ high-fructose insult. We found that ‘early single-hit’ neonatal orally 
administered 20% fructose solution programmed increased liver lipid accretion and 
microvesicular steatosis in adult male and female rats. However, exposure to the ‘double-hit’ 
(early and late) high-fructose did not result in exacerbated hepatic lipid accumulation in 
adulthood. Consumption of a ‘late single-hit’ high-fructose diet in adulthood resulted in 
visceral obesity. Neonatal orally administered SAC protected against programming of 
increased liver lipid accretion by neonatal orally administered 20% fructose solution but did 
not protect rats against visceral obesity induced by high-fructose diet consumption in 
adulthood. In the current study, the treatment regimens had no effect on growth performance, 
glucose tolerance, blood parameters, visceral organs morphometry, and kidney and liver 
function of male and female rats. 
 
4.3.1 Growth performance 
The current study reports no significant differences in the body masses of the male and 
female rats across treatment regimens at weaning and termination. However, both male and 
female rats across treatment regimens showed significant growth from weaning to 
termination. This suggests that the treatment regimens had no adverse effect on growth (body 
mass) of the rats. Work by Huynh et al. (2008) documented increased adulthood body masses 
and increased risk for obesity in Wistar rats to which a 10% fructose solution (first-hit) was 
orally administered during suckling and then fed 65% high-fructose diet (second-hit) in 
adulthood. The results of the current study where the neonatal oral administration of a 20% 
fructose solution represents the first-hit and the consumption of a 20% fructose drinking 
water in adulthood represents a second-hit, are at variance with the observations by Huynh et 
al. (2008). We speculate that the observed higher body masses and increased risk of obesity 
as reported by Huynh et al. (2008) could have been due to the higher caloric intake as 65% of 
the diet (in adulthood) was made up of fructose.  
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As discussed earlier, body mass is influenced by various factors in the short term, a longer 
term assessment of growth of growing animals is an assessment of various indices of the long 
bones. The similarity in the tibiae lengths, masses and Seedor indices of male and female rats 
across treatment regimens suggests that all the treatment regimens, including neonatal orally 
administered SAC, did not compromise or accelerate the growth performance of the rats. 
Previous studies have shown that the extracts and phytochemicals (diallyl sulphides and γ-L-
glutamyl-trans-s-1-propenyl-L-cysteine-sulfoxide) of the Amaryllidaceae family plants, 
namely garlic, onion and leeks have been shown to increase bone mass and density by 
increasing calcium absorption in the GIT and inhibiting osteoclasts and bone resorption in 
animals (Ebrahimzadeh-Bideskan et al., 2015; Ehnert et al., 2012; Chen et al., 2011; 
Mukherjee et al., 2006; Mühlbauer et al., 2002). Even though SAC is a phytochemical 
constituent of garlic, it can be orally administered in neonatal life as a prophylactic or 
therapeutic agent without adversely affecting growth performance. 
  
4.3.2 Glucose tolerance, blood parameters, and liver lipid  
While the oral glucose tolerance test (OGTT), a screening test for diabetes mellitus and pre-
diabetes mellitus (Hage et al., 2013), was established to evaluate the capability to handle an 
oral glucose load over a period time (Stumvoll et al., 2000), the total area under the curve 
(AUC) for OGTT is computed to evaluate the total increase in blood glucose over a period of 
time following an oral glucose load (Sakaguchi et al., 2012; Le Floch et al., 1990). An 
increased AUC for OGTT is indicative of a decreased ability to effectively respond to an oral 
glucose load (Sakaguchi et al., 2012). However, OGTT and AUC of OGTT are not adequate 
for evaluating insulin resistance. Thus the, minimally invasive, homeostatic model 
assessment of whole body insulin resistance (HOMA-IR) is used to quantify and evaluate 
insulin resistance (Matthews et al., 1985). An increased HOMA-IR is indicative of insulin 
resistance (Matthews et al., 1985).  
The current study reports no differences in glucose tolerance, the area under the curve for the 
oral glucose tolerance test, insulin concentration and insulin resistance (HOMA-IR) of male 
and female rats across treatment regimens. These findings suggest that treatment regimens 
did not affect the ability to tolerate an oral glucose load, insulin secretion neither did they 
cause insulin resistance. Studies have shown that the consumption of 20% fructose drinking 
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water (w/v) for 8 weeks causes hyperglycaemia, hyperinsulinemia, insulin resistance, 
hypertriglyceridemia and hypercholesterolemia in adult rats (Sandeva et al., 2015; Mamikutty 
et al., 2014; Benado et al., 2004; Dai and McNeill, 1995). Our findings suggest that the 
consumption of ‘late single-hit’ 20% fructose drinking water (w/v) for 8 weeks did not result 
in hyperglycaemia, hyperinsulinemia, insulin resistance, hypertriglyceridemia and 
hypercholesterolemia in male and female adult rats.  
In the current study, the ‘double-hit’ (early and late) fructose had no effect on fasting blood 
glucose concentration, plasma triglyceride, cholesterol and insulin concentration and insulin 
resistance of adult male and female rats. The findings from the current study on fasting blood 
glucose concentration are in accordance with Huynh et al. (2008) who reported no changes in 
the blood glucose concentration of Wistar rats administered a 10% fructose solution (first-hit) 
during suckling and fed a 65% high-fructose diet (second-hit) in adulthood. Huynh et al. 
(2008), whose findings are at variance with those of the current study, reported 
hyperinsulinemia and insulin resistance in Wistar rats that were orally administered a 10% 
fructose solution (first-hit) during suckling and fed 65% high-fructose diet (second-hit) in 
adulthood. Similarly, Sánchez-Lozada et al. (2007) reported rats fed a diet with 60% fructose 
in feed (w/w) for 8 weeks developed more severe metabolic derangements than rats that 
consumed of 10% fructose solution and standard rat chow for 8 weeks. The differences 
observed by Sánchez-Lozada et al. (2007) were attributed to the 60% fructose in feed (w/w) 
providing surplus calories as compared to the 10% fructose solution (w/v). Thus the variance 
in our finding and those by Huynh et al. (2008) may have been due to the variation in the 
method by which the ‘second-hit’ high-fructose diet was administered in adulthood [20% 
fructose drinking water (w/v) used in the current study versus 60% fructose in feed used by 
Huynh et al. (2008)].  
Fructose metabolism in the liver produces substrates for de novo lipogenesis (Wagnerberger 
et al., 2013). This results in decreased β-oxidation of fatty acids and increased hepatic lipid 
accumulation (Nomura and Yamanouchi, 2012) and subsequently dyslipidaemia and NAFLD 
(Liu et al., 2014). The similarity in the plasma triglyceride and cholesterol concentration of 
the rats across treatment regimens suggests that the treatment regimens did not alter plasma 
lipid (triglycerides and cholesterol) concentrations. Ching and colleagues (2011) reported the 
consumption of a high-fructose diet caused hypercholesterolemia, hypertriglyceridemia and 
increased hepatic lipid in Sprague-Dawley rats that were born to dams that were fed on a 
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high-fructose diet during gestation and lactation. Maternal high-fructose diet consumption 
during gestation and lactation has been shown to programme in resulting offspring, increased 
expression of lipogenic genes and increased susceptibility to developing hypertriglyceridemia 
and hypercholesterolemia (Ching et al., 2011; Alzamendi et al., 2010).  
Findings from the present study suggest that unlike the case with maternal high-fructose diet 
consumption where the rat pups are exposed to high-fructose during gestation and while 
suckling, despite the altricial developmental state of rat pups, neonatal orally administered 
20% fructose solution did not programme for increased susceptibility to develop 
hypertriglyceridemia and hypercholesterolemia in adult rats. The dissimilarities in our 
findings and those reported by Ching et al. (2011) and Alzamendi et al. (2010) could be 
related to variation in the duration of dietary (high-fructose diet) intervention and the model 
(neonatal oral administration of 20% fructose solution (current study) versus maternal high-
fructose diet consumption (Ching et al. (2011) and Alzamendi et al. (2010). The maternal 
high-fructose diet from gestation to lactation model used by Ching et al. (2011) and 
Alzamendi et al. (2010) caused hypertriglyceridemia and hypercholesterolemia in the rat 
dams however it is unclear whether the increased plasma lipids were directly transferred to 
the pups via the placenta or indirectly through milk during suckling. The increased plasma 
lipids in the dams may also alter how the foetuses develop in perinatal life (gestation and 
lactation) (Rodríguez et al., 2013). It is known that rat dams fed high-fructose diet produce 
milk that is rich in fatty acids thus contributing to hyperlipidaemia in the suckling pups 
(Mourot et al., 2010). In humans, fructose crosses the placenta (Goran et al., 2013), although 
we were unable to find literature on whether the same applies to rats. Humans and rodents 
have a haemochorial type of placentation (Soares et al., 2012) thus one would expect that 
there would be similarities in the maternal-foetal transfer of substances. However, Vickers et 
al. (2011) reported that despite increased plasma fructose concentration in high-fructose diet 
fed dams there was no increase in fructose in the milk that was extracted from the stomach of 
suckling pups. It is thus unlikely that the fructose is directly transferred through the milk 
during suckling. Thus the differences in the findings on plasma lipids of rats from the current 
study, which used a high-fructose neonatal diet model, and those reported by reported by 
Ching et al. (2011), who used a high-fructose maternal diet model could be attributed to the 
variance in the route of fructose exposure [direct neonatal fructose exposure used by the 
current study versus indirect foetal/neonatal fructose exposure used by Ching et al. (2011)].  
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In the current study, we showed that the accumulation of hepatic lipids was affected not only 
by the developmental age when the fructose was administered but also by the sex of the rats. 
Neonatal oral administration of a 20% fructose solution ‘early single-hit’ significantly 
increased liver lipid accretion in male and female adult rats (Tables 4.11 and 4.12 
respectively) despite them not receiving any more excessive fructose later in adult life. Our 
findings suggest that neonatal oral administration of a 20% fructose solution single-handedly 
programmed for increased liver lipid accumulation in adulthood in male and female rats. The 
‘early single-hit’ also resulted in the greatest accumulation of hepatic lipids in both sexes. 
Prenatal and or early postnatal maternal fructose consumption has been shown to alter 
expression of genes that are involved in lipogenesis and β-oxidation of free fatty acids 
(Yamazaki et al., 2016; Clayton et al., 2015; Rodríguez et al., 2013). Huynh et al. (2008) also 
showed that neonatal orally administered 10% fructose solution alone programmed increased 
fatty acid uptake and deposition in the skeletal muscle of Wistar rats by increasing skeletal 
muscle fatty acid transporters. These mechanisms may explain our findings. 
It was interesting that we found that the oral consumption of a high-fructose diet ‘late single-
hit’ in adulthood increased liver lipid accretion in female rats only (Table 4.12). The current 
study also reports that exposure to a ‘double-hit’ high-fructose diet (early and late) increased 
liver lipid accretion in the adult male rats only (Table 4.12). However, the ‘double-hit’ (early 
and late) high-fructose diet did not cause a higher hepatic lipid accretion than did the ‘early 
single-hit’ high-fructose diet.  
Thus, in summary, these findings suggest that both male and female rats were prone to 
developing fatty-liver disease when they were exposed to a high-fructose diet (20% fructose 
solution) as neonates, however the male rats were more prone than females to developing 
fatty-liver disease when they were exposed to ‘double-hit’ (early and late) high-fructose diet. 
The similarities in the liver lipid content of female rats subjected to a ‘double-hit’ of fructose 
and their counterparts on the control treatment regimen (Table 4.12), suggests that the 
‘double-hit’ high-fructose diet does not exacerbate neonatal fructose-induced programming 
of increased liver lipid accumulation. We hypothesise that this may be related to the anti-
insulinotropic and lipid-lowering effects of the high-fructose diet that were reported in the 
first experiment of the current study. These anti-insulinotropic and lipid-lowering effects of 
fructose in neonatal life may have imparted some adaptive effect to a high fructose diet in 
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later life. There is a need to interrogate at the cellular and molecular level the possible 
mechanisms that could explain the findings of the current study.  
An exciting finding in the current study was the observation that the neonatal oral 
administration of a combination of SAC + 20% FS to neonates (early fructose single-hit) 
without further excess fructose in adulthood resulted in significantly reduced liver lipid in the 
male rats (Table 4.11). As discussed earlier the ‘early single-hit’ of fructose resulted in the 
greatest accumulation of liver lipids in both males and females. However, neonatal oral 
administration of a combination of SAC and 20% fructose solution followed by 20% fructose 
drinking water in adulthood (double-hit with fructose) significantly increased liver lipid 
content in the male rats (Table 4.11). These findings suggest that even though neonatal orally 
administered SAC protected male rats against the programming of increased liver lipid 
accretion induced by neonatal orally administered 20% fructose solution (single early 
fructose hit), it (neonatal oral SAC administration) did not protect the male rats against 
increased liver lipid accumulation induced by ‘double-hit’ (neonatal and adult) fructose 
insult.  
The current study reports similarities in the liver lipid content from female rats on the control 
treatment regimen to that from female rats subjected to a combination of neonatal oral SAC 
and 20% fructose solution administration and or neonatal oral SAC administration with a 
high-fructose diet (20% fructose drinking water) in adulthood (Table 4.12). These findings 
suggest that neonatal oral administration of SAC protected female rats against increased liver 
lipid accretion induced by the adverse programming effects of neonatal orally administered 
20% fructose solution or high-fructose diet administered in adulthood. The protective effects 
of SAC are probably related to its antidiabetic, antiobesity and antioxidant activities as 
reported by several researchers (Asdaq, 2015; Saravanan et al., 2013; Saravanana and 
Pomurugan, 2012a).  
Interestingly, in the current study both male and female rats to which SAC was orally 
administered during their neonatal growth stage and received plain drinking water during 
adulthood had significantly higher liver lipid content compared to their counterparts on other 
treatment regimens (Tables 4.11 and 4.12, respectively). This finding suggests that similar to 
the neonatal orally administered 20% fructose solution, the neonatal orally administered SAC 
programmed rats for increased liver lipid accumulation in adulthood. In the first experiment 
(chapter 3) we reported that the beneficial (insulinotropic) effects neonatal orally 
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administered SAC may have caused the increased liver lipid accumulation that was observed 
in the suckling female rat pups. We, therefore, suspect that these observations may be linked 
to the insulinotropic effects of neonatal orally administered SAC that we noted in the first 
experiment (neonatal study). 
We propose that the sexually dimorphic effects of treatment regimens on the liver lipid 
accretion that were noted in the current study (discussed above) could be attributed to the 
variance in the sex hormones and physiological development in early-life between male and 
female rats. While testosterone is the principal sex hormone in males, in females the main sex 
hormones are oestrogen and progesterone (Juster et al., 2016; Kadowaki et al., 2006). 
Although the mechanisms are not yet fully understood, studies have shown that testosterone 
and oestrogen are involved in the regulation of various metabolic pathways (Kadowaki et al., 
2006) and thus play a role in the onset and prevalence various metabolic derangements such 
as NAFLD and MetS (Kim et al., 2012; Carulli et al., 2006). In male rats, the neural and 
endocrine systems have been shown to mature at an earlier age than in female rats (Sakuma, 
2009; Viveros et al., 2009) and thus could have contributed to sexually dimorphic responses 
to the treatment regimens. Even though our proposed theories could potentially explain the 
sexually dimorphic effects of the treatment regimens on liver lipid accretion (discussed 
earlier), there still is a need to further interrogate and identify the physiological mechanisms 
which attributed the sexually dimorphic responses or effects noted in the current study. 
 
4.3.3 Visceral organs morphometry 
Orally administered raw garlic juice was reported to cause injury to the intestinal lining 
resulting in intestinal atrophy in adult rats (Amagase et al., 2001). The observed adverse 
effect of garlic juice could be attributed to it containing multiple phytochemicals including 
allicin which has been reported to cause oxidative damage to the intestinal mucosa (Lawson, 
1993). The similarities in macro-morphometric parameters (masses and lengths) of the liver, 
small and large intestines of male and female rats across treatment regimens suggest that the 
treatment regimens did not compromise nor promote growth and development of viscera. Our 
findings suggest that neonatal orally administered SAC, which is a phytochemical constituent 
of garlic, did not cause atrophy or hypertrophy of visceral organs. Thus SAC can be orally 
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administered in neonatal life as a prophylactic agent without compromising the growth and 
development of the liver and GIT viscera.  
While increased visceral fat accumulation is associated with insulin resistance and the 
development of MetS, DM II and cardiovascular diseases (Esser et al., 2014; DeBoer, 2013; 
Makki et al., 2013), epididymal fat accumulation has been linked to infertility in males 
(Katib, 2015). In the present study, the ‘late single-hit’ or ‘double-hit’ (early and late) high-
fructose diet caused significantly heavier visceral and epididymal (in male rats) fat masses in 
male and female rats (Tables 4.9 and 4.10). Oral administration of ‘early single-hit’ high-
fructose diet had no effect on visceral and epididymal (in male rats) fat pad masses of male 
and female rats in adulthood (Tables 4.9 and 4.10). Our findings suggest that while the 
consumption of a ‘late single-hit’ high-fructose diet caused increased visceral and epididymal 
(in male rats) fat accumulation in rats, the orally administered ‘early single-hit’ high-fructose 
diet did not predispose the male and female rats to have increased visceral and epididymal (in 
male rats) fat accumulation in adulthood. The similarity in the visceral and epididymal (in 
male rats) fat pad masses of adult rats that were exposed to ‘late single-hit’ or ‘double-hit’ 
(early and late) high-fructose diet suggests that although the ‘double-hit’ high-fructose diet 
caused increased visceral and epididymal (in male rats) fat accumulation, it did not 
exacerbate the adiposity. Importantly our findings suggest that the ‘late single-hit’ or ‘double-
hit’ (early and late) high-fructose diet caused visceral obesity in the adult rats and thus 
increasing their susceptibility to developing metabolic derangements such as insulin 
resistance, MetS, and DM II. Additionally, exposure to the ‘late single-hit’ or ‘double-hit’ 
high-fructose diet increased epididymal fat accumulation in male rats and thus potentially 
increasing their risk of infertility (El-Wakf et al., 2015; Katib, 2015). Our findings are in 
agreement with several works that have indicated that high-fructose diet is associated with 
visceral obesity and increased epididymal fat pad accumulation (Pektaş et al., 2015; Tran et 
al., 2009; Huynh et al., 2008).  
In the current study, neonatal orally administered SAC did not protect the rats against visceral 
and epididymal (in male rats) fat accumulation induced by a ‘late single-hit’ and or ‘double-
hit’ high-fructose diet. These findings suggest that even though SAC showed protective 
effects against the high-fructose diet-induced excessive hepatic lipid accretion, it did not 
protect the rats against increased visceral and epididymal fat (male) accumulation induced by 
the ‘late single-hit’ and ‘double-hit’ high-fructose diet.  
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Non-alcoholic fatty liver disease is a progressive disease, and thus fatty liver disease scoring 
criteria systems such as the NAFLD activity score (NAS) are pivotal for evaluating and 
predicting the progression and severity of NAFLD (Kleiner et al., 2005). The NAS uses a 
semi-quantitative scoring system using the following histological criteria: steatosis, lobular 
inflammation and ballooning (Kleiner et al., 2005). Steatosis refers to the excessive 
accumulation of lipid in the liver and can be categorised as macrovesicular and 
microvesicular steatosis (Nativ et al., 2014). Whilst the former (macrovesicular) steatosis, is 
characterised by few large fat droplets within the hepatocytes and displaced nuclei (Mulder et 
al., 2015), the latter (microvesicular) steatosis, is characterised by multiple tiny lipid droplets 
within the hepatocytes (Mulder et al., 2015). The manifestation of steatosis with lobular 
inflammation and ballooning is indicative of fatty-liver disease that has progressed to 
steatohepatitis with hepatocyte degeneration (Kleiner et al., 2005). While lobular 
inflammation characterised by mononuclear cell infiltration of the hepatic lobule, ballooning 
is characterised by hepatocyte apoptosis, cytoplasm clearing and enlargement (Kleiner et al., 
2005).  
The current study reports the presence of microvesicular steatosis in the liver of male and 
female rats that were orally administered an ‘early single-hit’ fructose diet (20% fructose 
solution) only or ‘late single-hit’ fructose (20% fructose drinking water) only (Figures 4.11 
and 4.12). These findings suggest that ‘single-hit’ (neonatal or adulthood) and ‘double-hit’ 
fructose-diet exposure caused microvesicular steatosis in male and female rats and support 
our findings which suggested that neonatal oral administration of fructose programmed for 
increased liver lipid accretion in adulthood. Microvesicular steatosis was not observed in the 
liver histology sections of male and female rats that were orally administered SAC and 20% 
fructose solution during suckling and received plain drinking water in adulthood. This further 
suggests that neonatal orally administered SAC attenuated the programming of increased 
liver lipid accretion induced by neonatal oral administration of a 20% fructose solution. The 
present study also reports the presence of microvesicular steatosis in the liver of male rats 
that were orally administered of a combination of neonatal SAC and 20% fructose solution 
followed by the consumption of 20% fructose drinking water in adulthood (double-hit with 
fructose) and in female rats that were orally administered neonatal SAC only (Figures 4.11 
and 4.12). These findings suggest that neonatal oral administration of SAC caused 
microvesicular steatosis in female rats and did not protect the male rats against 
microvesicular steatosis induced by ‘double-hit’ (early and late) high-fructose diet. The 
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microvesicular steatosis that was induced by neonatal orally administered SAC in adult 
female rats may be related to its (SAC’s) programming of increased liver lipid accretion in 
adulthood. Microvesicular steatosis is associated with decreased hepatic β-oxidation and 
mitochondrial dysfunction (Tandra et al., 2011). Thus the observed microvesicular steatosis 
may possibly signify symptoms of decreased hepatic β-oxidation and hepatic mitochondrial 
dysfunction.  
Even though we observed increased liver lipid accretion and hepatic microvesicular steatosis 
in the rats that were exposed to early or late ‘single-hit’ or double-hit fructose insult (Tables 
4.11 and 4.12; Figures 4.11 and 4.12), there were similarities in the number of hepatocytes in 
a linear field, hepatocyte size, hepatocyte ballooning score, steatosis score, inflammation 
score, and total NAFLD activity score (NAS) of male and female rat across treatment 
regimens. This suggests that the despite increased liver lipid accretion and the presence of 
microvesicular hepatic steatosis in the rats that were exposed to early or late ‘single-hit’ or 
‘double-hit’ high-fructose, none of the treatment regimens had adverse effects on hepatocyte 
density or caused NASH.  
 
4.3.4 Surrogate markers of liver and kidney function 
The similarity in surrogate markers of liver (ALT and ALP activity) and kidney (creatinine 
and blood urea nitrogen concentration) function of male and female rat across treatment 
regimens in the present study suggests that the treatment regimens no adverse effects on liver 
and kidney function. The consumption of high-fructose diets, mainly in feed, has been 
observed to cause renal and hepatic impairments that manifest in the form of decreased 
excretory function resulting in increased blood urea nitrogen and creatinine concentration 
(Johnson et al., 2010; Sánchez-Lozada et al., 2008; Johnson et al., 2007) and hepatocellular 
damage that results in increased activity of ALT and aspartate aminotransferase (AST) (Hou 
et al., 2014). None of the high-fructose diet (early single-hit, late single-hit and double-hit) 
interventions used in the current study resulted in renal or hepatic impairments. This could be 
attributed to the variance in the amount of fructose administered (20% fructose drinking 
water used in the current versus 60% fructose in feed used by Johnson et al. (2010), Sánchez-
Lozada et al. (2008) and Johnson et al. (2007).  
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An important aspect of studies aimed validating the efficacy of phytochemicals as 
ethnomedicines is assessing their potential toxicity. In antiobesity studies, where weight loss 
is evaluated, an assessment of toxicity would eliminate the potential of pseudo-medicinal 
induced weight loss due to the toxicity of the ethnomedicinal phytochemicals under 
validation. Our findings show that neonatal orally administered SAC did not have any long-
term toxic or adverse effects on the liver and kidney and thus can be administered during 
neonatal development phase as a prophylactic agent for high-fructose diet-induced fatty-liver 
disease.  
 
4.4 Conclusion  
There are similarities and differences in the responses of the sexes to high-fructose diets and 
neonatal SAC. The timing of high-fructose diet intervention also plays a role in the response. 
The consumption of a ‘late hit’ high-fructose diet in adulthood, regardless of early 
intervention, resulted in visceral obesity in both male and female rats. The increased visceral 
obesity was not attenuated in rats where SAC was orally administered during the neonatal 
growth stage. Neonatal oral administration of a 20% fructose solution (single-hit) 
programmed the male and female rats to develop increased liver lipid accretion in adulthood. 
Thus the suckling growth stage is an important period of plasticity where the oral 
administration of a 20% fructose solution (simulating a high-fructose diet) exerted adverse 
metabolic programming effects on the liver lipid accretion and the possibility of an increased 
risk of developing fatty liver disease(s) in adulthood. Importantly, the programming of 
increased liver lipid accretion by the ‘single-hit’ neonatal oral administration of a 20% 
fructose solution was mitigated by neonatal oral administration of SAC in male and female 
rats. We thus conclude that neonatal oral administration of SAC to suckling Wistar rat pups 
protected them against adverse fructose-induced neonatal metabolic programming of fatty 
livers in adulthood. We suspect that the mechanisms by which SAC exerted the 
beneficial/protective effects are mainly related to its insulinotropic effects. This inference 
requires further probing and validation. It should also be noted that although neonatal orally 
administered SAC showed beneficial effects in a sexually dimorphic manner, its (SAC) use 
has the potential to cause fatty-liver disease.  
The next chapter outlines the major conclusions from the study, points out the limitations to 
the study and suggests recommendations for future studies.  
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CHAPTER 5: CONCLUSION, 
LIMITATIONS AND 
RECOMMENDATIONS 
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The current study was executed in two major experiments. In the first experiment we 
investigated the potential of neonatal orally administered SAC (150 mg/kg body mass per 
day) to protect against the development of high-fructose diet-induced metabolic 
derangements by specifically determining its effects on growth performance, blood 
parameters, liver metabolites, and surrogate markers of liver and kidney function of 
suckling Wistar rats to which a 20% fructose solution (high-fructose diet) was orally 
administered. There is increased plasticity during the suckling period and thus dietary 
interventions during this period can alter growth, development and function of various 
physiological systems. The findings of the first experiment were as follows: 
i. neonatal oral administration of 20% fructose solution induced hypoinsulinemia in 
female rat pups but not in their male counterparts suggesting that female rat pups were 
susceptible to the insulin-lowering effects of neonatal orally administered 20% fructose 
solution. This is one of the first animal studies to show that neonatal oral administration 
of 20% fructose solution decreases plasma insulin in female rat pups. The mechanisms 
by which the neonatal orally administered 20% fructose solution reduced plasma insulin 
concentration in female rat pups are unclear. We theorise that mechanisms could be 
related to the delayed development of the endocrine system in female rats and possibly 
to fructose altering satiety via the hypothalamus-pituitary-adrenal-leptin axis. However, 
leptin and ghrelin which are involved in the regulation of satiety and pancreatic β-cell 
development and functionality were not determined in the current study. We thus 
recommend that future studies evaluate leptin, ghrelin and pancreatic β-cell 
development and functionality when investigating the effects of high-fructose diets in 
early-life (gestation and lactation). This might provide more insight into the possible 
mechanisms by which neonatal oral administration of 20% fructose solution decreases 
blood insulin concentration in female rats. 
ii. neonatal orally administered SAC attenuated the high-fructose diet-induced 
hypoinsulinemia in female rat pups, indicating potential insulinotropic effects of SAC in 
female pups. 
iii. neonatal orally administered SAC increased insulin in male pups. These findings 
suggest that even though SAC exerted insulinotropic effects in both male and female rat 
pups, these effects were more pronounced in male pups. Thus SAC potentially could be 
used to ameliorate insulin related disturbances in diabetics. Future studies need to 
further investigate the insulinotropic effects of SAC, potential adverse outcomes from 
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SAC usage and potential exploitation of SAC as a prophylactic agent for the prevention, 
management, and treatment of metabolic disturbances such as DM II. 
iv. neonatal orally administered SAC increased liver lipid accretion in female rat pups. This 
suggests that the use of SAC in young females might increase the risk of developing 
NAFLD. The current study did not evaluate the lipid profile of the hepatic lipids. This 
would have provided insight on the types of lipids and fatty acids that accumulated in 
the liver due to the neonatal oral administration of SAC in suckling female rat pups. 
Thus we recommend that future studies should consider evaluating the lipid profile 
when analysing tissue lipid content. Additionally the activity and expression of hepatic 
lipogenic enzymes, proteins and genes would possibly provide some clarifications on 
the possible mechanisms by which SAC increased hepatic liver lipid content in female 
rat pups.  
 
In the second experiment, we investigated whether neonatal oral administration of SAC 
conferred protection against an ‘early or late single-hit’ or ‘double-hit’ fructose-induced 
metabolic derangement in adulthood. The findings of the second experiment were as 
follows: 
i. the consumption of a high-fructose diet in adulthood increased visceral fat of male and 
female rats. However, neonatal oral administration of SAC did not protect rats against 
visceral obesity induced by high-fructose diet consumption in adulthood.  
ii. ‘single-hit’ neonatal orally administered fructose programmed increased liver lipid 
accretion without causing overt NAFLD in adulthood in male and female rats, 
indicating that male and female rats were susceptible to the programming of increased 
liver lipid accumulation in adulthood induced by neonatal oral administration of ‘single-
hit’ 20% fructose solution. ‘Early single-hit’ high-fructose diet exerted programming 
effects mainly in the liver and may have increased the risk of developing NAFLD. It 
should be noted that in the neonatal (first experiment) study changes in liver lipid and 
glycogen content were noted in suckling female rats orally administered 20% fructose 
solution only. This suggests that while female rats are susceptible to the short- and long-
term adverse effects of neonatal orally administered 20% fructose solution, the male rats 
are resistant to the short-term adverse effects of neonatal orally administered 20% 
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fructose solution and are susceptible to the long-term adverse effects of neonatal orally 
administered 20% fructose solution. 
iii. a ‘late single-hit’ high-fructose diet increased liver lipid accretion in female rats but not 
in male rats and ‘double-hit’ (early and late) high-fructose diet increased liver lipid 
accretion in male rats but not in female rats. These findings suggest that while female 
rats are susceptible to the increased liver lipid induced by ‘single-hit’ high-fructose diet 
consumption in adulthood the male rats are susceptible to increased liver lipid induced 
by ‘double-hit’ fructose. 
iv. neonatal oral administration of SAC attenuated the programming of increased liver lipid 
accretion induced by neonatal oral administration of ‘single-hit’ 20% fructose solution 
during suckling in male and female rats. Firstly, these findings suggest that neonatal 
oral administration of SAC attenuated increased liver lipid accretion induced by 
neonatal oral administration of ‘single-hit’ 20% fructose solution in adult female rats. 
Secondly, neonatal oral administration of SAC protected male and female rats against 
programming of liver lipid accumulation induced by neonatal oral administration of 
‘single-hit’ 20% fructose solution. Neonatal oral administration of SAC protected 
female rats against increased liver lipid accretion induced by ‘single-hit’ high-fructose 
diet consumption in adulthood but it did not protect male rats against increased liver 
lipid induced by ‘double-hit’ fructose. We thus conclude that neonatal orally 
administered SAC protected against the adverse programming of increased liver lipid 
accretion by neonatal ‘single-hit’ with a 20% fructose solution in both male and female 
rats. However, SAC may exert some of its protective effects in a sexually dimorphic 
manner. The mechanisms by which SAC exerted the beneficial/protective effects 
against the adverse effects of the 20% fructose solution (at the neonatal stage) and a 
high-fructose diet (adulthood) model utilised by the current study have not been 
elucidated. However, we theorise that the mechanisms may be related to the antiobesity, 
antidiabetic, antioxidant and hepatoprotective activities of SAC, which were reported by 
other studies (Asdaq, 2015; Takemura et al., 2013; Saravanan et al., 2010).  
v. neonatal oral administration of SAC alone programmed increased liver lipid accretion 
without causing NAFLD in male and female rats, indicating that neonatal oral 
administration of SAC exerted programming effects which resulted in increased non-
pathological liver lipid accretion in both male and female rats in adulthood. Importantly, 
in the neonatal (first stage experiment) study, neonatal orally administered SAC 
increased liver lipid in suckling female rat pups and increased insulin in male rat pups. 
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The programming effects of SAC could be linked to the metabolic changes exerted by 
neonatal oral administration of SAC. Nonetheless, the mechanisms by which neonatal 
orally administered SAC programmed increased liver lipid accretion in adulthood in 
male and female rats still require interrogation. To shed some light on the possible 
mechanisms, future studies should consider including investigations on the molecular 
components such as the effects of SAC on the methylation, modification and regulation 
genes that code for lipogenic enzymes. 
 
Overall we conclude that the period of suckling is a critical period where dietary 
interventions such as high-fructose diet can exert short- and long- term adverse metabolic 
programming effects that increase the susceptibility to metabolic derangements in a 
sexually dimorphic manner. Thus we recommend that prophylactic use of antidiabetic and 
antiobesity interventions such as SAC during the suckling period could aid in mitigating 
the incidence of obesity, NAFLD, MetS and DM II in childhood and adulthood. We 
conclude that the neonatal orally administered SAC has the potential to protect specific 
tissues against the short- and long-term adverse outcomes of fructose-induced metabolic 
programming. However, we acknowledge the need to validate the mechanisms involved in 
the beneficial outcomes of neonatal orally administered SAC. Future studies should always 
use both male and female rats when investigating the metabolic programming so that they 
do not omit on the sexually dimorphic responses. Moreover, such studies should perform 
an assessment on multiple physiological systems and organs. This will ensure that 
physiological system specific and tissue specific responses are not omitted.  
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Appendix 2: Modification of the ethics clearance 
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Appendix 3: NAFLD Activity Score  
Non-Alcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)-semi quantitative 
for 1, 2 and 3.  
 
A. Criteria assessed: 1. hepatocellular ballooning (H and E) 
2. Steatosis (H and E) 
3. Inflammation (H and E) 
Location of the changes: perivenular (zone 3), perisinusoidal (zone 2) and periportal (zone 
1). Steatosis can be classified as macrovesicular or microvesicular. 
 
B. Semi quantitative: Grading or Scoring 
Scored from 0-3  
Steatosis 
0- < 5% 
1- 5-33% 
2- 33-66% 
3- > 66% 
Inflammation 
0- None or no foci per camera field (approx. X200) 
1- < 2 foci per camera field 
2- 2-4 foci per camera field 
3- > 4 foci per camera field 
Ballooning 
0. None 
1. A few cells 
2. Many cells and often prominent ballooning 
 
C. Correlation between total NAFLD activity scores and an overall histological diagnosis 
of steatohepatitis 
 
NAFLD activity score  Histological diagnosis of steatohepatitis 
>5      Probable or definite NASH 
3–4     Uncertain 
< 2     Not NASH 
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Appendix 4: Rat insulin enzyme-linked immunosorbent assay (ELISA) kit protocol 
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